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SUMMARY 
The aim of this thesis was to investigate the properties of novel platinum compounds 
with possible potential as anticancer agents, and to determine how their behaviour 
could lead to a better understanding of the chemistry involved.  The final criteria were 
improvement of their anticancer behaviour.   
 
Since many questions are still unanswered as to the role of sulfur in anticancer 
action, studies were undertaken to synthesize novel platinum(II) complexes having 
non-leaving groups consisting of a combination of an aromatic nitrogen and 
thioetherial sulfur capable of forming a five membered ring upon coordination.  The 
structural unit was 1-methyl-2-methylthioalkyl/aryl.  Numerous complexes formed by 
these ligands each having chloro, bromo, iodo and oxalato leaving groups were then 
fully characterized.  The results obtained by the various synthetic methods were 
compared and explained in terms of the chemistry involved.  The role of the sulfur 
donor was indicated in both the halo- and oxalato-complexes and proved to be 
strongly influenced by the nature of the leaving groups.  Their differences are 
reflected in their anticancer behaviour.   
 
The study was extended to mononitroplatinum(IV) complexes, in view of the 
kinetically stable platinum(IV) compounds and advantages related to this.  A specific 
mononitroplatinum(IV) complex which proved to have good anticancer and 
STAT 3 properties could according to the literature not be synthesized successfully in 
a good yield and a high degree of purity.  The results of extensive studies showed 
that the main problem centred around the simultaneous reactions in equilibrium 
during the synthesis.  A number of these species formed as a result of side reactions 
could be identified and their close separation factors indicated chromatographically.  
The mechanism of these reactions and the unstable intermediate species involved 
could be rationalized and compared to analogues in the literature.   
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All the complexes studied were characterized by spectral and thermal methods both 
in solution as well as the solid state.  Their anticancer behaviour towards three 
anticancer cell lines (Hela, MCF 7, Ht 29) were determined and acted as a guide 
towards possible structural modifications for their improved capability.  Three crystal 
structures of platinum(II) complexes were determined.  The extent of the ionization of 
the platinum(II) complexes as well the redox potentials (Pt(II) / Pt(IV)) of the 
platinum(IV) complexes were particularly important factors pertaining to  their 
anticancer action.   
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CHAPTER 1 
INTRODUCTION 
1.1 Introduction 
Platinum based chemotherapeutic drugs have been the principle means by which 
cancer has been treated for the past 30 years.  These anticancer agents were 
unusual in that they employ an inorganic coordination complex as the active entity 
thus creating a new field of research for inorganic chemists.   
 
The biological activity of platinum compounds was serendipitously discovered by 
Rosenberg et al.1
Figure 1.1
 in 1965 during the investigation of the effect of an applied 
electric field on cell division of Escherichia coli bacteria.  They discovered that the 
active compounds were the platinum complexes cis-diamminedichloroplatinum(II) 
or cisplatin, , and cis-diamminetetrachloroplatinum(IV) which had formed 
from the reaction of the platinum electrode in an acidic medium in the presence of 
chloride and ammonium ions.2,3  Cisplatin, formally known as Peyrone’s chloride 
after its inventor Michele Peyrone in 1844, played an important role in the 
clarification of geometric isomerism by Werner and enabled Chernyaev to 
postulate the “trans-effect” theory.4,5,6   
 
Figure 1.1: The structure of cisplatin.   
After the discovery by Rosenberg extensive work led to 
cis-diamminedichloroplatinum(II) entering phase I clinical trials in 1971.7  Approval 
of cisplatin for the treatment of testicular and ovarian cancer was given in 1978.  It 
was effectively used in the treatment of testicular and ovarian cancers, as well as 
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supplementing the treatment of various carcinomas including oropharyngeal, 
bronchogenic, cervical and bladder carcinomas.8
The chemical structure of cisplatin consists of two ammine groups strongly bonded 
to the platinum, and two chloro atoms which act as ‘leaving’ groups which is a 
classical type of uncharged cis-configuration square planar platinum(II) complex.  
This type of complex has been favoured since the early landmark studies by 
Cleare and Hoeschele performed soon after the recognition of the antineoplastic 
properties of cisplatin on structure-activity relationships within platinum(II) 
compounds.
  To date, this prototypical 
anticancer drug remains one of the most effective of the chemotherapeutic agent 
in clinical use.   
 
9,10,11
Cisplatin is administered in a chloride-containing solution intravenously as short 
infusions either by a single-dose or a split-dose schedule.  Following the 
injection/infusion the drug circulates in the blood primarily as the neutral 
compound due to the relatively high concentration of chloride ions (∼100 µM) that 
suppresses hydrolysis.  Cisplatin thus reaches the outer surface of cancer cells 
(and normal cells) as a neutral molecule.  The uptake of cisplatin is not saturable 
and therefore the limiting factor for accumulating platinum in the cell is its 
concentration.  Cisplatin enters the cell by passive diffusion, as indicated by the 
fact that this process does not have a pH optimum, and is unaffected by the 
presence of structural analogues.
  These studies provided guidelines for the development of new 
platinum drugs.   
 
 12  Once inside the cell, where the chloride ion 
concentration is diminished (∼4 µM), the conditions facilitate hydrolysis.  This 
results in the replacement of the chloro ligands with water molecules to form the 
highly reactive monoaqua and diaqua species, viz. [Pt(NH3)2(OH2)Cl]+ and 
[Pt(NH3)2(OH2)2]2+.  The Pt(NH3)2(OH)Cl specie may also be formed.  The further 
formation of the dihydroxy specie Pt(NH3)2(OH)2, is unlikely under physiological 
conditions.   
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Figure 1.2: Structures of cisplatin (left) and its hydrolysis products. 
The biochemical mechanism of cisplatin cytotoxicity involves the binding of the 
cationic aquated species to nucleophilic sites on DNA and non-DNA targets.13,14  
The binding of cisplatin to the DNA is kinetically, rather than thermodynamically, 
controlled.  As mentioned above the formation of [Pt(NH3)2(OH2)Cl]+ and 
[Pt(NH3)2(OH2)2]2+ are the rate-limiting steps for DNA binding.  The preferential 
coordination sites are the N7 atom of either/both guanine and adenine purine 
nucleobases.  Initially monofunctional adducts are formed but most of these react 
further to produce interstrand or intrastrand crosslinks.  The formation of these 
cisplatin-DNA cross-links structurally distort the double helix and subsequently 
induce cell death through apoptosis, necrosis or both.,,  However, it is known that 
cisplatin also form a large number of adducts in mitochondria DNA lacking 
histones.  These adducts differ from the above in that the mitochondria are unable 
to carry out nucleotide excision repair (NER), a major pathway for removing 
cisplatin-DNA adducts.15
A large number of cellular components, such as RNA, proteins, membrane 
phospholipids, thiol-containing peptides and microfilaments, which make up the 
cytoskeleton, can react with cisplatin before it reaches the desired location.  In fact 
only 5-10% of covalently bound cell-associated cisplatin is bound to DNA.  Due to 
the strong affinity of platinum towards sulfur-donor ligands, molecules such as the 
tripeptide glutathione (GSH) which are present in cells at a concentration of 
0.5 - 10 mM, probably make these the most important platinum scavengers.  
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Glutathione, and other thiol-containing biomolecules (cystine), bind rapidly and 
irreversibly to platinum.  These interactions render the resultant platinum 
complexes inactive or detoxified, as these complexes are kinetically inert.16  The 
GSH-platinum complexes are actively transported out of the cell (ATP-dependent 
efflux) thus contributing to the lowering of drug accumulation in the cell.  A diagram 
illustrating the mechanism of cisplatin entry into the cell and the possible 
intracellular reactions is given in Figure 1.3.   
 
 
Figure 1.3: Schematic representation of cisplatin adducts formation. 
The use of the effective cisplatin was hampered by several disadvantages that 
included severe toxicity such as nephrotoxicity, neurotoxicity, and emetogensis.17
• Reducing toxicity and detoxification of the complexes.  
  
In addition to the high systemic toxicity, inherent or acquired resistance was a 
second problem often associated with platinum-based drugs, which further limited 
their clinical use.  The limited aqueous solubility of cisplatin has also been a 
negative feature and has restricted its administration.  These drawbacks led to the 
search for other antitumour active platinum complexes with better pharmacological 
properties.  The research in improving anticancer drugs was aimed at:   
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• Developing compounds with different DNA interactions than cisplatin in an 
effort to circumvent the resistance mechanisms related to DNA 
repair/tolerance.   
Adhering to these guidelines thousands of platinum compounds were synthesized 
and their anticancer properties were evaluated as antitumour agents.  Only twenty 
eight have entered human clinical trials.,18
Cisplatin analogues: These platinum compounds adhere to the set of structure-
activity relationships identified by Cleare and Hoeschele.
  The numerous selected compounds 
could be divided into only four categories according to structural differences.   
 
10,19  The relationships 
state that for mononuclear square planar platinum(II) compounds to be antitumour 
active, it should contain either two monodentate or one bidentate amine ligand, 
which function as the non-leaving groups and two monodentate or one bidentate 
anionic groups of intermediate binding strength which act as the leaving groups.  
Cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) (carboplatin) is an 
important example of this type.   
Trans compounds: Compounds similar to Type 1 but with a trans orientation. In 
recent years, several trans-platinum compounds have been reported to possess 
promising antitumour activity.  They can be divided into three subgroups.20
i. Trans-platinum(II) complexes with planar ligands   
   
ii. Trans-platinum(II) complexes with iminoether ligands 
iii. Trans-platinum(II) complexes with aliphatic amine ligands   
Platinum(IV) compounds: The development of oral active anticancer agents 
reinitiated the interest in the kinetically more inert platinum(IV) compounds.  The 
platinum(IV) compound of interest that showed promise is 
bis(acetato)amminedichloro(cyclohexylamine)-platinum(IV) (JM216, satraplatin).  It 
is generally believed that platinum(IV) complexes are reduced to platinum(II) by 
extracellular and intracellular agents prior to DNA binding.  An added advantage of 
platinum(IV) complexes is that they can be chemically modified at the two axial 
ligand sites.  This property plays a large role in the complex lipophilic nature which 
could potentially circumvent resistance.   
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Multinuclear platinum complexes:  Multinuclear platinum complexes were 
synthesized that form radically different platinum-DNA adducts with the objective 
of circumventing platinum resistance.  An example of this approach was 
multinuclear platinum complexes with bridging linkers.  Large numbers of these 
complexes were synthesized by Farrell and colleagues showing activity in both 
cisplatin-sensitive and -resistant cell lines.  The most important of these 
complexes is the trinuclear platinum compound, trans-[bis[trans-diamminechloro-
platinum(II)(μ-1,6-hexanediamine)]]-diammineplatinum(II), BBR 3464, which is 
currently undergoing clinical development.21
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Figure 1.4: Examples of platinum compounds that are used as anticancer agents or have 
been evaluated for possible therapeutic application.   
During an extensive literature survey of platinum anticancer compounds the 
following parameters were identified as being vital in the development of new 
anticancer agents.   
• Fundamental Chemistry of Platinum(II) and Platinum(IV) 
• Kinetics 
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• Stereochemistry 
• Biomolecule interaction 
• Biocompatibility 
• Mode of DNA binding 
• Interaction of STAT function 
These parameters will be discussed in full hereafter.   
 
1.2 Chemical Parameters Vital for the Development of 
Platinum Anticancer Agents   
1.2.1 Fundamental Chemistry of Platinum(II) and Platinum(IV)   
It is well established that platinum(II) has a strong preference for square-planar 
coordination geometry,22 rationalized by the crystal field stabilization energy 
resulting from its d8 (t2g6 eg2) electronic configuration.23 Figure 1.5  The  shows the 
crystal field splitting diagram for a square planar complex.   
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Figure 1.5: The crystal field splitting of a square planar complex. 
Platinum(II) is a 16-electron system thus violating the 18-electron rule.  This is due 
to the fact that one of the d-orbitals has high energy, and do not readily accept 
electrons.  This electron system operates, without exception, in the spin-paired 
state (diamagnetic).   
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Platinum(II) has filled d-orbitals for π back bonding thus preferring σ-donor, 
π-acceptor ligands.  Platinum readily bonds to soft donor ligands such as PR3 and 
sulfur-donor groups (σ-donor, π-acceptor). It can also bond to intermediate type 
ligands such as nitrogen-donor ligands and chloride as well as hard donor ligands.  
The bonding with these ligands is essentially covalent.  The standard reduction 
potentials show that platinum(II) has a much greater affinity for covalent chloride 
than for water.24,25
[PtCl4]2-  +  2e- Pt(s)  +  4Cl
-      + 0.758 V
[Pt(H2O)4]2+  +  2e- Pt(s)            + 1.188 V
   
 
This shows just how low its affinity for small neutral oxygen donor ligands is.  High 
covalent interaction results in the formation of inert complexes, where bond-
breaking cannot readily be achieved, even in a polar oxygen donor solvent like 
water.  Although a vacant orbital in the valence band is available, relatively high 
activation energy is required for its involvement.  When this occurs an activated 
5-coordinated complex is formed, influenced by the leaving group.  The square 
planar platinum(II) complexes are therefore relatively inert although ionization can 
occur, especially with ligands having donor atoms of high electronegativity such as 
nitrate, sulphate etc.  When the platinum(II) complexes are aquated the kinetics 
becomes faster which has a negative influence on their anticancer properties.  
Even in the cases where the polarity in the Pt-Cl bond can be considered 
moderate ligand exchange can still be too fast for effective anticancer action.   
 
In a very recent publication it was shown that the “tetraaqua complex of 
platinum(II)” in aqueous solution actually has four planar coordinated water 
molecules and one coordinated water at a somewhat longer distance at the apex 
of a square pyramid.  The bond in such an instance will have a very significant 
electrostatic component.  This factor and the small size of the oxygen atom allows 
for the formation of the distorted square pyramidal structure.  This behaviour 
greatly facilitates ligand exchange.  Furthermore, the same article states that the 
cis-diamminediaqua platinum(II) behaves in a very similar manner namely that it 
forms a distorted square pyramidal structure.  This explains why its specie is very 
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reactive.  The main reasons being, firstly, the platinum bonded oxygen is quite 
polar and, secondly this donor atom is really a miss match for the 5d transition 
metal due to its hard nature.23,26,27,28
Researchers therefore started to look at means to slow down the kinetics of 
platinum complexes.  The kinetics of ligand exchange reactions is affected by the 
oxidation state of the platinum centre.  This was arguably the rationale behind the 
development of six-coordinate platinum(IV) complexes which obey the 18-electron 
rule. The t
   
 
2g
6 eg0
Figure 1.6
 electronic configuration of platinum(IV), with its high crystal field 
stabilization energy ( ), coupled with the higher effective nuclear charge 
(relative to platinum(II)), makes its complexes kinetically inert.  This has also made 
these complexes more amenable to oral administration as they would be better 
able to resist aquation than their platinum(II) congeners.29
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Figure 1.6: The crystal field splitting of an octahedral complex. 
Studies have shown that the degree of inertness is also a function of the electron-
withdrawing capability and size of the axial and equatorial ligands.30
Figure 1.4
  This has 
important implications especially if the platinum(IV) complexes were to be reduced 
too quickly. In such cases the potential advantages, such as reduced side effects 
and reduced deactivation en route, of the less reactive platinum(IV) specie are 
lost. For example, clinical studies of tetraplatin, , were abandoned at 
phase one due to its severe toxicity. This was attributed to its rapid rate of 
reduction in blood plasma (occasioned by the electronegative axial chloro ligands) 
and subsequent side-reactions with proteins.31   
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[PtCl6]2-  +  2e- [PtCl4]
2-  +  2Cl-      + 0.726 V  
The parameters that influence the kinetics of ligand exchange, in both platinum(II) 
and platinum(IV), will be discussed.   
 
1.2.2 Kinetics   
The antitumour properties of platinum-containing drugs are attributable in large 
measure to the kinetics of their ligand displacement reactions.  If the rate of 
exchange is too fast the platinum complex would react with biological thiol entities 
such as metallothionein proteins, methionine or glutathione.  Once these reactions 
have occurred they are irreversible under biological conditions, effectively making 
the platinum complex inert.  Thus detoxification occurs before the complex could 
reach the cancer cells, in conjunction with severe systemic toxicity.  Too slow 
ligand exchange would result in the drug being inert and although this would make 
the drug available for DNA binding the chance of that happening will be slim.10,  An 
intermediate exchange rate is thus desirable.   
 
Ligand exchange of square planar platinum(II) complexes generally occurs by an 
associative process (SN2 mechanism) involving a distorted pentacoordinated 
intermediate.  However, a dissociative mechanism (SN
Figure 1.7
1) may be favoured with 
bulky ligands.  These mechanisms are illustrated in .   
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Figure 1.7: The dissociative (SN1) and associative (SN2) paths.32
CNˉ ~ CO ~ olefins > thioethers ~ Hˉ ~ arsines ~ phosphines > SC(NH
 
A general rule applicable to ligand exchange in square planar complexes is the 
“trans-effect”.  That is the capability of a coordinated ligand to labilise a ligand 
trans to it.  The normal order of trans-directing is:   
2)2 ~CH3ˉ >
 C6H5ˉ ~ NO2ˉ ~ Iˉ ~ SCNˉ > Brˉ ~ Clˉ > amines ~ NH3 ~ OHˉ ~H2O.   
The above sequence was based on the kinetics of reaction of the platinum 
complexes of the ligands with pyridine.  Upon inspection of this sequence it is 
clear that sulfur-donor ligands behave very differently to chlorides, amines and 
water, i.e. the ligands commonly found in the body.  This has important 
implications for heavy metals introduced into body fluid.  A sulfur donor, such as a 
thiol, will readily displace platinum-bound ligands such as chloride.  In addition, the 
highly labilizing nature of the sulfur donor will facilitate substitution of ligands trans 
to it; the nett effect being to irreversibly alter the structure of the drug, potentially 
rendering it inactive.  Sulfur-donor ligands are used to demetallate mercury and 
lead from biological systems.  It is also known that cisplatin is eliminated via the 
urine with a significant proportion of the platinum bonded to sulfur atoms.16,,33 
 
There are a number of exceptions to the above sequence, which are important in 
the action of platinum anticancer agents.   
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i. An important factor is that the nature of the co-ligands can greatly influence 
the behaviour of a coordinated ligand. For example, when platinum 
complexes have sulfur-donor ligands as well as co-ligands having donor 
atoms of high electronegativity (such as nitrogen and oxygen), the 
trans-effect of the sulfur-donor ligand will be much smaller than expected. 
This is due to an increase in the effective nuclear charge on the platinum 
centre, which reduces its π-backbonding capability toward the sulfur 
nucleophile. Such properties are referred to as biphillic.   
ii. A second source of disturbance of the nucleophilicity sequence arises in 
sterically hindered systems where the effect of size and shape of the 
nucleophile becomes more important than its “normal order”. Reversals in 
nucleophilicity can occur.  Bulky ligands would slow down ligand exchange 
in that they would hinder the formation of a 5-coordinate intermediate.  The 
compound cis-amminedichloro-(2-picoline)platinum(II), ZD0473 (AMD473) 
was developed with the aim to reduce the susceptibility to inactivation by 
elevated levels of thiols, such as glutathione, in the body.,   
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Figure 1.8: Structures of cis-amminedichloro(2-methylpyridine)platinum(II) 
(ZD0473) (left) and its analogue cis-amminedichloro(3-
methylpyridine)platinum(II) (right). 
The crystal structures of cis-2-methyl and -3-methyl were compared and the 
most notable difference was the orientation of the picoline ring with respect 
to the platinum.  The analysis showed that the methyl group situated in the 
2-position of the pyridine ring, with the Pt-CH3
9
 axis nearly perpendicular to 
the platinum square plane, sterically hinders an axial approach to the 
platinum centre and therefore partially protects from associative ligand 
exchange. ,17,34   
~ 13 ~ 
 
iii. Bond lengths therefore force constants and stretching frequencies, are 
important. For example, the electronegativity of a donor atom trans to a 
Pt-Cl bond determines its bond length and therefore its lability; the Pt-Cl 
bond length is 2.31 Å trans to ammine and 2.37 Å trans to phosphorous in 
P(CH3)3 32.    
iv. In compounds having adjacent ligands of weak trans-effects a new 
parameter becomes dominant namely the cis-effect.  This effect is 
illustrated in Pt(NH3)2Cl2
32
 by that under normal conditions the trans-effect of 
the chloride is larger than the ammine.  However, the opposite occurs in 
reality.    
v. The enhanced stability resulting from the chelate effect will slow down 
ligand exchange.   
A good example of this is carboplatin.  It was found that its aquation rate 
was a hundred times slower than cisplatin.35
1.2.3 The Effect of Stereochemistry   
  This can be attributed to the 
enhanced stability of the chelated weak acid, 1,1-cyclobutanedicarboxylate.   
It should be borne in mind that these factors often operate simultaneously.   
 
Stereochemistry plays an integral role in both the functioning of biological systems, 
and in the design of therapeutic agents used in such environments.  The effect of 
stereochemistry in platinum-group metal complexes is largely determined by the 
non-leaving groups and, to a lesser extent, the leaving groups.  The following sets 
of parameters influence the stereochemistry of platinum and are discussed 
individually but it must be remembered that they are interrelated and operate 
simultaneously.   
i. Stereochemical crowding is an important parameter in decreasing the 
ligand exchange rate.  Crowding of donating nitrogen donor ligands by alkyl 
groups not only slows down the rate, but also provides a barrier to the large 
sulfur atoms present in biological systems which can detoxify the agent.  
This can also limit organ toxicity.   
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ii. The degree of stereochemical crowding has an effect on activity.  
Experiments conducted by Cleare and Hoeshelle on alkyl-substituted 
amines revealed that as substitution on the nitrogen donor atom increases, 
anticancer activity tend to decrease.  This was further supported by 
Hambley when stated that the presence of at least one hydrogen atom on 
each of the two am(m)ine groups is essential for activity.36
iii. It has been shown that oxaliplatin has a comparable adduct formation to 
that of cisplatin, thus one would expect that the guanine-guanine platinum 
adducts to be structurally similar.
  This means that 
the length and size of the substituted alkyl groups lie within a “window” for 
the complexes to be active.   
37,38  However, Scheeff conducted 
molecular modelling calculations on the adducts formed and found that the 
diaminocyclohexane (dach) moiety of oxaliplatin protrude more suggesting 
a narrowing of the major groove of the DNA.39  Further work conducted 
resulted in the postulate that the more hydrophobic and bulky nature of the 
dach ligand made it a more effective inhibitor of replication and transcription 
than a cis-diammino ligand.40,41
iv. Stereochemistry plays a role in the resistance of the antitumour drug.  This 
is evident in oxaliplatin which forms similar DNA adducts to cisplatin.  The 
cytotoxicity of cisplatin depends on the ability of the proteins of the 
mismatch repair pathway (MMR) to recognise and bind to the Pt-adduct.
   
,42  
Cell lines that are deficient in MMR are resistant to cisplatin, for they are 
able to replicate the DNA part of the cisplatin-induced lesions (replicative 
bypass) and therefore do not undergo apoptosis.43,44  In the case of 
oxaliplatin MMR does not recognise nor bind to the Pt-adducts due to steric 
hindrance by the dach ligand thus making cisplatin resistance cells 
susceptible to oxaliplatin.,,,45
v. Lipophilicity, which is related to stereochemistry, can play an important role 
in activity because passive uptake across the lipid bilayer, which makes up 
the cell membrane, is facilitated by higher lipophilicity.
   
46  The degree of 
lipophilicity can be altered much more readily in platinum(IV) than in 
platinum(II) due to the additional axial coordination sites.  It’s been reported 
that there is a steady increase in cytotoxicity with an increase in the 
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aliphatic chain attached to axial carboxylato groups.47,48  This increased 
cytotoxcity was related to the intracellular accumulation which is directly 
dependent on the lipophilicity of the compound.   
 
1.2.4 Biomolecule Interaction: Influence of Sulfur-Donor Ligands 
(S-N interaction)   
When platinum(II)-containing anticancer agents are present in biological systems it 
is obvious that sulfur donors will play a very prominent role in their interaction.  A 
significant amount of sulfur-donors (thioethers, thiols) together with a large number 
of relatively weak trans-directing ligands like nitrogen-donors (aliphatic, aromatic 
nitrogens) and, oxygen-donors (anionic: carboxylates, bicarbonate, phosphates 
and neutral ones including water) are present in biological systems.  A further 
refinement of classification should be recognized, namely, that there are two types 
of sulfur-donors.  These are σ-donor π-donor (thiolates, thiourea) and σ-donor 
π-acceptors (thioethers) ligands.  The former bonds irreversibly with platinum(II), 
whereas the latter type can be replaced by aromatic nitrogens like N7 of guanine.49
thiols (glutathione) > Guanine N
   
 
Ligand exchange studies performed on platinum(II) anticancer agents under in 
vivo conditions (pH 7 and the presence of Clˉ) showed that the order of 
replacement was  
7 > thioether (methionine) > Adenine N7 49.  
The reason for concentrating on the aromatic nitrogens (N7
Figure 1.9
) of guanine and 
adenine is the fact that these two nitrogen atoms are largely involved in 
coordination during DNA binding of the anti-cancer agents.  In order to investigate 
possible reasons for this sequence it was thought useful to obtain space-filling 
models of guanine, , and adenine, Figure 1.10, as well as their charge 
distribution values.   
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Figure 1.9: Space filling and charge distribution models for guanine. 
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Figure 1.10: Space filling and charge distribution models for adenine. 
A comparison of the two relevant N7
i. The guanine N
 atoms revealed the following: 
7
ii. The negative charges on the two atoms adjacent to the N
 atom was less stereochemically crowded than that of 
adenine.   
7 atoms differed 
significantly in that those of the guanine were higher than those of the 
adenine.  This results in a greater potential of induction (electron transfer) 
from these atoms to N7
iii. The N
 upon bonding to platinum(II).   
7 of guanine and adenine have pKb values of 11.2 and 14.8 
respectively thus indicating that the N7 of guanine is more basic and 
therefore forms a stronger sigma bond to platinum.50
iv. The greater hydrogen-bonding capability of guanine plays a role in stability 
of the Pt-DNA adduct.
   
51,52  This phenomenon is evident by the secondary 
interaction with the nearby oxygen atom in guanine and repulsion with NH2
Figure 1.11
 
in adenine.  ( )   
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Figure 1.11: The cis-platinum complex binding at guanine vs adenine. 
In order to rationalize the sequence further, the relevant chemical aspects of sulfur 
donors had to be considered. 
 
The two types of sulfur atoms in the sequence are just as different from each other 
as the two types of nitrogen atoms.  The thiol sulfur can readily be deprotonated 
by ‘soft’ 4d or 5d transition metals, in effect changing it from a neutral to a 
monoanionic form, with all the covalent equipment available to satisfy the 
nephelauxetic character of the metal.  Thioethers, however, can be regarded as 
virtually neutral sulfur atoms having a lower order of donicity.   
 
The question arises as to what precautions can be taken to limit the effect of 
sulfur-donation. In an attempt to answer this question a space-filling model for the 
typical biothio-compound cysteine was constructed.  (Figure 1.12)   
 
S
O
N
C
H
H
H
H
           
Figure 1.12: Space-filling and charge distribution diagrams of cysteine. 
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Two factors stand out. Firstly, there is a slight negative charge already present on 
the sulfur before deprotonation.  Secondly, if the size of the sulfur atom is 
compared with that of the aromatic nitrogen donor atoms it is obvious that the 
sulfur atom is very bulky.  (Compare Figure 1.9 and Figure 1.10 with Figure 1.12)  
This phenomenon in itself has significant implication on the kinetics.  Since it is 
known that ligand exchange of platinum(II) complexes occurs mainly via a trigonal 
bipyramidal intermediate32,53,54
34
, stereochemical crowding of the platinum(II) square 
planar complex will result in a lower exchange rate.  It is expected that ligand 
exchange of a bulkier coordinated sulfur atom will be slower than for the nitrogen 
atom.  There is some evidence of this in literature. ,17   
 
Another factor that contributes to controlling the effect of sulfur-donors, especially 
those of thioethers (methionine), is the use of chelated nitrogen-donors.55  Such 
ligands would increase the thermodynamic stability of the complex as well as 
providing a bigger barrier towards replacement. 
 
The interactions of sulfur-donor ligands in biological systems are further 
complicated by the observation that some sulfur-donor ligands actually enhance 
the activity of platinum agents when co-administrated.  The exact nature of the 
interaction of these rescue agents with anticancer agents is not clear, though it is 
thought that they may protect the metal centre from detoxification.  However, it is 
known that thioethers which do not react irreversibly with anticancer agents are 
effective in protection.  An example of this is that it was found that cisplatin was 
more effective in the presence of methionine.56
In addition some sulfur containing biomolecules (glutathione, methionine, cysteine 
and serum albumin) may actually play a intricate role in activating platinum(IV) 
complexes.  For these complexes to exert their full cytotoxic effect they need to be 
reduced to their platinum(II) analogues.
   
31,57,58   
 
~ 19 ~ 
 
1.2.5 Biocompatibility   
There are a number of factors that need to be considered for a drug to become 
compatible with a biological system.  Compounds must be able to easily pass 
through the cell membrane in order to reach its target, namely, the cellular DNA.  It 
has been found that essentially any molecule will diffuse across a lipid bilayer of 
the plasma membrane down its concentration gradient.59
1.2.5.1 Solubility  
  The rate at which this 
happens will depend on the size of the molecule and its hydrophobicity.  In 
addition it will be advantageous for the compounds to have a higher solubility 
within the blood stream, because this will enhance its biocompatibility.   
 
The importance of lipophilicity has been emphasized in a previous paragraph.  
However, increased lipophilicity reduces the aqueous solubility, which is also 
needed for the transfer of the agent from the blood to the cell.  This can somewhat 
be increased by introducing polar groups into the complex.  This may be achieved 
by using oxocations like oxalate, malonate etc. or even by introducing polar groups 
as part of the non-leaving moiety.  This has been done for carboplatin, oxaliplatin 
and numerous other platinum compounds.   
 
Solubility may further be increased by the oxidation of the platinum(II) complex to 
its platinum(IV) analogue.  It was found that iproplatin (cis,cis,trans-
PtCl2(OH)2(isopropylamine)2
31
), CHIP, JM9) was two orders of magnitude more 
soluble than its platinum(II) congener (44.1 vs 0.22 mM).    
 
1.2.5.2 Membrane Transport   
For a compound to be effective as an anticancer agent it is essential for it to enter 
into the tumour cell.  It is suggested that approximately one half of the initial drug 
uptake is due to passive diffusion and that the other half occurs by facilitated 
diffusion60 through a gated channel in the cell wall.61,62,63  Since the interior of the 
cell membrane consists of hydrophobic hydrocarbon ‘tails’, making the drug more 
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hydrophobic or lipophilic will enhance transport into the cell.64,65,66,67
17
  For example, 
the case of (bis(acetato)amminedichloro(cyclohexylamine)-platinum(IV) (JM216).  
As a result it was shown that the high lipophilicity resulted in it entering the cell 
predominantly through passive diffusion. ,62   
 
It has been shown that the greater the lipophilic nature of complexes, the more 
easily they enter the cell, thus circumventing resistance due to decreased platinum 
accumulation.64,65,66,67  Carboxylate and carbamate ligands are suitable ligands 
since they contain polar and lipophilic regions.29  Several platinum(IV) complexes 
have been prepared using this concept, for example, 
(amminedibutyratodichloro(cyclohexylamine)-platinum(IV) (JM221).65   
 
Higher antitumour activity can also be achieved by increasing the hydrophobicity.  
The major 1,2-intrastrand crosslinks can create a hydrophobic notch at the 
damage site, which can specifically be bound by damage-recognition proteins, 
thus shielding it from nucleotide excision repair (NER) activity.12  Therefore, 
enhancing this mechanism by using more hydrophobic compounds may prevent 
resistance.  There is experimental evidence to corroborate this supposition.  In a 
study three types of platinum analogues, with increased hydrophobic 
characteristics, were synthesized.  The most hydrophobic molecule, 
methylpyridineplatinum(II), was the most cytotoxic, followed by 
methylpyrazineplatinum(II), and then the pyridineplatinum(II).68,69
1.2.6 Mode of DNA Binding   
   
 
The antitumour drug cisplatin exerts its cytotoxic effect primarily by interacting with 
cellular DNA.  This binding of DNA is kinetically rather than thermodynamically 
controlled.12  Thus the formation of the active monoaqua specie [Pt(NH3)2Cl(H2O]+ 
is the rate-limiting step for DNA binding.  This positively charged complex is 
thought to be electrostatically attracted to the negatively charge DNA helix and 
subsequently binds to the N7 atom of a guanine base forming a monofunctional 
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adduct.70
9
  This is followed by hydrolysis of the second chloride and closure of the 
monofunctional adduct to form a stable bifunctional adduct or a crosslink. ,12,71
70
  In 
the case of carboplatin and oxaliplatin this process of binding is much slower due 
to their lower hydrolysis rates.    
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Figure 1.13: Types of cisplatin-DNA adducts and their frequency of formation.72
The adduct profile of cisplatin, 
 
 
Figure 1.13, includes 1,2-GpG intrastrand cross-
links (60-65%) and 1,2-ApG intrastrand cross-links (20-25%). Minor adducts such 
as intrastrand 1,3-GpNpG (~10%), intrastrand 1,3-GpG (~2%) and interstrand 
cross-links (<1%) have also been observed.13   
 
There is much debate over which of the above adducts are responsible for the 
activity of cisplatin.13,73  Support for the abundant 1,2-GpG adducts came from 
findings that the nucleotide excision repair (NER) system, an important DNA repair 
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pathway, repaired 1,3-intrastrand adducts more efficiently than 1,2-intrastrand 
adducts.13  In addition, the 1,2-GpG adduct proved to be the most inhibitory lesion 
of DNA polymerases involved in DNA replication.12  The argument that the 
intrastrand rather than the interstrand lesions were responsible for cytotoxicity was 
supported by observations that trans-diamminedichloroplatinum(II), which formed 
interstrand cross-links more efficiently and rarely formed intrastrand lesions, was 
considerably less cytotoxic.73   
 
1.2.7 Inhibition of STAT Function   
The current application of cisplatin and its analogues as anticancer agents is 
predominantly based on their DNA-damaging effects which contribute to cell 
death.74  However, recently evidence indicated that cisplatin modulates mitogen-
activated protein kinase (MAPK) signaling pathways.75
74
  These pathways are 
critical in cellular responses to growth factors and cytokines are characterized by 
the activation of the signal transducer and activator of transcription (STAT) family 
of cytoplasmic transcription factors. ,75  Recently some platinum compounds 
(cis-diamminetrichloronitroplatinum(IV) (CPA 7), trichloronitroethylenediamine-
platinum(IV) (CPA 1), IS3 295 and platinum(IV) tetrachloride) were shown to have 
very promising results in inhibition of the STAT function.74,75  Although there are 
numerous STAT proteins, the persistent activation of specific STAT proteins, 
particular STAT 3 and STAT 5, occurs with high frequency in a wide range of 
tumours.  The signalling mechanisms involved are complex and beyond the scope 
of this work, but to understand the action of the platinum compounds in this 
process we need to briefly look at the fundamentals involved.   
 
1.2.7.1 Normal STAT function 
STAT’s are activated by many cytokines and growth factors which lead to a 
specific biological response.  The activation of STAT’s is dependent upon tyrosine 
phosphorylation, which is induced by protein tyrosine kinases of growth factor 
receptors and receptor-associated cytoplasmic kinases.  Many tyrosine kinases, 
including JAKs (Janus kinases), RTKs (receptor tyrosine kinases), and non-RTKs 
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can phosporylate STAT proteins.  This in turn allows phosphotyrosine (pTyr)-SH2 
interactions between two STAT monomers, and the formation of dimers, which 
then translocate to the nucleus.  Once inside the nucleus the active STAT’s bind to 
specific DNA response elements and regulate the expression of genes essential 
for cell proliferation, differentiation, development, and survival.76
Figure 1.14
  This process is 
summarized in the .   
 
Figure 1.14: The model for STAT 3 signalling.76 
1.2.7.2 Disrupted STAT Function in Cancer Cells 
Cancer cells utilize a mechanism whereby tyrosine kinases that are not associated 
with specific receptors can activate STAT proteins directly. The resultant STAT 
proteins are in a state of constant activation, thereby bypassing the normal finely 
tuned control mechanisms and causing a malfunction in the cellular signalling 
apparatus.77  It is well-established that constitutively active STAT 3 is one of the 
molecular abnormalities that contribute to oncogenesis by several mechanisms.78  
Aberrant STAT 3 promotes uncontrolled growth and survival through dysregulation 
of gene expression, including the inhibition of p53, and thereby contributes to 
oncogenesis.  The p53 protein is involved in the ‘maintenance’ of DNA. When 
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mutations are found the levels of p53 rise and bind to specific segments of the 
DNA, which activate or inactivate certain genes involved with cell growth. If the cell 
cannot repair the defects, p53 initiates apoptosis, or programmed cell death.79  
Moreover, persistent active STAT 3 induces tumour angiogenesis by upregulation 
of vascular endothelial growth factor induction, and modulates immune functions in 
favour of tumour immune evasion.  The most potent angiogenesis-inducing signal 
is vascular endothelial growth factor (VEGF).  Studies have shown that STAT 3 is 
a direct transcriptional activator of the VEGF gene.80
78
  Further the up-regulation of 
STAT 3 promotes the expression of genes that act to inhibit apoptosis.    
 
1.2.7.3 Platinum STAT Interaction   
As mentioned earlier, particular platinum compounds have been identified to 
posses STAT 3 inhibition activity.  Turkson et al.74 found that the novel 
platinum(IV) compounds, CPA 1, CPA 7, and platinum(IV) tetrachloride blocked 
STAT 3 activity in vitro at low micromolar concentrations.  These effects are 
stronger and more selective against malignant cells that contain persistently active 
STAT 3 than those that do not.  In contrast, cells that do not contain persistent 
STAT 3 activity were only marginally affected by these compounds.  In addition, 
CPA 7 was found to be the most potent compound in vitro, in whole cells and in 
animal models of cancer.74   
Furthermore, the complex IS3 295 functions as a STAT 3 inhibitor by interacting 
with both the inactive monomer and activated dimer thus repressing STAT 3 
phosphotyrosine levels, DNA-binding activity, and transcriptional regulation.  The 
activity is thought to be as a result of conformational changes in the STAT 3 
protein or due to irreversible binding of IS3 295 to STAT 3.75  Studies have shown 
that unlike the classical DNA alkylating agents such as cisplatin and oxaliplatin, 
there is very little evidence that IS3 295 denatures the STAT 3 target area 
(consensus binding oligonucleotide sequence or hSIE) on the DNA.75   
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1.3 The Chemistry Involved in Coordination   
1.3.1 General 
The chemical properties of platinum and palladium (later 4d-transition metals) 
greatly determined the procedures used in the preparation of the complexes 
isolated.  Important factors considered in preparations were, the slow kinetics, the 
impact of the trans-effect on the exchange rate and the fact that ligands with soft 
donor atoms such as nitrogen, sulfur and phosphorous are preferred to oxygen-
donor ligands.  Almost without exception, a single starting material, K2PtCl4, is 
applied for all the syntheses.  When the envisaged compound does not contain 
chloro species K2PtCl4 can readily be transformed into K2PtX4
1.3.2 Halide chemistry   
.   
 
When monodentate ligands (L) are added to a solution of K2MX4
K2MX4  +  2L ML2X2(aq)  +  2X
-  +  2K+    (Molecular form)     Eq. 1
ML2X2(aq) ML2X2(s)                                                              Eq. 1(a)
2ML2X2(aq) ML4
2+
(aq)  +  MX42-(aq)      (Auto-ionization)        Eq. 2
ML42+(aq)  +  MX42-(aq) ML4MX4(s)                                          Eq. 2(a)
 the following 
general reactions can occur. The reactions are set out in equations 1-3 below.   
 
ML2X2(aq)  +  2L ML4
2+
(aq)  +  2X-(aq)          (Ionization)            Eq. 3
ML42+(aq)  +  2X-(aq) [ML4]X2(s)                                              Eq. 3(a)  
When M = Pt, X = monoanionic leaving group, L = monodentate non-leaving group.  Analogous 
reaction scheme can be drawn up for bidentate leaving and non-leaving groups.   
 
The reactions represented by equation 1 and 1(a) are very important since the 
molecular from has the greatest potential as anticancer agents.  Cisplatin was a 
typical example.  Auto-ionized species (equations 2 and 2(a)) are unimportant in 
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anticancer action.  Similarly, the ionized species (equation 3) also does not seem 
too important in the above connection.   
 
In addition to the above equilibria, and especially relevant to equation 1, is the 
phenomenon of cis/trans isomerism.  This is important since the cis form is 
preferred to the trans form in anticancer activity.81   
The equilibria in equation 1 - 3 were observed in systems were L = am(m)ine and 
X = Cl‾.  The chemistry associated with these equilibria needs to be fully 
understood in order to facilitate the search for new ligands to be studied.   As a 
prototype reaction system the well studied example of K2PtCl4/NH3 will be 
considered.  It can be assumed that the chloro complexing of platinum(II) will be 
stepwise.  Consider equation 1 - 3.  The reverse reactions will occur during ligand 
replacement of Cl- by NH3. Thus, with a gradual increase of free NH3 to a [PtCl4]2- 
solution the [PtCl3NH3]-, PtCl2(NH3)2, [PtCl(NH3)3]+ will form stepwise and will 
stop at [Pt(NH3)4]2+ when large excess of free NH3 is present.  In an intermediary 
phase some [Pt(NH3)4]2+ (small amount) can coexist with some [PtCl4]2-.  The 
course of the reaction will be determined by relative solubilities, of Pt(NH3)2Cl2 as 
compared to [Pt(NH3)4][PtCl4], 1(a) and 2(a). When a lukewarm solution of 0.1 
mole of K2PtCl4 is reacted with 0.2 mole of NH3 in the presence of 0.5 moles of 
NH4Cl and left to stand for two days at room temperature and a further day at 0°C, 
a mixture of cisplatin Pt(NH3)2Cl2 (mainly) and Magnus salt, [Pt(NH3)4][PtCl4], and 
even [PtCl(NH3)3]2[PtCl4], is obtained.82  This is typical of monodentate amine 
reactions with [PtCl4]2-.  It must be remembered that although the co-existence of 
the [Pt(NH3)4]2+ and [PtCl4]2- species may be relatively small, the high lattice 
energy of the +2 -2 complex (Magnus salt) renders it very insoluble. The 
trans-directing capability of Cl- > NH3 results in the formation of some cisplatin.  In 
further reactions, however, the "cis-effect" takes over and Cl- becomes the leaving 
group.  As a result of the above equilibria the best method for the synthesis of pure 
cisplatin is not by the direct reaction of ammonia with K2PtCl4.  The so called 
‘silver method’ was developed many years ago in which this obstacle was 
overcome by a step of reactions indicated underneath.83   
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K2PtCl4  +  4I- K2PtI4  +  2NH3 cis-PtI2(NH3)2
cis-PtI2(NH3)2  +  2Ag+NO3- Pt(NH3)2(H2O)2
2+  +  2Cl- cis-PtCl2(NH3)2  
The above method generally produces relatively high yields, however, it is not 
flawless since Ag+ contamination, I- and I3- contamination as well as OH- species 
of platinum(II) can accompany the final products.  A further limitation is that 
platinum chloro-complexes, which contain neutral ligands having donor atoms with 
which Ag+ forms very stable compounds, cannot be expected to be used in this 
way to produce complexes with other anions then Cl-.  This will be particularly true 
for neutral sulfur-donor ligands such as thioethers.84
1.4 Objective of this Thesis   
  This aspect will be discussed 
in Chapter 3.   
 
In light of the above, it is understandable that precautions must be taken to 
circumvent unwanted side-reactions.  This includes the stringent adherence to 
stoichiometric ratios, slow addition of ligand, etc.   
 
The objective of this thesis was to study the development of compounds that could 
be potential anticancer agents.  In order to achieve this literature synthetic 
methods were studied and altered to prepare these compounds.  The testing of 
the compounds proved that some of them have significant potential.   
This was accomplished in the following sequence:  
Further studies on sulfur-donors were performed using a specially synthesized 
thioether-imidazole chelate system as the ligand.  These ligands were then used in 
the synthesis of their coordination compounds.  The modification of the specific 
selected sulfur is discussed in the introduction of Chapter 3.   
 
The corresponding oxalato-complexes were discussed in Chapter 4.  These 
complexes were specifically selected to determine whether the oxalato group 
would significantly slow down ligand exchange rate.   
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The interest in platinum(IV) behaviour was stated in the introduction.  In a recent 
development where NO2 gas was used as an oxidant, prototypes were 
synthesized which exhibited very promising anticancer action.  This led to the 
renewal involvement of this area in chemistry.  The main attention were directed at 
the cis-diamminetrichloronitroplatinum(IV) complex, CPA 7.  The synthetic method 
of this compound had problems with reference to its purity and yield.  Extensive 
research was undertaken towards understanding the reactions involved and the 
purification of the compounds.  (Chapter 5)   
 
In all the above cases mentioned attention were given to structural composition, 
mass spectrometry, ionization, kinetics and cytotoxic testing.  Simultaneously, the 
final products were produced in a 1 g scale with a high degree of purity.   
 
The experimental procedures for the syntheses of both ligands and complexes will 
be detailed in Chapter 2.   
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CHAPTER 2 
EXPERIMENTAL 
2.1 Introduction   
This chapter describes the experimental procedures used to synthesize the 
ligands and coordination compounds.  This will also deal with the physical 
methods used to characterize these compounds.  The synthetic methods will be 
described in detail to enable the reproduction of these compounds in the future.   
 
The chemical arguments involved in the development of the synthetic procedures 
used in the syntheses of the coordination compounds will be incorporated in the 
discussion in each of the relevant chapters.  This was because these syntheses 
were a culmination of a series of experiments performed in which many 
parameters were altered. 
 
2.2 Preparation of Starting Compounds   
The precursor for all the platinum compounds was potassium 
tetrachloroplatinate(II) (K2PtCl4).  The method used was an adaptation of that 
provided by Keller85
2.2.1 Potassium Tetrachloroplatinate(II) K
.   
 
2PtCl4
The platinum salt was synthesised from the platinum metal via three distinct steps 
which will be described.   
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2.2.1.1 Preparation of Hexachloroplatinate(IV) Acid Solution H2PtCl6
Pure platinum metal (10.0 g, 51.3 mmol) was dissolved in 200 mL hot aqua regia 
solution.  The solution was concentrated to a slurry paste by heating.  The paste 
was dissolved in 200 mL concentrated HCl and then re-evaporated to a slurry 
paste.  This was repeated a second time.  The resultant slurry was dissolved in 
250 mL of 1M HCl.   
 
   
2.2.1.2 Preparation of Potassium Hexachloroplatinate(IV) K2PtCl6
A 250 mL aliquot of a 0.46 M KCl solution (8.5 g, 114 mmol) was added dropwise 
to 250 mL of the hexachloroplatinic acid solution.  A bright yellow precipitate of 
K
   
2PtCl6 formed almost instantaneously and continued throughout the addition of 
KCl solution.  An equal volume of 95% ethanol was added to the mixture and it 
was left on ice for 1 - 2 hours.  The resultant yellow crystalline K2PtCl6
2.2.1.3 Preparation of Potassium Tetrachloroplatinate(II) K
 was filtered 
and washed twice with 50 ml portions of 50% ethanol, once with 50 mL 95% 
ethanol and 3 times with 50 mL portions of ether where after it was dried in an 
oven at 50°C.  Yield: 99% 
 
2PtCl4
Potassium Hexachloroplatinate(IV) (21.0 g, 50.6 mmol) was suspended in 200 ml 
distilled water in a 90°C water bath.  A saturated aqueous solution of sulfur dioxide 
(SO
  
2) was added in 5 mL portions over a time period and sufficient time was 
allowed between additions (approx. 10 minutes) for all the SO2 odour to 
disappear.  The time intervals were gradually lengthen as the reduction neared 
completion.  Addition of SO2 was stopped when only a very small portion of solid 
K2PtCl6 remained in an intense red solution.  The platinum solution was filtered 
while hot, to remove the unreacted K2PtCl6, after which the supernatant was 
concentrated.  During this procedure 5 mL of concentrated HCl was added.  The 
solution was cooled in an ice bath.  The resultant red crystalline K2PtCl4 was 
filtered, washed with acetone, and dried in the oven at 50°C.  Yield: 70-80%   
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2.2.2 Potassium bis-oxalatoplatinum(II) K2Pt(C2O4)
Potassium tetrachloroplatinate(II) (2.08 g, 5.0 mmol) and 16 equivalents of 
potassium oxalate (14.77 g, 79.9 mmol) was dissolved in 30 ml distilled water at 
90°C and stirred for 1 hour maintaining the temperature at 90°C after which the 
reaction mixture was left at 5°C for two hours.  The resultant K
2 
2Pt(C2O4)2·2H2
2.2.3 cis-Diamminedichloroplatinum(II) Pt(NH
O 
precipitate that formed was filtered, washed 5 times with 15 mL distilled water, 
once with 10 mL acetone and dried in an oven at 50°C.  Yield: 95%. 
 
3)2Cl2
2.2.3.1 Preparation of Diamminediiodoplatinum(II) Pt(NH
   
3)2I2
Potassium tetrachloroplatinate(II) (6.0 g, 14.5 mmol) was dissolved in 60 mL water 
to which was added a 20 mL solution containing 10 equivalents KI 
(24 g, 145 mmol).  The solution was stirred for 40 min at room temperature.  While 
stirring 4 mL of concentrated NH
   
3 was added dropwise.  The solution was 
parafilmed and stirred at room temperature for four hours.  The yellow precipitate 
was filtered and washed with 15 mL portions of water, ethanol and diethyl ether 
respectively.  The Pt(NH3)2I2
2.2.3.2 Preparation of Diamminedichloroplatinum(II) Pt(NH
 was dried in the oven at 50°C.  Yield: 95%   
 
3)2Cl2
Silver nitrate, 1.95 equivalents (4.53 g, 26.7 mmol) was dissolved in 20 mL water 
and added to a suspension of Pt(NH
   
3)2I2 (6.6 g, 13.67 mmol) in 20 mL water.  The 
mixture was stirred overnight at room temperature in the dark.  The mixture was 
centrifuged until the supernatant liquid was clear.  This was decanted and filtered 
to remove any remaining AgI.  A solution containing 10 equivalents of lithium 
chloride (5.8 g, 137 mmol) in 15 mL water was added.  The solution was stirred 
overnight at room temperature after which it was cooled at 5ºC for 2 hours.  The 
yellow precipitate was filtered and washed with 15 mL ethanol and diethyl ether 
respectively.  The Pt(NH3)2Cl2 was dried at 50ºC in an oven.  Yield: 85%   
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2.3 Synthesis of the NS-Donor Ligands   
2.3.1 1-Methyl-2-methylthioalkylimidazole   
These ligands were prepared in three consecutive steps.  All these compounds 
were prepared in the same manner as described below.  The difference was that 
in the final step the appropriate alkylthiol was used.   
 
2.3.1.1 1-Methyl-2-methylthioethylimidazole (mmtei) 
Step 1: 
A solution of 1-methylimidazole (46.8 g, 0.57 mol) dissolved in 675 mL of 40 % 
formaldehyde was refluxed for 3 days.  Sodium hydroxide (60 g, 1.5 mol) and 
2 liters of water were subsequently added and the volume reduced to 
approximately 500 mL where after the product was extracted 5 times with 200 mL 
portions of chloroform.  The chloroform portions were combined, dried with 
anhydrous sodium sulfate and the solvent removed by distillation under vacuum.  
A yellow oil of 1-methyl-2-hydroxymethylimidazole was obtained.  Yield 58-60%   
 
Step 2: 
1-methyl-2-hydroxymethylimidazole (37.4 g, 0.33 mol) dissolved in 150 mL pre-
dried chloroform was added dropwise to thionyl chloride (144 mL, 1.99 mol) 
dissolved in 150 mL pre-dried chloroform while maintaining the temperature of the 
reaction solution between 15-20°C.  The solution was subsequently refluxed for 
3½ hours after which the solvent and excess thionyl chloride was removed by 
distillation.  The oil obtained was triturated with a mixture of diethylether:propan-2-
ol (1:1).  The white precipitate of 1-methyl-2-chloromethylimidazole⋅HCl was 
filtered and rinsed twice with diethylether.  Yield 87-89%   
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Step 3: 
Ethanethiol (1.1 mL; 0.055 mol), dissolved in 40 mL of a 5% ethanolic NaOH 
solution (0.05 mol NaOH), was added dropwise to 1-methyl-2-
chloromethylimidazole⋅HCl (10 g, 0.05 mol) also dissolved in 40 mL of a 
5% ethanolic NaOH solution (0.05 mol NaOH).  The mixture was stirred overnight 
at room temperature after which the NaCl formed was filtered and 150 mL dilute 
sodium carbonate solution (± 0.2 M) was added.  The mixture was extracted 
5 times with 100 mL chloroform portions.  The chloroform portions were combined 
and were washed twice with distilled water, dried with anhydrous sodium sulfate 
and the solvent removed under vacuum. The remaining oil was distilled under high 
vacuum (88-90°C at 10 Torr) to yield the yellow 1-methyl-2-
methylthioethylimidazole liquid.  Yield 68-70%   
 
Analysis 
Infrared Data (liquid film) 
ν(C=N) 1678, ν(C=C) 1497, δ(C=N-C=C) 1454, ν(CH2-S) def 1420 cm-1 
ν(CH2-S) wag 1285cm-1   
NMR Data 
1H δ (300 MHz, CDCl3):  1.16 (3H, t, S-CH2-CH3), 2.48  
(2H, m, S-CH2-CH3), 3.63 (3H, s, CH3-N), 3.72 (2H, s, C-CH2
2.3.1.2 1-Methyl-2-methylthiomethylimidazole (mmtmi) 
-S),  
6.78 and 6.82 (2H, 2×s, Ar-H) 
 
Alkylthiol: 21% CH3SNa aqueous solution.   
Properties 
The clear light yellow oil boiled between 80-82°C at ±1 Torr. 
Yield:  65% 
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Analysis 
Infrared Data (liquid film) 
ν(C=N) 1674, ν(C=C) 1497, δ(C=N-C=C) 1454, ν(CH2-S) def 1427 cm-1   
ν(CH2-S) wag 1285 cm-1   
NMR Data 
1H δ (300 MHz, CDCl3):  2.89 (3H, s, S-CH3), 3.50 (3H, s, CH3-N), 3.59 
(2H, s, C-CH2
2.3.1.3 1-Methyl-2-methylthiopropylimidazole  (mmtpi) 
-S), 6.70 and 6.75 (2H, 2×s, Ar-H) 
 
Alkylthiol: propanethiol.   
Properties 
The light yellow oil boiled between 82-86°C at ±1 Torr). 
Yield:  57% 
Analysis 
Infrared Data (liquid film) 
ν(C=N) 1678, ν(C=C) 1497, δ(C=N-C=C) 1458, ν(CH2-S) def 1420 cm-1, 
ν(CH2-S) wag 1285 cm-1   
NMR Data 
1H δ (300 MHz; CDCl3):  0.85 (3H, m, S-CH2CH2-CH3), 1.45  
(2H, m, SCH2-CH2-CH3), 2.38 (2H, t, S-CH2-CH2CH3), 3.59  
(3H, s, N-CH3), 3.69 (2H, s, C-CH2
2.3.1.4 1-Methyl-2-methylthiophenylimidazole  (mmtphi) 
-S), 6.76 and 6.81 (2H, 2×s, Ar-H) 
 
Alkylthiol: thiophenol.   
Properties 
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The light yellow oil boiled between 142-152°C at ±1 Torr. 
Yield:  69% 
Analysis 
Infrared Data (liquid film) 
ν(C=N) 1686, ν(C=C) 1493, δ(C=N-C=C) 1439, ν(CH2-S) wag 1408 cm-1, 
ν(CH2-S) def 1285 cm-1   
NMR Data 
1H δ (300 MHz; CDCl3):  3.59 (3H, s, N-CH3), 4.2 (2H, s, C-CH2
2.3.1.5 1-Methyl-2-methylthiobenzylimidazole (mmtbzi) 
-S),  
6.82 and 6.93 (2H, 2×s, Ar(imd)-H), 7.22-7.43 (5H, m, Ar(ph)-H) 
 
Alkylthiol: benzylthiol. 
Properties 
The light yellow oil boiled between 130-140°C at ±1 Torr. 
Yield:  65% 
Analysis 
Infrared Data (liquid film) 
ν(C=N) 1651, ν(C=C) 1493, δ(C=N-C=C) 1454, ν(CH2-S) wag 1420 cm-1   
ν(CH2-S) def 1285 cm-1   
NMR Data 
1H δ (300 MHz; CDCl3):  3.59 (3H, s, N-CH3), 3.72 (4H, 2×s, C-CH2-S), 6.82 and 
6.93 (2H, 2×s, Ar(imd)-H), 7.22-7.43 (5H, m, Ar(ph)-H) 
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2.4 Syntheses of the Platinum(II) Complexes 
2.4.1 Synthesis of Platinum(II) Complexes with Neutral Bidentate 
NS-Ligands.   
2.4.1.1 Halo-Complexes 
Table 2.1: Colour and yields of the chloro-complexes prepared by the direct method. 
Method A:  (Direct Method)   
Potassium tetrachloroplatinate(II) (0.457 g, 1.10 mmol) was dissolved in 15 mL 
distilled water to which was added dropwise 1.15 molar equivalent of the relevant 
ligand (1.27 mmol) dissolved in 2 mL acetone.  The solution was stirred overnight 
at room temperature after which the resultant precipitate was filtered, washed 
once with 3 mL cold distilled water and dried in oven at 50°C.   
Complex Yield Colour Code 
Pt(mmtmi)Cl2 67   Pink J7.2D 
Pt(mmtei)Cl2 78   Pink J5.2D 
Pt(mmtpi)Cl2 78   Pink J13.2D 
Pt(mmtphi)Cl2 93   Pink J14.2D 
Pt(mmtbzi)Cl2 74   Pink J16.2D 
 
Method B: (Silver method)   
Potassium tetrachloroplatinate(II) (1.0 g, 2.41 mmol) was dissolved in 15 mL 
distilled water at room temperature to which was added dropwise, while stirring, 
10 equivalents of KI (4.0 g, 24.10 mmol) dissolved in 5 mL distilled water.  The 
mixture was stirred for 15 minutes at room temperature after which 10 mL of 
acetone was added.  The relevant ligand, 1.15 equivalents, dissolved in 3 mL 
acetone was added dropwise while stirring.  During the addition of the ligand an 
extra 20 mL of acetone was added simultaneously.  The reaction mixture was 
stirred overnight at room temperature after which the precipitate was filtered and 
oven dried at 50°C.  The precipitate which formed was PtLI2. 
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Table 2.2: Colour and yields of the iodo-complexes. 
Complex Yield Colour Code 
Pt(mmtmi)I2 83   Orange J7.5 
Pt(mmtei)I2 80   Orange J5.5 
Pt(mmtpi)I2 78   Brown J13.5 
Pt(mmtphi)I2 93   Yellow J14.5 
Pt(mmtbzi)I2 74   Brown J16.5 
 
The PtLI2 which was synthesised in the above reaction was suspended in 1.95 
molar equivalents of silver nitrate dissolved in 8 mL distilled water and 2 mL 
acetone.  The suspension was stirred overnight in the dark at room temperature.  
The silver iodide and unreacted PtLI2 were removed by centrifugation.  The 
relevant salt (LiCl or KBr) 10 equivalents was dissolved in a minimum amount of 
distilled water and added dropwise to the [PtL(H2O)2]2+ solution causing the 
precipitation of PtLX2.  The reaction mixture was stirred overnight at room 
temperature which, after the precipitate was filtered, was washed with a small 
portion of distilled water and diethyl ether respectively.  The PtLX2
Table 2.3: Colour and yields of the halo-complexes prepared by the silver method. 
 was oven dried 
at 50°C.   
Complex Yield Colour Code 
Pt(mmtmi)Cl 75 2 Yellow J7.2 
Pt(mmtei)Cl2 60   Yellow J5.2 
Pt(mmtpi)Cl 79 2 Yellow J13.2 
Pt(mmtphi)Cl2 65   Yellow J14.2 
Pt(mmtbzi)Cl 70 2 Yellow J16.2 
Complex Yield Colour Code 
Pt(mmtmi)Br 57 2 Yellow J7.3 
Pt(mmtei)Br2 65   Yellow J5.3 
Pt(mmtpi)Br2 62   Yellow J13.3 
Pt(mmtphi)Br2 65   Yellow J14.3 
Pt(mmtbzi)Br2 50   Yellow J16.3 
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2.4.1.2 Oxalato-complexes 
Table 2.4: Colour and yields of the oxalato-complexes prepared by the direct method. 
Method A:  (Direct Method)   
Potassium bis-oxalatoplatinum(II) bishydrate (0.5 g, 1.03 mmol) was dissolved in 
20 mL distilled water in a 90°C water bath to which was added dropwise, while 
stirring, 1.03 mmol of the relevant ligand dissolved in 2 mL acetone.  The 
platinum(II) solution was stirred for 1½ hours at 90°C and subsequently at room 
temperature overnight. The resultant precipitate was filtered, washed once with a 
5 mL portion of cold distilled water and dried in an oven at 50°C.   
Complex Yield Colour Code 
Pt(mmtmi)(C2O4 55 )  Yellow J7.1D 
Pt(mmtei)(C2O4 52 ) Yellow J5.1D 
Pt(mmtpi)(C2O4 65 ) Yellow J13.1D 
Pt(mmtphi)(C2O4 62 ) Yellow J14.1D 
Pt(mmtbzi)(C2O4 64 ) Yellow J16.1D 
 
Method B: (Silver method)   
The relevant PtLI2 (0.50 g) was suspended in 1.95 equivalents of AgNO3 
dissolved in 8 mL distilled water and 2 mL acetone.  The suspension was stirred 
overnight in the dark at room temperature.  The AgI and unreacted PtLI2 were 
removed by centrifugation.  Potassium oxalate monohydrate, 3 equivalents, was 
dissolved in an minimum amount of distilled water and added dropwise to the 
[PtL(H2O)2]2+ solution causing the precipitation of PtL(C2O4).  The mixture was 
stirred overnight at room temperature which, after the precipitate was filtered, was 
washed with a small portion of distilled water and diethyl ether respectively.  The 
PtL(C2O4) was oven dried at 50°C.   
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Table 2.5: Colour and yields of the oxalato-complexes prepared by the silver method 
Complex Yield Colour Code 
Pt(mmtmi)(C2O4 53 )  Cream J7.1 
Pt(mmtei)(C2O4 62 ) Cream J5.1 
Pt(mmtpi)(C2O4 68 ) Cream J13.1 
Pt(mmtphi)(C2O4 55 ) Cream J14.1 
Pt(mmtbzi)(C2O4 66 ) Cream J16.1 
 
Elemental Analysis 
Table 2.6: Elemental analysis of the iodo-complexes.   
 
Complex 
%C   %H   %N   %S   
Exp Cal Exp Cal Exp Cal Exp Cal 
J7.5 12.3 12.2 1.7 1.7 4.5 4.7 5.4 5.4 
J5.5 15.7 13.9 2.3 2.0 4.4 4.6 4.9 5.3 
J13.5 15.4 15.5 2.3 2.3 4.5 4.5 5.3 5.2 
J14.5 20.4 20.2 1.8 1.9 4.2 4.3 4.8 4.9 
J16.5 22.8 21.6 2.1 2.1 3.7 4.2 5.3 4.8 
 
Table 2.7: Elemental analysis of the chloro-complexes by the silver method.   
 
Complex 
%C   %H   %N   %S   
Exp Cal Exp Cal Exp Cal Exp Cal 
J7.2 17.7 17.7 2.5 2.5 6.6 6.9 7.5 7.9 
J5.2 20.1 19.9 2.9 2.9 6.5 6.6 7.5 7.6 
J13.2 21.8 22.0 3.2 3.2 6.1 6.4 7.2 7.4 
J14.2 28.3 28.1 2.6 2.6 5.6 6.0 6.8 6.8 
J16.2 29.4 29.8 2.9 2.9 5.3 5.8 6.5 6.6 
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Table 2.8: Elemental analysis of the bromo-complexes by the silver method.   
 
Complex 
%C %H %N %S 
Exp Cal Exp Cal Exp Cal Exp Cal 
J7.3 14.3 14.5 1.9 2.0 5.3 5.6 6.4 6.5 
J5.3 16.9 16.5 2.4 2.4 5.4 5.5 6.4 6.3 
J13.3 18.5 18.3 2.7 2.7 5.1 5.3 6.0 6.1 
J14.3 24.0 23.6 2.2 2.2 4.9 5.0 6.0 5.7 
J16.3 25.1 25.1 2.5 2.5 4.5 4.9 5.6 5.6 
 
Table 2.9: Elemental analysis of the chloro-complexes by the direct method.   
 
Complex 
%C %H %N %S 
Exp Cal Exp Cal Exp Cal Exp Cal 
J7.2D 17.4 17.7 2.6 2.5 6.9 6.9 7.7 7.9 
J5.2D 20.5 19.9 2.7 2.9 6.4 6.6 6.3 7.6 
J13.2D 22.3 22.0 3.0 3.2 6.3 6.4 7.3 7.4 
J14.2D 28.3 28.1 2.4 2.6 5.6 6.0 7.0 6.8 
J16.2D 30.4 29.8 2.7 2.9 5.1 5.8 7.2 6.6 
 
Table 2.10: Elemental analysis of the oxalato-complexes by the silver method.   
 
Complex 
%C %H %N %S 
Exp Cal Exp Cal Exp Cal Exp Cal 
J7.1 22.5 22.6 2.4 2.4 6.1 6.6 7.5 7.5 
J5.1 23.9 24.6 2.8 2.8 5.8 6.4 7.3 7.3 
J13.1 26.4 26.5 3.1 3.1 6.3 6.2 7.1 7.1 
J14.1 31.9 32.0 2.5 2.5 5.7 5.8 6.6 6.6 
J16.1 33.1 33.5 2.8 2.8 5.2 5.6 6.3 6.4 
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Table 2.11: Elemental analysis of the oxalato-complexes by the direct method.   
 
Complex 
%C %H %N %S 
Exp Cal Exp Cal Exp Cal Exp Cal 
J7.1D 22.5 22.6 2.4 2.4 6.4 6.6 7.5 7.5 
J5.1D 24.5 24.6 2.8 2.8 6.3 6.4 7.3 7.3 
J13.1D 26.1 26.5 2.8 3.1 5.9 6.2 7.2 7.1 
J14.1D 31.5 32.0 2.5 2.5 5.5 5.8 6.5 6.6 
J16.1D 33.3 33.5 2.9 2.8 5.5 5.6 6.4 6.4 
 
The elemental analyses were satisfactory for most of the complexes but some 
iodo-complexes were impure.  For example, In the case of J16.5 the somewhat 
high percentage for the carbon and sulfur could readily be explained by presuming 
the presence of unreacted ligand.  (Table 2.6)  However, this would not affect the 
syntheses of the complexes using these complexes as starting material.  This was 
confirmed by the fact that the analyses of the bromo- and chloro-complexes by the 
silver method were acceptable.   
 
2.4.2 Synthesis of Platinum(IV) mononitro complexes.   
2.4.2.1 cis-Diamminetrichloronitroplatinum(IV) CPA 7 
Method A: (Patent Method) 
Nitrogen dioxide gas production 
The patents required the use of a NO2 cylinder in the synthesis of CPA 7.  Due to 
the large volume of NO2 required and the high price of a cylinder it was decided to 
synthesize the NO2 gas in situ.  This was accomplished by the dropwise addition 
of concentrated HNO3
 
 on copper metal.   
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Apparatus Setup: 
N2 Gas
Cu Metal
NO2 Gas
Reaction Vessel
Concentrated 
        HNO3
 
Figure 2.1: The graphical representation of the reaction setup for the synthesis of CPA 7 
by method A.   
Synthetic method  
cis-Diamminedichloroplatinum(II) (1.0 g, 3.3 mmol) was suspended in 150 mL ultra 
deionized water and 50 mL dichloroethane.  A 5 mL solution containing 1 
equivalent NaCl was added.  Nitrogen dioxide gas was bubbled through the 
solution while stirring at room temperature until a blue solution was formed.  The 
mixture was stirred overnight in the dark at room temperature.  The volume of the 
solution was reduced by blowing air over it stirring for two days.  The resultant 
precipitate was washed with 15 mL diethyl ether and filtered.  The product was 
dried overnight in an oven at 50°C.   
Yield: 90% 
Colour: Yellow 
Purity: 20% 
 
cis-Diamminedichloroplatinum(II) (1.0 g, 3.3 mmol) was suspended in 100 mL 
absolute acetone. Nitrogen dioxide gas was bubbled through the solution while 
stirring at room temperature for 1 hour until a yellow solution was formed.  The 
Method B: (Acetone Method) 
~ 43 ~ 
 
volume of the solution was reduced by blowing air over it at room temperature 
while stirring overnight.  The resultant precipitate was suspended in 15 mL methyl 
acetate, filtered and washed twice with 3 mL aliquots of methyl acetate.  The 
product was dried overnight in an oven at 50°C.   
Yield: 38% 
Colour: Cream  
Purity: 83% 
 
Method C: (Nitric Acid Method) 
Cis-Diamminedichloroplatinum(II) (1.0 g, 3.3 mmol) was suspended in 10 mL 
concentrated HNO3
2.4.2.2 Diamminetetrachloroplatinum(IV) Pt(NH
 (69%) in a closed system.  The solution was stirred overnight 
at room temperature.  The resultant precipitate was filtered and washed twice with 
3 mL aliquots of methyl acetate.  The product was dried overnight in an oven at 
50°C.   
 
Yield: 36% 
Colour: Cream  
Purity: 96% 
3)2Cl4 
The same apparatus setup was used as for the CPA 7 synthesis.  
Cis-Diamminedichloroplatinum(II) (1.0 g, 3.3 mmol) was suspended in 100 mL 
absolute acetone. Chlorine gas was bubbled through the solution while stirring at 
room temperature for 4 hours until a yellow solution was formed.  The chlorine gas 
was produced by the dropwise addition of concentrated HCl on solid KMnO
Method A:  
4.  The 
volume of the solution was reduced by blowing air over it at room temperature 
while stirring overnight.  The resultant precipitate was suspended in 15 mL ether, 
filtered and washed twice with 3 mL aliquots of ether.  The product was dried 
overnight in an oven at 50°C.   
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Yield: 95% 
Colour: Yellow  
Purity: 28% 
 
i. Nitrosyl gas production
Method B:  
86
The NOCl gas was produced by the slow dropwise addition of concentrated HCl 
on solid NaNO
 
2
N2 Gas
NaNO2
NOCl gas
Reaction Vessel
B
Concentrated 
        HCl
A
Drying Tube with 
Anhydrous CaCl2
C
.  The apparatus used is shown below.  Three drying tubes A, B 
and C were attached containing, sodium nitrite (to absorb hydrogen chloride), 
potassium chloride which has been moistened with an amount of water equivalent 
to 2.4% of its dry weight (to absorb nitrogen dioxide), and anhydrous calcium 
chloride respectively.   
 
Figure 2.2: The graphical representation of the apparatus for the in citu preparation of 
nitrosyl chloride.   
 
ii. Synthetic method 
cis-Diamminedichloroplatinate(II) (1.0 g, 3.3 mmol) was suspended in 100 mL dry 
absolute acetone. Nitrosyl chloride gas was bubbled through the solution while 
stirring at room temperature, for 4 hours, forming a green solution.  The solution 
was stirring overnight at room temperature while bubbling air through it.  The 
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resultant yellow precipitate was filtered and washed twice with 10 mL aliquots of 
ether.  The product was dried overnight in an oven at 50°C.   
Yield: 80% 
Colour: Yellow  
Purity: 95% 
 
2.5 Analysis Techniques 
2.5.1 Elemental Analysis 
Microanalysis for C, H, N, and S was performed at the University of Cape Town.  
The samples were analysed by a Fisons Elemental Analyser 1108 CHNS-O.   
2.5.2 Infrared Spectroscopy 
Infrared spectra were recorded in the range 4000-200 cm-1
2.5.3 NMR Spectrometry 
 using the single beam 
mode using an Excalibur HE FTS3100 spectrophotometer.  Solid samples were 
compressed with dry potassium bromide into discs and scanned with nitrogen gas 
as reference.  Liquid samples were spread as a thin film between sodium chloride 
plates and scanned using the empty plates as reference.   
 
The 300.13 MHz 1H-NMR spectra were recorded on a Bruker 300 MHz 
spectrometer using SiMe4 as the internal standard.  The samples were prepared 
using CDCl3 as solvent.   
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2.5.4 Inductively-Coupled Plasma Emission Mass Spectrometry. 
(ICP-MS)  
The platinum content of the samples prepared for both the solubility studies and 
cytotoxicity testing were analysed using a Perkin Elmer SCIEX Elan-6100 ICP-MS 
Spectrometer.  The ICP settings used are given below in Table 2.12.   
Table 2.12: General ICP settings used. 
 Settings 
RF Power 1.4 kW 
Coolant gas 15 L/min 
Nebulizer gas flow 0.7 L/min 
Dwell time per AMU 50 ms 
Sweeps/reading 10 
Readings/replicate 2 
Replicate 10 
 
The isotopes 194Pt and 195
2.5.5 Fast Atom Bombardment (FAB) Mass Spectrometry 
Pt were used for optimal analysis.  The standards and 
samples were prepared in 0.1 M HCl aqueous medium.  The concentrations were 
in the range of 5-1000 µg/L.   
 
FAB mass spectra were obtained from the University of Potchefstroom.  The 
spectra were recorded on a VG70-70E mass spectrometer using a VG2035 data 
system.  All samples were analysed under positive-ion operating conditions.  An 
Ion Tech saddle-field using xenon as bombardment gas (8 kV, 1 mA) was 
employed to record the spectra.  The mass spectrometer was operated at 6 kV 
and the magnetic analyser was scanned at 5 s per decade between 500-100 Da. 
The matrix used was glycerol or 3-nitrobenzylalcohol.   
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2.5.6 Electrospray Ionization Mass Spectrometry (ESI-MS) 
Electron spray mass spectra were obtained from Shimoda Biotech.  
Measurements were carried out on an LCQ Deca instrument (Finnigan, San Jose, 
CA, USA) in either positive or negative ionization mode.  For infusion studies the 
samples, in appropriate solvent, were directly infused at a flow rate of 10 μL/min 
using a 500 μL Unimetrics HPLC syringe and the instruments own syringe pump.  
A 50% MeCN/10 mM ammonium formate/0.06% formic acid solution was used as 
sheath liquid at a flow rate of 150 μL/min.  The tip of the fused silica capillary (i.d. 
100 μm, o.d. 190 μm) was positioned 0.5 to 1.0 mm inside the tip of the stainless 
steel sprayer capillary allowing direct contact with the analysis solution.  The 
electrospray atmospheric pressure ionization probe was maintained in position 2.  
The parameters of the instrument were tuned utilising an infusion solution of 
Pt(dach)Cl2
• Positive ion mode instrument settings 
 in MeCN (10 μM at 10 μl/min). 
The instrument parameters were tuned using the ammonium adduct [M+NH4]+
Table 2.13
.  
The following settings were used:  ( ) 
Table 2.13: Positive ion mode settings.   
 Settings 
Nitrogen sheath gas flow rate 80 arbitrary units 
Nitrogen auxiliary gas flow rate 20 arbitrary units 
Sprayer voltage 3.5 kV 
Capillary voltage 46.0 V 
Tube lens offset 55.0 V 
Multipole 1 offset -5.25 V 
Lens 49 voltage -28.0 V 
Multipole 2 offset -10.00 V 
Multipole RF amplitude (V p-p) 400 V 
Entrance lens -62.0 V 
Maximum injection time 100 ms 
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• Negative ion mode instrument settings 
The parameters of the instrument were tuned using the formate adduct 
[M+HCOO]- Table 2.14.  The following settings were used:  ( )   
Table 2.14: Negative ion mode settings.   
 Settings 
Nitrogen sheath gas flow rate 80 arbitrary units 
Nitrogen auxiliary gas flow rate 20 arbitrary units 
Sprayer voltage 5.0 kV 
Capillary voltage -12.0 V 
Tube lens offset 5.0 V 
Multipole 1 offset 5.25 V 
Lens 49 voltage 46.0 V 
Multipole 2 offset 10.00 V 
Multipole RF amplitude (V p-p) 400 V 
Entrance lens 38.0 V 
Maximum injection time 100 ms 
 
2.5.7 EV-CAD 
The ability to select and isolate specific ions for further fragmentation studies 
provides another method for the characterisation of the analytes.  In mass spectral 
studies sufficient energy is applied to the trap to effect the fragmentation e.g. 
[M+NH4]+ → [M-X+S]+ or [M-X+S]+ → [M-2X-H+S]+.  By stepwise application of a 
supplementary RF voltage (0-5 V) to the end caps of the ion trap, the energy 
within the trap is increased.  The selected complex begins to fragment i.e. collision 
associated dissociation (CAD) occurs.  The fragmented ions (daughter ions) are 
then detected yielding a mass spectrum.   
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The curve constructed from the amount of energy applied to the trap (X-axis) 
versus the decrease in ion abundance (Y-axis) of the specific ion cluster is known 
as an EV-CAD curve.  The E½ values are defined as the collision energy required 
for a 50% drop in the relative ion abundance of the precursor complex.87
2.5.8 HPLC-UV  
   
Liquid Chromatography separations were performed on a Waters HPLC system 
consisting of a WISP 717 autosampler, 600E quaternary gradient pump and 484 
variable wavelength UV-Vis detector.  Two HPLC separation columns were used 
during this study.  The samples were prepared in a 2.5% acetonitrile solution 
before injection.  The flow rate was altered from 1.2 – 0.8 mL/min.  The 
specifications of each are listed in Table 2.15.  
Table 2.15: HPLC separation columns used during this study.   
Supplier Phase Dimension 
YMC Hydrosphere C18 
120 Å 5 μm 
250 x 4.6 mm 
Phenomenex Curosil PFP 5 μm 250 x 4.6 mm 
 
2.5.9 Thermal gravimetric analysis (TGA) 
TGA were performed on a TGA 2050 Thermogravimetric Analyser using 
TA instrument-Advantage software for Thermal Analysis.  The data obtained was 
analysed using a TA Universal Analysis 2000 program.  All samples were heated 
at a rate of 4°C / minute in a nitrogen atmosphere.  
 
2.5.10 Cyclic Voltammetry  
Cyclic voltammetric experiments were performed on a BAS100-Epsilon instrument 
at 25°C with a scan rate of 100 mV/s. Each platinum(IV) complex was dissolved in 
0.1 M KCl solution to a final concentration of 2.1 mM. Nitrogen was bubbled 
through the solution to remove oxygen. A glassy carbon electrode was used as the 
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working electrode, Ag/AgCl was used as the reference electrode, and a platinum 
wire used as the auxiliary electrode. 
2.5.11 Solubility Studies 
The solubilities of the complexes was measured by suspending the compound in 
2 mL water and stirring at room temperature for 30 min at 25°C after which the 
mixture was centrifuged until the supernatant liquid was clear.  The supernatant 
liquor was diluted so that the platinum concentrations were suitable for ICP-MS 
analysis.  In most cases a 1000 times dilution was sufficient.   
 
2.5.12 Crystallographic Analysis 
Full X-ray structure determinations were performed on three platinum complexes.  
The diffraction data was collected at the University of the Witwatersrand using a 
Bruker SMART 1K CCD area detector diffractometer with graphite 
monochromated MoKα radiation (50 kV, 30 mA).  The collection method involved 
ω-scans of width 0.3°.  Data reduction was carried out using SAINT+ (Bruker, 
1999)88 and absorption corrections were made using the program SADABS 
(Sheldrick,1996)89. 
The WinGX 1.64.0290 suite of programs was used to solve the crystal structures 
using either direct methods or the Pattersen approach. Refinement was done 
using SHELXS-9791.  Non-hydrogen atoms were first refined isotropically followed 
by anisotropic refinement by full matrix least-squares calculation based on F2. 
Hydrogen atoms were positioned geometrically and allowed to ride on their 
respective parent atoms with one exception. Torsional angles and least squares 
planes of selected atoms were calculated using PARST92.  Diagrams were 
generated using ORTEP93
2.5.13 Cytotoxicity Evaluation 
. 
 
All the complexes prepared in this thesis were tested for anticancer action 
according to known literature methods94,95 by the Biochemistry department of the 
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Nelson Mandela Metropolitan University under the supervision of Dr. M. van de 
Venter.  The compounds were tested on colon (Ht 29), breast (MCF 7) and 
cervical cancer (HeLa) cell lines. Cisplatin was used as reference. A summary of 
the general method used is given below.   
 
The complex to be tested was dissolved in RPMI 1640 and 10 % foetal calf serum 
and incubated at 37°C for 30-45 minutes to produce a 200 μM solution.  Cisplatin 
was similarly dissolved such that it produced a 1 mM solution. The solution was 
subsequently filtered through a syringe filter (0.22 μm filter) before use.  Three 
dilutions were used for anticancer testing namely 10, 50 and 100 μM and the 
above solutions were diluted accordingly.  The actual concentrations of these 
samples were obtained by analysing samples of them by ICP-MS.  Seed cells 
were prepared at a density of 6000 cells / well in a 96-well plate and incubated at 
37°C for 22-28 hours.  The medium was removed and 200 μL of the 10, 50 and 
100 μM complex solutions were added and allowed to incubate at 37°C for 
24-48 hours.  A MTT assay was performed to determine the amount of active cells 
remaining.   
 
Dose response curves will be prepared for selected complexes, as well as positive 
controls, in order to obtain IC50 values.  The concentrations used will be 100, 50, 
25, 10, 5 and 1 µM.  IC50
2.5.14 Chemicals Used 
 values will be calculated from the log-dose response 
curves using GraphPad Prism 4.   
 
CHEMICAL SUPPLIER 
Acetone  (99%)  SMM Chemicals 
Acetonitrile  (99.8%)  Riedel-de Haen 
Ammonium solution (25%)  Associated Chemical Enterprises(ACE) 
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CHEMICAL SUPPLIER 
Benzyl mercaptan  (>99%) Fluka 
n-Butyl Acetate  Merck 
Calcium Chloride Anhydrous Merck 
Chloroform  (99%) Unilab 
Copper Metal (99.8%) Riedel-de Hean 
Diethyl ether  (99%) SaArchem 
Diethyl Oxalate Fluka 
Dichloromethane AR SMM 
Di-iso-Butyl Ketone Merck 
Dimethyl formamide  (99%) Minema 
2,2-Dimethoxy Propane Fluka 
Ethanol  (95%) Merck 
Ethanethiol  (97%) Aldrich 
Ethyl Acetate SaArchem 
Formaldehyde 40% ACE 
Hydrochloric acid  (37%) SMM Instruments 
Isopropanol  (99%) Minema 
Lithium Chloride Fluka 
Methanol  (99.5%) SaArchem 
1-Methylimidazole  (≥99%) Fluka 
Methyl Acetate Fluka 
4-Methyl-2-Penatone Aldrich 
Nitric acid  (69%) Riedel-de Haen 
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CHEMICAL SUPPLIER 
Nitrogen  (99.999) Afrox 
Platinum metal  (99.9999%) Impala platinum 
Potassium bromide  AR ACE 
Potassium chloride  AR SaArchem 
Potassium hydroxide pellets  GPR Labchem 
Potassium iodide  AR SMM Instruments 
Potassium oxalate monohydrate  (99.5%) Riedel-de Haen 
Potassium permangenate SaArchem 
Propanethiol  (99%) Aldrich 
Silver nitrate  (99%) SaArchem 
Sodium carbonate anhydrous AR Unilab 
Sodium hydroxide pellets AR Labchem 
Sodium Nitrite SaArchem 
Sodium sulphate anhydrous AR ACE 
Sodium thiomethyl 21% Aldrich 
Tert-Butyl Alcohol Fluka 
Tetrahydrofuran SaArchem 
Thionyl chloride  (99%) Fluka 
Thiophenol  (98%) Merck-Schuchardt 
Toluene  (99%) SMM Chemicals 
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CHAPTER 3 
PLATINUM(II) COMPLEXES WITH 
BIDENTATE NS LIGANDS 
3.1 Introduction   
The biological activity of platinum anti-tumour agents is controlled by their complex 
chemical reactions with various biomolecules throughout the body.  It is generally 
accepted that platinum(II) drugs such as cisplatin, cis-PtCl2(NH3)2, when reaching 
the cellular target DNA, form 1,2-intrastrand cross-links with the aromatic nitrogen 
atom (N7) of the guanine bases which act as cytotoxic adducts.96  A relatively 
small percentage of the drug reaches the target.  This is due to the removal of the 
drug by “side reactions” with biochemicals in the blood and normal tissue in 
organs.97  These side reactions lower the efficiency of the anticancer action and 
lead to various toxicities, for example nephrotoxicity, gastrointestinal toxicity and 
possible bone marrow suppression.98  Sulfur donor molecules such as glutathione, 
cysteine and methionine plays important roles in these “secondary reactions”.99  
This can be related to the strong interaction between platinum(II) and “soft” sulfur 
donors.  These reactions are very complex due to a number of factors of which 
thermodynamic and kinetic factors are probably the most important.   
 
Studies regarding relative donicities of sulfur donors suggest that they can be 
divided into two groups with reference to their action on platinum(II) complexes.  
Firstly, those with σ-donor π-donor capabilities such as thiolates and thiourea.100  
These ligands react irreversibility with platinum(II).  Secondly, groups containing 
σ-donor π-acceptor sulfur atoms such as thioethers, and dimethylsulfoxide.  These 
can be substituted by the N7 atom of guanine to give the thermodynamically more 
stable Pt-nucleobase adducts.   
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Kinetic factors play an important role since in spite, of the above thermodynamic 
effect, the platination of sulfur donors, such as thioethers, occurs in two hours 
whereas that of the N7 16 of guanine takes 15 hours under comparable conditions.   
These kinetic differences are likely to play a role in the “protective action” of sulfur 
donors and the possibility of creating a “drug reservoir”.5   
 
Although progress has been made in understanding the various facets of 
platinum-sulfur interaction with regard to their anticancer behaviour the 
simultaneous equilibria involved are numerous and exclusive interpretations are 
not readily reached.4,5,101
In light of the need for more information regarding the action of sulfur donor 
ligands in anticancer action of platinum(II) complexes, a project was initiated to 
study the properties of platinum(II) complexes.  The thioether group was 
specifically chosen rather than the more dominant thiol group, since it was known 
that the latter reacts virtually irreversibly with platinum(II) under the pH values 
operative in a biological system.  A bidentate ligand with a thioethereal sulfur atom 
in combination with an aromatic nitrogen donor atom, which can potentially act as 
a five-membered chelate with platinum(II), was selected.  The donicity of the 
thioetherial sulfur could somewhat be limited by attaching an electron withdrawing 
group such as benzyl to the sulfur.  The resultant platinum(II) complex would still 
be thermodynamically and kinetically stable.  The basic structure selected to 
achieve this was N-alkyl-2-methylthioalkyl/aryl imidazole.  (
   
 
Figure 3.1)   
N
N
R1
CH2SR2
where R1 = always CH3
           R2 = CH3, C2H5, C3H7, phenyl, benzyl  
Figure 3.1: The NS Donor Ligands. 
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These non-leaving groups would allow ligand substitution to occur thus facilitating, 
a change to the stereochemistry, hydrophobicity and sulfur donor strength.  This 
enabled a study of the influence of these parameters on anticancer action to be 
studied.   
 
A change in the R2
i. An increase in chain length and subsequently inductive effect increases the 
donor strength of the ligands.   
 group changes the above parameters.  For example:   
ii. Introduction of a phenyl substituent reduces the donicity of the sulfur atom 
while simultaneously enhancing its π-acceptor capability.   
iii. A benzyl substituent introduces an angular plane which is shown in 
literature to enhance anticancer action.102
iv. An increase in organic bulk of the ligands increases hydrophobicity of the 
complexes but limits their aqueous solubility.   
   
Molecular modelling calculations were performed to obtain information regarding 
the extent of the steric effect of the substituent on the R2
A)  
 group of the ligands.  
Space filling (A) diagrams were obtained which were useful in illustrating the steric 
hindrance.  For clarity the ball-and-stick (B) diagrams were also obtained.   
  B)  
Figure 3.2: The space filling as well as the ball-and-stick model of mmtmi.   
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A)    B)  
Figure 3.3: The space filling as well as the ball-and-stick model of mmtei.   
A)    B)  
Figure 3.4: The space filling as well as the ball-and-stick model of mmtpi.   
A)   B)  
Figure 3.5: The space filling as well as the ball-and-stick model of mmtphi.   
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A) B)  
Figure 3.6: The space filling as well as the ball-and-stick model of mmtbzi.   
The above diagrams illustrate the structures of the free ligands in their lowest 
energy state. Minor structural rearrangement of the ligands would be required to 
form a five membered chelate ring upon complexation with the platinum.  The 
number of permutations resulting from isolating complexes using the above 
ligands and various anionic leaving groups were large.  In order to simplify 
identification of the complexes the following conventions were adopted:   
Jx (where x = a integer) refers to the dicationic part of the platinum(II) complex.   
• J7 = 1-methyl-2-methylthiomethyl imidazole (mmtmi) eg. [Pt(mmtmi)] part 
• J5 = 1-methyl-2-methylthioethyl imidazole (mmtei) 
• J13 = 1-methyl-2-methylthiompropyl imidazole (mmtpi) 
• J14 = 1-methyl-2-methylthiomphenyl imidazole (mmtphi) 
• J16 = 1-methyl-2-methylthiombenzyl imidazole (mmtbzi) 
The type of leaving group is indicated by an additional integer.   
• .2 indicates the chloro   
• .3 indicates the bromo   
• .5 indicates the iodo   
For example J7.2 indicates [Pt(mmtmi)Cl2]   
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The addition of a D indicates that the direct method was used in the synthesis, for 
example, J7.2D.   
Besides studying the effects of changing the structures of the thioimidazole 
non-leaving groups the effect of the leaving groups were also investigated.  The 
leaving groups were limited in this study to the halogens.  The synthesis of the 
ligands and their platinum(II) complexes employing different counterions were 
reported in Chapter 2.   
 
3.2 NS Bidentate Ligands   
3.2.1 General Synthetic Method   
The synthesis of the NS bidentate ligands required the monoalkylated imidazole 
1-methylimidazole as a precursor.  This chemical was commercially available.  
The method used to synthesize the 2-methylthio-1-alkylimidazole ligands required 
the reaction of the monoalkylated imidazole with formaldehyde which yielded the 
2-hydroxymethylimidazole derivative.  This product was reacted with thionyl 
chloride to produce the corresponding alkyl halide.  The alkyl halide was reacted 
with the appropriate thiol-derivative to yield the 2-methylthioimidazole ligand.  
Individual detailed synthetic procedures are described in Chapter 2.   
 
3.2.2 Characterization of the Ligands   
3.2.2.1 NMR Spectroscopy   
The purity of the synthesized ligands was confirmed by 1
3.2.2.2 Infrared Spectroscopy 
H-NMR spectroscopy.  
The spectral data can be viewed in Chapter 2.   
 
Observed infrared spectral bands were consistent with those expected for the 
functional groups in the ligands.  Spectral data of the ligands were then used to 
interpret the infrared spectra of the corresponding complexes.  All the spectral 
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data are tabulated in Table 3.1.  A spectrum of the ligand mmtmi is shown in 
Figure 3.7.   
 
 
 
 
Table 3.1: Selected infrared spectral data of the NS bidentate ligands and their corresponding complexes.   
Ligand/ 
Complex 
υ(C=N) υ(C=C) ring δ(C=N-C=C) υ(CH2 υ(CH-S) def 2 υ(Pt-N) -S) wag υ(Pt-X) 
mmtmi 1674(m) 1497(s) 1454(m) 1427(m) 1285(s)     
J7.2 1653(s) 1503(s) 1457(m) 1420(s) 1266(s) 480(m) 341(s) 
J7.2D 1636(s) 1493(s) 1458(m) 1420(s) 1265(m) 482(w) 320(s) 
J7.5 1653(s) 1497(s) 1457(m) 1420(s) 1260(m) 478(s) - 
J7.3 1653(s) 1497(s) 1456(m) 1418(m) 1265(s) 478(m) - 
                
mmtei 1678(m) 1497(s) 1454(s) 1420(m) 1285(s)     
J5.2 1636(m) 1501(s) 1444(m) 1407(m) 1260(m) 480(s) 334(s) 
J5.2D 1636(s) 1497(s) 1451(s) 1400(m) 1270(s) 490(w) 320(s) 
J5.5 1653(m) 1497(s) 1443(m) 1400(m) 1260(s) 473(m) - 
J5.3 1620(m) 1500(s) 1447(m) 1406(m) 1261(m) 474(w) - 
                
mmtpi 1678(m) 1497(s) 1458(s) 1420(m) 1285(s)     
J13.2 1636(s) 1499(s) 1456(s) 1402(m) 1265(m) 478(m) 322(s) 
J13.2D 1639(w) 1504(s) 1458(m) 1404(s) 1246(w) 486(m) 323(s) 
J13.5 1636(s) 1496(s) 1458(s) 1400(s) 1267(m) 482(s) - 
J13.3 1637(m) 1497(s) 1458(s) 1402(s) 1260(s) 482(s) - 
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Table 3.1: Continue  
Ligand/ 
Complex 
υ(C=N) υ(C=C) ring δ(C=N-C=C) υ(CH2 υ(CH-S) def 2 υ(Pt-N) -S) wag υ(Pt-X) 
mmtphi 1686(m) 1485(s) 1439(s) 1408(s) 1285(s)     
J14.2 1636(m) 1496(s) 1443(s) 1406(s) 1280(w) 492(s) 320(s) 
J14.2D 1635(m) 1501(s) 1443(m) 1400(s) 1280(w) 486(m) 327(s) 
J14.5 1640(m) 1498(s) 1441(s) 1400(m) 1280(m) 489(s) - 
J14.3 1653(s) 1506(s) 1441(m) 1404(s) 1285(m) 492(s) - 
                
mmtbzi 1651(m) 1493(s) 1454(s) 1420(m) 1285(s)     
J16.2 1621(m) 1497(s) 1453(s) 1402(m) 1250(m) 474(m) 314(s) 
J16.2D 1635(m) 1497(s) 1454(s) 1419(m) 1285(w) 482(m) 327(s) 
J16.5 1635(m) 1494(s) 1452(s) 1409(m) 1261(m) 480(m) - 
J16.3 1635(s) 1497(s) 1456(m) 1416(m) 1275(w) 482(m) - 
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Figure 3.7. The infrared spectrum of mmtmi.   
All infrared spectra of the ligands exhibited υ(C=N) stretch in the 1650 cm-1 region, 
υ(C=C) ring vibration stretch in the 1500 cm-1 region and δ(C=N–C=C) ring 
vibration stretch in the 1450 cm-1 region.103  The υ(C=N) stretch frequency of the 
imidazole undergoes a shift upon coordination, making it the most informative.  
The υ(CH2-S) def and υ(CH2-S) wag were two other bands which shift upon 
coordination.  These were found in the region 1420 cm-1 and 1280 cm-1 
respectively.104,105,106
Figure 3.7
  The infrared spectrum of mmtmi showing the above 
assignments are shown in .   
 
3.3 The Halo-Complexes   
3.3.1 Introduction   
The methods for the preparation of these compounds were given in the 
experimental Chapter.  During the development of these methods it was realised 
that the nature and purity of these products were a function of the sequence in 
~ 64 ~ 
 
which leaving and non-leaving groups were added.  The effect of this sequence on 
the purity of a specific complex was investigated.  For this reason two procedures 
were studied for each of the Pt(NS)X2
3.3.1.1 Direct Method (D)   
 where X = I, Br, Cl complexes.  The first 
was the direct ligand exchange method (D) and the second the silver method (Ag).   
 
Since extensive studies were performed in this laboratory on the synthesis of 
oxaliplatin by the direct ligand exchange and since this method produced good 
results with diamines, it was thought worthwhile to apply it to the preparation of 
thioimidazole complexes.107  Furthermore it was previously shown that palladium 
complexes could be prepared in this way.108  In the case of the reaction of diamine 
ligands (NN) with K2PtCl4 mixtures of the auto-ionized [PtCl4]2- [Pt(NN)2]2+ specie 
and the molecular Pt(NN)X2 specie were detected.  When this method was applied 
in the synthesis of the Pt(NS)X2 pale pink solids were obtained.  The pink colour of 
the compound raised the suspicion that [PtCl4]2-
Figure 3.8
 was present.  The species 
composition of these products could not be determined unambiguously by 
common analytical methods such as CHNS analysis and infrared spectroscopy.  
Fast atom bombardment mass spectrometry (FAB) indicated the presence of 
molecular ion species in all complexes prepared by this method but for some 
complexes the auto-ionized species were also present.  (  and Figure 
3.9)   
 
Figure 3.8: FAB mass spectrum of J7.2D showing molecular specie. 
Molecular specie 
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Figure 3.9: FAB mass spectrum of J5.2D showing both auto-ionized and molecular 
species. 
Application of the electrospray ionization mass spectrometry (ESI-MS) revealed 
the presence of both species in solutions of all compounds.  The reason for this 
discrepancy will be discussed later.  In light of the results obtained from the study 
of the direct method this method was not applied further.   
 
3.3.1.2 Silver Method (Ag)   
The fact that the previous method resulted in mixtures prompted a modification of 
the synthetic method for the platinum(II) complexes.  An important factor in the 
formation of the auto-ionized specie was the extent of the ion pairing between 
[Pt(NS)2]2+ and [PtCl4]2-.  Furthermore the stability of [PtCl4]2- also affects the 
formation of the auto-ionized specie.  This prompted to proceed over the 
iodo-complex.  Thus the coordinated iodide would have to be removed by the 
addition of Ag+.  This initially brought doubt about whether the ‘silver method’ could 
be used, knowing the high affinity of Ag+
K2PtCl4  +  4I- K2PtI4  +  NS Pt(NS)I2
Pt(NS)I2  +  2Ag+NO3- Pt(NS)(H2O)2
2+  +  2Cl-  +  AgI Pt(NS)Cl2
 for sulfur donors.  However, the great 
stability of AgI prevented interference from the thioether group.  The method for 
the synthesis of the platinum(II) complexes was similar to the method used to 
synthesize cisplatin.  The reaction sequence for the silver method is given below.   
 
 
Auto-ionized species Molecular species 
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The iodo-complexes formed proved to be virtually the pure molecular species.  As 
a result these complexes could be used to prepare the analogues chloro- and 
bromo-complexes in the molecular from.   
 
Our initial investigation not to use the silver method rested on the knowledge of the 
high affinity of Ag+ for sulfur.  The fact that this did not happen needed to be 
explained.  The rationalisation consisted of two parts.  Firstly, it is known that silver 
prefers linear coordination.  For example, ammine-complexes are more stable 
than the ethylenediamine complexes due to the requirement of linear coordination.  
This requirement may be the reason why Ag+ does not compete with platinum(II) 
for the sulfur in the case of the NS chelate ligands.  Especially since the square 
planar platinum(II) can accommodate the chelate ligand.  Secondly, the great 
stability of AgI.  The Ag+ reacts with the freed iodide ions as the ligand displaces 
them, thus lowering the iodide concentration continually.  After the addition of Ag+ 
the platinum is in the [Pt(NS)(H2O)2]2+ state possibly with some coordinated nitrate 
groups as well.  The addition of two moles chloride rapidly promotes the neutral 
complex formation.  (Pt(NS)Cl2) 
 
In the direct method the NS ligand will almost instantaneously replace the 
equivalent in chloride ions thus increasing the free chloride ion concentration.  It is 
therefore possible that a small amount of [PtCl4]2- can form especially if the 
stability of [Pt(NS)2]2+
3.3.2 Characterization of the Complexes 
 is large.  Thus producing the auto-ionized specie or 
mixtures.  This is dependent on the relative solubility.   
 
The results of the CHNS analysis are given in Chapter 2.  These results could not 
differentiate between different structural forms having the same empirical formula, 
for example [Pt(NS)X2] vs [PtX4]2- [Pt(NS)2]2+   
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In order to obtain the chemical structure of the complexes infrared spectroscopy 
and mass spectrometry data was used.   
 
3.3.2.1 Infrared Spectroscopy   
The infrared spectra of all the complexes were obtained and tentative assignments 
of the informative vibrations are provided in Table 3.1.  The infrared spectrum of 
J5.2 is shown below in Figure 3.10.  The shifts in the ν(C=N), ν(CH2-S) def and 
ν(CH2
Table 
3.2
-S) wag frequencies with respect to those of the free ligand were an 
indication that both the nitrogen and the sulfur atom of the ligand coordinated with 
the platinum.  The shifts obtained for all these complexes are tabulated in 
.  A further indication of coordination bond formation was the identification of 
the ν(Pt-N) and ν(Pt-X) stretch frequencies.   
 
Figure 3.10: The infrared spectrum of J5.2.   
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Table 3.2: The ν(C=N), ν(CH2-S) def and ν(CH2
Complex 
-S) wag shifts of the halo-complexes.   
υ(C=N) 
υ(CH2
υ(CH
-S) 
def 2
Shifts 
-S) wag 
Shifts Shifts 
J7.2 -21 -7 -19 
J7.2D -38 -7 -20 
J7.5 -21 -7 -25 
J7.3 -21 -9 -20 
J5.2 -42 -13 -25 
J5.2D -42 -20 -15 
J5.5 -25 -20 -25 
J5.3 -58 -14 -24 
J13.2 -42 -18 -20 
J13.2D -39 -16 -39 
J13.5 -42 -20 -18 
J13.3 -41 -18 -25 
J14.2 -50 -2 -5 
J14.2D -51 -8 -5 
J14.5 -46 -8 -5 
J14.3 -33 -4 0 
J16.2 -30 -18 -35 
J16.2D -16 -1 0 
J16.5 -16 -11 -24 
J16.3 -16 -4 -10 
 
The ligands showed negative υ(C=N) and υ(CH2
108
-S) shifts upon complex 
formation.   These negative shifts indicated delocalization of electrons from the 
ligand to the Pt-N and Pt-S bonds.  These values for the chloro-complexes were 
quite similar to the analogous palladium(II) complexes previously synthesized in 
these laboratories.    
 
It was hoped that a detailed study of the above shifts would provide evidence for 
the auto-ionized specie.  The υ(C=N) shifts in the spectra revealed no conclusive 
evidence of a trend when changing the leaving groups from iodide to chloride.  
This, however, is only partially true when keeping the leaving group constant and 
altering the R2 group.  In the case of the bromide and iodide there is a perceivable 
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trend.  The chloro-complexes, Silver method, showed an increase in shift as one 
move from methyl to propyl with the phenyl having the highest shift.  The benzyl 
did not fit in the trend.  The fact that the phenyl derivative had the highest υ(C=N) 
shifts suggested particularly strong Pt-N interaction.  Comparing the shifts 
obtained from the spectra of the compounds prepared by the direct method of 
those by the silver method a difference was seen.  However, no trends could be 
identified.   
 
The υ(Pt-N) stretch bands for the complexes were all assigned in the region 
482-470 cm-1 105.   When comparing the bands of the compounds prepared by the 
direct method with those of the silver method it was found that in general the 
bands had higher energy and lower intensity.   
 
The υ(Pt-X) stretch frequency could only be identified in the chloro-complexes.  
The reason for this was that the υ(Pt-Br) and υ(Pt-I) stretches occur at low 
frequency which was beyond the practical range of the instrument.  The medium 
intensity band between 340-315 cm-1
105
 were assigned to the υ(Pt-Cl) stretch 
frequency.   These bands were either split or even double.  This was indicative 
of a cis conformation.   
 
3.3.2.2 Mass Spectrometry   
The mass spectra of the compounds were determined by two different methods, 
namely, fast atom bombardment (FAB) and electron spray ionisation (ESI).  These 
spectra can be viewed at the end of the chapter.  In the former the sample was 
injected as a suspension in a non-polar solvent.  This method mainly identified the 
compounds in their solid state.  In the latter method the samples were dissolved in 
a mixture of water and acetonitrile before injection.  Greater energy was applied 
resulting in more fragmentation of the compounds.  (Chapter 2)   
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As mentioned before the possible occurrence of auto-ionization during the 
synthesis posed a real problem.  A method was required to differentiate between 
the two species.  The previously discussed characterization methods could not 
distinguish between the monomeric compound and its double salt.  However, 
identification was possible with mass spectrometry as it has the ability to reveal 
the molecular mass of a compound.   
 
The mass spectra of all the complexes will be discussed and the differences in the 
spectra obtained from compounds prepared by the two synthetic routes will be 
highlighted.   
 
The mass spectral data for the iodo-complexes, captured by the FAB method 
indicated the presence of virtually only the monomolecular species.  (Figure 3.11)  
In the case of the ESI method there were indications of small amounts of 
auto-ionized species.  This observation may be described to limited ionization 
which occurred in the acetonitrile/water mixture before the sample was injected.  
The ESI mass spectrum of J5.5 with the important peaks assigned is shown in 
Figure 3.12.   
 
Figure 3.11: The FAB mass spectra of J5.5 showing only the molecular ion specie.   
Molecular specie 
~ 71 ~ 
 
 
300 350 400 450 500 550 600 650 700 
m/z 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
 
495.7 
494.7 
518.8 
496.7 519.9 
622.7 350.2 
391.1 
621.6 351.2 392.1 390.1 623.7 
545.9 
367.9 546.9 521.8 
432.1 368.9 418.1 
531.7 404.0 466.8 445.1 625.7 548.9 340.1 380.9 605.5 
575.6 306.1 633.9 681.6 665.7 694.1 
319.9 
649.4 603.6 
602.7 
604.6 650.3 
588.6 
543.9 
574.7 
337.8 652.4 381.0 349.9 573.7 515.9 606.7 694.9 484.0 634.3 426.8 506.7 381.9 456.7 687.5 655.3 
MeCN pos 
MeCN neg 
16. 
14. 
15. 
6. 
7. 
3. 
4. 
12. 
2. 
1. 
 
Figure 3.12: The ESI mass spectrum of J5.5. 
The above figures illustrate the differences between the two methods with regards 
to the amount and nature of information gathered.  The FAB method mainly 
reports the molecular specie and some breakdown products, whereas the ESI 
method shows the presence of the molecular specie as well as species from 
secondary reactions.  Since data collected by the ESI method reflects the solution 
chemistry of the compounds, these spectra will be discussed in more detail to 
illustrate the behaviour of the compounds in solution.  The results from the FAB 
spectra are tabulated at the end of the chapter.  (Table 3.14)   
 
Upon close inspection a considerable number of species could be identified in the 
ESI spectra. The significant species are listed in Table 3.3.   
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Table 3.3: ESI mass spectral data for the iodo-complexes.   
 J7.5 J5.5 J13.5 J14.5 J16.5 
Positive Mode      
Mono Molecular species      
1) M+H 590 + 605 619 652 667 
2) M+NH4 607 + 622 636 670 684 
3) M-I 463 477 491 525 539 
4) M-I+H2 481 O 495 509 543 557 
5) M-I+CH3 504 CN 518 532 566 581 
6) M-2I 337 349 363 398 412 
7) M-2I+H2 355 O/OH 368 381 416 429 
8) M-2I+H2 372 O+OH 385 400 433 447 
      
Auto-ionized Species      
9) [PtL2] 478 2+ 506 534 602 630 
10) (PtL2 463 )-R 477 491 525 539 
11) (PtL2 448 )-2R 448 448 448 448 
12) [(PtL2)CN-] 503 + 532 560 628 655 
13) [(PtL2)X-] 608 + 633 660 729 756 
      
Negative Mode      
14) M-H 590 + 603 617 651 666 
15) M+CHOO 635 - 649 663 697 710 
16) M-R 574 - 574 574 574 574 
M refers to Pt(NS)X2
The formula of the ion associated and ionized species as found in both modes are 
listed in the first column of 
.   
 
Table 3.3.  For example, Item 3 refers to a fragment 
having lost one iodide while item 5 refers to the same fragment plus an acetonitrile 
solvate.   
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Species 1 - 8 can be related to the monomolecular species of the complex, where 
as species 9 - 13 can be related to the auto-ionized species.  For specie 10 the -R 
signifies the S-R bond breaking, forming an anionic sulfur atom.  Specie 12 can be 
related only to the demethylation of acetonitrile and than the solvolysis of the auto-
ionized specie.  The last specie in the positive ion mode 13 can be related to the 
association of an ionized iodide with the dicationic specie.   
 
Only three species could be identified in the negative ion mode.   
14: Deprotonation of the molecular specie. 
15: Formate associated specie of the molecular ion.   
16: The dealkylation of the bonded thioether.   
 
The molar masses of the identified species are represented in columns 2 - 6 of 
Table 3.3.  Values in red refer to species found in the spectra of the complexes 
produced by the silver method, which clearly yields mainly the monomeric species.  
The ones in red with a blue (D) attached are species present in the compounds 
produced by the direct method (Only in the chloro-complexes table).  The molar 
masses in blue represent the auto-ionized species present.  Black represents 
fragments which could be anticipated in the spectra but were not found.   
 
The interpretation of the data sometimes was troublesome for some of the cluster 
peaks could be associated with both the molecular ion and auto-ionized species.  
However, the clusters were invariably closer to the values expected for the 
molecular ion species.  Further these compounds were used in the preparation of 
the bromo- and chloro-complexes.  These were found to have the molecular ion 
form.  It would be very unlikely that these compounds could be prepared from the 
auto-ionized iodo starting material.   
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The behaviour of the iodo-complexes was surprisingly similar.  The only exception 
was J7.5.  No evidence was found for the ionization of the second iodide, which 
precluded the presence of species 6 to 8.  (Table 3.3)   
Table 3.4: ESI mass spectral data for the bromo-complexes. 
 J7.3 J5.3 J13.3 J14.3 J16.3 
Positive Mode      
Mono Molecular species      
1) M+H 498 + 510 523 558 573 
2) M+NH4 512 + 526 540 576 590 
3) M-Br 416 430 443 478 492 
4) M-Br+H2 433 O 447 461 495 510 
5) M-Br+CH3 456 CN 470 484 519 534 
6) M-2Br 337 349 363 398 412 
7) M-2Br+H2 353 O/OH 368 381 416 429 
8) M-2Br+H2 371 O+OH 385 400 433 447 
      
Auto-ionized Species      
9) [PtL2] 477 2+ 506 534 602 630 
10) (PtL2 463 )-R 477 491 525 539 
11) (PtL2 448 )-2R 448 448 448 448 
12) [(PtL2)CN-] 504 + 532 560 628 655 
13) [(PtL2)X-] 557 + 586 613 681 709 
      
Negative Mode      
14) M-H 493 + 507 521 557 572 
15) M+CHOO 539 - 552 567 601 616 
16) M-R 480 - 480 480 480 480 
 
When the spectra of the bromo-complexes were considered evidence was found 
for the formation of ionized species.  Possible evidence of the auto-ionized specie 
was found in the case of J16.3 in the form of a peak at m/z 630+.  This could be 
assigned to the [PtL2] specie.  However if the compound was auto-ionized traces 
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for species 10 - 13 should have also been present.  It was therefore assumed that 
the peak at 630+
Table 3.4
 was suspicious.  Complex J7.3 was the only one not to have the 
dicationic species, which was similar to its iodo analogue J7.5.  ( )   
Table 3.5: ESI mass spectral data for the chloro-complexes. 
 J7.2 J5.2 J13.2 J14.2 J16.2 
Positive Mode      
Mono Molecular species      
1) M+H 407 + 421 435 470 484 
2) M+NH4 424 (D) + 438 (D) 452 (D) 486 (D) 501 (D) 
3) M-Cl 372 385 399 (D) 433 447 
4) M-Cl+H2 389 (D) O 403 (D) 418 451 (D) 465 
5) M-Cl+CH3 412 (D) CN 427 (D) 441 474 (D) 489 
6) M-2Cl 337 349 (D) 363 (D) 398 (D) 412 (D) 
7) M-2Cl+H2 353 O/OH 368 381 416 429 (D) 
8) M-2Cl+H2 371 O+OH 385 400 (D) 433 447 (D) 
      
Auto-ionized Species      
9) [PtL2] 477 (D) 2+ 506 (D) 534 (D) 602 (D) 630 (D) 
10) (PtL2 463 (D) )-R 477 (D) 491 (D) 525 539 (D) 
11) (PtL2 448 (D) )-2R 448 (D) 448 (D) 448 448 (D) 
12) [(PtL2)CN-] 504 (D) + 532 560 (D) 628 655 
13) [(PtL2)X-] 513 (D) + 541 (D) 568 (D) 637 (D) 664 (D) 
      
Negative Mode      
14) M-H 405 (D) + 420 (D) 433 (D) 467 (D) 481 (D) 
15) M+CHOO 451 (D) - 465 (D) 479 (D) 513 (D) 527 (D) 
16) M-R 392 - 392 (D) 392 (D) 392 392 (D) 
 
In the case of the chloro-complexes ionization occurs to a greater extent than in 
the bromo- and iodo-complexes.  The spectra of J7.2 and J16.2 showed some 
evidence of the auto-ionized species although they were produced by the silver 
method.  In both cases the peaks were small indicating that it was a minor 
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impurity.  (Figure 3.44 and Figure 3.48)  This impurity could be removed by 
recrystallization from acetonitrile.   
 
The above results show that the amount of the auto-ionized specie was related to 
synthetic procedure.  In the direct method the auto-ionized specie was 
predominant.  In contrast the silver method produces mainly the molecular specie.  
This was compelling evidence to show that the silver method was superior to the 
direct method in the preparation of complexes used in this study.  As for analysing 
the behaviour of complexes in solution the ESI method was deemed preferable to 
the FAB method.   
 
3.3.3 Properties of the Complexes.   
3.3.3.1 Solubility  
The aqueous solubilities of the bromo- and chloro-complexes were determined as 
described in Chapter 2.  The data is shown in Table 3.6.   
Table 3.6: Aqueous solubility for the bromo-and chloro-complexes.   
Complex 
Solubility (µM) 
Chloro (Ag* Chloro (D) ** Bromo ) 
J7.2 or 3 686 2327 104 
J5.2 or 3 876 1113 235 
J13.2 or 3 436 1009 152 
J14.2 or 3 255 213 89 
J16.2 or 3 165 165 52 
* Silver Method used 
From the data it was evident that increasing hydrophyllic nature on the R
** Direct Method used 
2 group 
resulted in a decreased aqueous solubility.  As expected, the hydrophobicity of the 
ligands, and therefore the complexes were proportional to the length and bulkiness 
of the R2 group.  Complexes J5.2 and J5.3 proved to be the exception to the trend.  
Their non conformity could be rationalised by the fact that both of these complexes 
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undergo complete ionization in water.  The data showed that the more covalent 
bromo-complexes were more insoluble than their chloro analogues.  It should be 
noted that the solubilities of J14.3 and J16.3 were below 100 µM.  This made 
cytotoxic testing problematic as a concentration of 100 µM was required.  Testing 
at a lower concentration was performed.   
 
When comparing the solubilities of the chloro-complexes prepared by the two 
methods it was noticed that the complexes prepared by the direct method were 
more soluble.  This was not expected due to the fact that the direct method 
produced mixtures with the auto-ionized specie being the main component.  This 
made the direct comparison between the two methods improbable.   
 
3.3.3.2 Thermal Stability   
Thermogravimetric analysis was used to study the thermal behaviour of the 
complexes up to a maximum temperature of 450-500°C.  Two studies were 
performed firstly, an attempt was made to study the thermal stability of the 
complexes with respect to ligands while the anions was kept constant.  Secondly, 
the thermal stability as a function of the halides was determined as the ligands 
was maintained constant.   
 
The thermogravimetric curves of the chloro-complexes are depicted below in 
Figure 3.13.  Inspection of the curves shows thermal stability of the complexes up 
to 200°C.  Thereafter, rapid mass loss transitions were observed.  The reactions 
related to the mass losses could not be identified.  These reactions were followed 
by a gradual mass decrease until the end of the selected temperature range.  
There was no definite trend relating to the size of the R2 group in the ligands with 
respect to thermal stability.  The complexes J5.2, J13.2 and J14.2 showed an 
increase in stability with increase in size of the R2 group.   
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Figure 3.13: Thermogravimetric curves of chloroplatinum(II) complexes. 
 
Figure 3.14: Thermogravimetric curves of the halo-complexes of J5. 
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The ligand mmtei was selected in the study of stability as a function of the halogen 
ion.  The curves in Figure 3.14 indicate that the thermal stability decreases from 
the chloro- to bromo- to iodo-complex.   
 
3.3.3.3 Cytotoxicity   
The cytotoxicity of the bromo- and chloro-complexes was measured by testing 
them on three types of cancer cell lines as described in Chapter 2.  It should be 
noted that due to insolubility not all the complexes could be evaluated at the 
100 µM level.  The results are shown in Table 3.7.  The values obtained refer to 
the percentage killing that the complexes induced.  A zero value indicates that the 
compound has no inhibiting effect.  The standard deviations are given in brackets.  
The results showed these halo-complexes to be poor anticancer agents.   
 
 
 
 
Table 3.7: Anticancer test results of the halo-complexes. 
Complex HeLa HT 29 MCF 7 Actual Conc (µM) 
  10 50 100 10 50 100 10 50 100 10 50 100 
Cisplatin 85 (2) 88 (1) 88 (1) 77 (2) 79 (1) 79 (1) 76 (2) 76 (1) 84 (1) 8.8 44 88 
J7.3 6 (4) 2 (2) 1 (2) 14 (3) 7 (2) 2 (2) 0 (4) 0 (8) 0 (4) 1.6 8.1 16.2 
J5.3 0 (9) 4 (6) 2 (11) 2 (5) 0 (5) 2 (12) 0 (20) 0 (9) 0 (3) 2.8 14.1 28.2 
J13.3 9 (5) 2 (5) 1 (6) 4 (4) 9 (4) 8 (3) 0 (9) 0 (8) 0 (12) 0.3 1.6 3.3 
J14.3 3 (7) 1 (2) 0 (9) 2 (4) 4 (5) 0 (1) 0 (10) 0 (4) 0 (10) 0.1 0.5 1 
J16.3 7 (4) 9 (8) 1 (8) 8 (5) 3 (3) 3 (6) 0 (15) 0 (17) 0 (4) 0.1 0.5 1 
Complex HeLa HT 29 MCF 7 Actual Conc (µM) 
  10 50 100 10 50 100 10 50 100 10 50 100 
Cisplatin 87 (1) 85 (1) 85 (1) 56 (3) 67 (1) 70 (1) 73 (2) 74 (1) 80 (1) 9.9 49.5 99 
J7.2 4 (1) 1 (6) 2 (4) 11 (7) 6 (3) 2 (9) 16 (13) 2 (8) 7 (7) 1.9 9.6 19.2 
J5.2 8 (2) 5 (1) 2 (7) 12 (2) 11 (4) 3 (4) 5 (3) 2 (6) 12 (8) 6.7 33.6 67.1 
J13.2 16 (3) 12 (4) 4 (4) 16 (4) 11 (5) 8 (8) 18 (9) 13 (7) 0 (22) 1.4 7.1 14.1 
J14.2 14 (6) 8 (5) 11 (7) 17 (6) 7 (2) 6 (6) 22 (20) 18 (22) 27 (8) 0.5 2.3 4.7 
J16.2 13 (21) 15 (3) 13 (13) 20 (7) 15 (7) 9 (5) 15 (27) 18 (21) 12 (14) 0.5 2.3 4.6 
 
* Each of the above results is an average of four measurements.   
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3.3.3.4 Rate of Ionization   
An important property of the complexes with respect to cytotoxicity is the rate at 
which the halogen leaving group is substituted.  This was measured by mass 
spectrometry as described in Chapter 2.  The results of these experiments are 
shown in Figure 3.15 to Figure 3.23.  In order to simplify the interpretation of the 
data obtained, similar ion clusters were grouped together. For example, ions such 
as [M-Cl]+, [M-Cl+H2O]+ and [M-Cl+MeCN]+ were designated [M-Cl+S]+ and 
deemed to represent the mono dechloronated species. Similarly [M-2Cl-H]+, 
[M-2Cl-H+H2O]+ and [M-2Cl-H+ACN]+ were designated [M-2Cl+S]+ and deemed to 
represent the di dechloronated species.  As the ionization was a two step process 
the results are reported in two parts.   
 
Rate of the First Ionization Step 
The effect of the NS ligands on the ionization rate of the molecular species, i.e. 
[Pt(NS)X2] (X = Cl-, Br- and I-) 
[Pt(NS)X2]  +  S [Pt(NS)XS]
+  +  X-
was studied.   
 
This was done at room temperature through monitoring the concentration of the 
molecular species as a function of time.  Pure water could not be used as a 
solvent.  A 10% acetonitrile aqueous solution was selected as solvent.  The 
reason for the use of this solvent mixture was that all the species have significant 
solubility in it.  Furthermore water could not be used because the iodo-complexes 
were virtually insoluble and the chloro-complexes ionized instantaneously making 
kinetic studies impossible.   
The results in Figure 3.15 show that the ionization rate of the first chloride was 
very fast and virtually independent on the non-leaving ligands.  The initial 
ionization rate of J7.2 was slower than the rest.   
The results in Figure 3.16 show the ionization rates of the first bromide ion.  It can 
be seen that the ionization rate of J7.3 was the slowest while J5.3 was the most 
rapid.  The remaining complexes had similar ionization rates within experimental 
error with no desirable trends.   
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Figure 3.15: The rate of ionization of the first chloride.   
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Figure 3.16: The rate of ionization of the first bromide.   
The results of the iodo-complexes are shown in Figure 3.17.  It may be 
remembered that from Chapter 2 that the CHNS analysis indicated that some of 
the iodo-complexes were impure.  This fact did not affect the accuracy of the 
results due to the manner the experiment was designed.  The measurements were 
reported relative to the reading at time zero.  The presence of impurities played no 
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role in these measurements.  Again J5.5 was the most labile complex.  However, 
surprisingly J7.5 was the second most labile.  The remaining complexes showed 
no desirable trends.   
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Figure 3.17: The rate of ionization of the first iodide. 
Inspection of the above results showed a trend in the ionization rates depending 
upon the nature of the halogen.  This was summarised for J7 and J5 in Figure 3.18 
and Figure 3.19 respectively.  The ionization rates of the iodo-complexes are 
significantly slower.  The ionization rates of the bromo-complexes are slower than 
the chloro-complexes.  However, the differences between these rates are not 
large.   
 
The trends for the complexes which contained J7 and J5 showing the slowest and 
most rapid ionization rates could not be explained as easily.  Two factors of 
several which effect ionization rates would be the strength of the Pt-X bond trans 
to the sulfur and steric properties.  Methyl being the smallest R2 group would result 
in the least steric interaction.  This could result in a slower ionization rate.  
However, the halogen that ionizes first is trans to the sulfur-methyl group and 
would be unaffected by its size.  Furthermore if steric properties were the cause of 
the rapid ionization a noticeable trend would result as the size of the R2 group 
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increases.  This was not found.  The magnitude of the Pt-X bond strength is 
depended on the trans-effect.  Substituting a methyl with an ethyl group on the 
sulfur would marginally increase its sigma donor properties which, in turn would 
weaken the trans Pt-X bond.  This could explain why J5.2 was more labile.  
However, if this was the explanation J13.2 would be the most labile which are 
shown not to be the case.  A third factor that needed attention was the stability of 
the [Pt(NS)X]+ specie.  If these decompose rapidly it would affect the rate of the 
first ionization step.  The system was so complex that no conclusive theory 
explaining the anomalous behaviour of the methyl and ethyl R2
0
20
40
60
80
100
120
0 0.5 1 1.5 2 2.5 3 3.5 4
N
or
m
al
is
ed
 a
re
a
Time (min)
J7.2 J7.5 J7.3
 groups could be 
found.   
 
Figure 3.18: The difference in ionization rates of Cl-, Br- and I- complexes of J7.   
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Figure 3.19: The difference in ionization rates of Cl-, Br- and I-
Rate of Second Ionization Step   
 complexes of J5.   
The rate at which [Pt(NS)X]+
Figure 3.20
 decreased with time was measured for the 
complexes and was illustrated in  to Figure 3.23.  The amount of the 
[Pt(NS)X]+ present at a point in time depended on two reactions.  Firstly, the rate 
of formation of [Pt(NS)X]+ and secondly, the rate of ionization-degradation of the 
[Pt(NS)X]+.  If the rate of the ionization was faster then the graph would show a 
steady decrease in the amount of [Pt(NS)X]+.  If the reverse was true then it would 
indicate a increase in the amount of [Pt(NS)X]+
The results for the chloro-complexes, 
.  In the experiment time was 
allowed for the formation of the monoionic specie before measurements were 
made.   
 
Figure 3.20 indicated that the [Pt(NS)X]+
The results for the bromo-complexes, 
 
ionizes more rapidly than it was formed.  The sequence that was found are as 
follows J13.2 > J5.2 ≥ J16.2 > J14.2 > J7.2.   
 
Figure 3.21, are particular interesting.  The 
J5.3 shows that the rate of ionization of [Pt(NS)Br]+ was more rapid than the rate 
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of formation.  The reverse was found for J7.3 the [Pt(NS)Br]+
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 that did not ionize at 
a measurable rate, it being the final product.   
 
Figure 3.20: The difference in ionization rates of the solvated monochloro species.   
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Figure 3.21: The difference in ionization rates of the solvated monobromo species.   
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Figure 3.22: The difference in ionization rates of the solvated monoiodo species.   
The results for the iodo-complexes are shown in Figure 3.22.  In interpreting these 
results it must be remembered that time was allowed for the formation of the 
monocationic specie.  The graph shows that in general the monocationic specie 
was stable and did not ionize to the dicationic form during the experimental period.  
Only J5.5 showed a tendency for ionization.   
 
In conclusion the above results show that the formation of the monocationic 
species was rapid even in a water/acetonitrile medium.  It is known that the kinetic 
stability of the molecular from is an important facet in providing a platinum 
compound with anticancer properties.  The rate at which the Pt(NS)X2
Figure 3.23
 compound 
prepared undergo ionization was compared with that of cisplatin is illustrated in 
.  This graph clearly shows a reason why the cytotoxic properties of 
these compounds are inferior to cisplatin.   
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Figure 3.23: The ionization rate of the cisplatin compared to that of the chloro-complexes.   
 
3.3.3.5 Thermodynamic Stability   
Evaluation of the relative thermodynamic stability of the halo-complexes was 
accomplished using EV-CAD.  This method measured the amount of energy 
required to fragment the complexes.  This amount of energy was measured to 
achieve a 50% drop in the molecular ion specie.  The complex with the higher E½ 
was considered more stable than the complexes with E½ lower values.  
(Chapter 2)   
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Figure 3.24: Results obtained from the EV-CAD study of the various halo-complexes 
depicting the amount of energy required to cause a 50% reduction of the 
[Pt(NS)X]+
• The stability of the complexes follows the pattern: chloro > bromo > iodo 
within the same non-leaving group.   
 specie.   
The following observations could be made from the data: 
• The complex stability also decreases as the non-leaving group becomes 
more hydrophobic.   
These results are complimentary to the thermal analysis results which showed 
very similar trends.   
An interesting observation can be made by inspecting the thermal and kinetic 
results.  It was found that the less thermodynamically stable complexes are the 
more kinetically inert.   
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3.3.4 Structures 
Single crystal x-ray crystallography is the most common techniques used in the 
determination of the structure of compounds isolated as solids.  The technique has 
limitations.  In this study mixtures were obtained.  In order to isolate crystals 
suitable for data collection slow crystallization was required.  The crystals isolated 
may not necessary be of the compound which formed the major component in 
solution.  It merely represented the compound which was least soluble.  It was 
shown that the compounds in molecular form were the least soluble.  Single 
crystal x-ray analysis was limited to these compounds.  Two complexes were 
selected for the following reasons:  
• To verify that the molecular from was prepared.   
• The influence of the positive and negative inductive effect of the R2
• The steric effect of the R
 group.   
2
Pt(mmtei)Cl
 group on reaction rates.   
2 and Pt(mmtbzi)Cl2
3.3.4.1 Structural Determination of Pt(mmtei)Cl
 were therefore selected.   
 
The structures of the selected compounds were determined by single crystal x-ray 
crystallography and molecular modelling calculations.   
 
2
The Ortep diagram of Pt(mmtei)Cl
.   
2 Figure 3.25 can be viewed in .  Appendix A 
contains the stereo view of the complex.   
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Figure 3.25: The structural representation of Pt(mmtei)Cl
1P
2 
The compound crystallized out as yellow prisms.  The diffraction data collected at 
-100 ºC, was found to be of good quality and corrected for absorption.  Both the 
structure solution and refinement was accomplished without any difficulty.  The 
structure of the compound was solved using the space group .  A Goodness-of-
fit of 1.084 and R-Value of 0.0218 (l > 4σ[l]) and 0.0232 (all data), indicated that 
the structure had converged and refined.  A summary of the structure details, 
fractional coordinates and isotropic/anisotropic factors are provided in Appendix A.   
 
The refinements of the non-hydrogen atoms were done anisotropically.  The 
temperature factors were all satisfactory: Ueq
The hydrogen atoms were positioned geometrically and allowed to ride on their 
respective parent atoms.  The temperature factors were also obtained from the 
 varied from 0.019 to 0.038 (for C13).  
The terminal methyl group (C13) showed the largest temperature factor.  This was 
understandable as it was expected to experience the greatest amount of 
oscillation.   
 
~ 92 ~ 
 
parent atoms.  For the methyl group the factor was assumed 50 % greater than 
the carbon atom.  In all the other cases a 20 % factor was used.   
Table 3.8: Selected bond lengths in Pt(mmtei)Cl2
Atom 
.   
Distance Atom Distance 
Pt - N(1) 1.9965(35) N(1) - C(5) 1.3889(51) 
Pt - S 2.2428(11) C(2) - N(3) 1.3347(51) 
Pt - Cl(1) 2.3027(11) C(2) - C(3) 1.4965(58) 
Pt - Cl(2) 2.3246(12) N(3) - C(4) 1.3774(55) 
S - C(3) 1.8383(42) N(3) - C(6) 1.4772(54) 
S - C(12) 1.8244(38) C(4) - C(5) 1.3527(58) 
N(1) - C(2) 1.3464(52) C(12) - C(13) 1.5253(67) 
 
Table 3.9: Selected bond angles in Pt(mmtei)Cl2
Atoms 
.   
Angle Atoms Angle 
S – Pt - N(1) 85.89 (11) N(1) - C(2) - C(3) 123.21 (35) 
N(1) - Pt - Cl(2) 92.72 (11) C(2) - N(3) - C(4) 107.99 (35) 
Cl(2) - Pt - Cl(1) 92.17 (4) C(2) - N(3) - C(6) 125.52 (37) 
S – Pt - Cl(1) 89.21 (4) N(3) - C(4) - C(5) 107.02 (37) 
Pt – S - C(3) 102.35 (15) C(4) - C(5) - N(1) 108.64 (37) 
C(12) – S - C(3) 102.07 (2) S - C(3) - C(2) 108.76 (29) 
C(2) - N(1) - C(5) 106.08 (33) C(13) – C(12) – S 111.05 (3) 
C(2) – N(1) - Pt 119.57 (28) C(12) – S - Pt 105.79 (15) 
N(1) - C(2) - N(3) 110.25 (36)   
 
The bond distances and angles were as expected and the esd values (estimated 
standard deviation) for both were low.  A number of observations could be made:  
• The Pt-Cl(2) (2.3246(12)) bond length was considerably longer than the 
Pt-Cl(1) (2.3027(11)) bond length.  This can be explained by the Cl(2) being 
trans to the sulfur atom, bringing the trans-effect into play.   
• The bond lengths of the imidazole ring structure were in the region of 
1.33-1.38 Å which is typical for sp2 C-C and C-N bond distances.  It was 
expected that the aromatic character of the imidazole ring would have made 
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it planar in symmetry.  (Table 3.10)  Deviation from planarity was found to 
be very small.   
• The coordination sphere of the platinum was not perfectly square planar.  
The platinum atom is slightly raised out of the plane towards the ethyl 
group.  Furthermore the N(1)-Pt-S angle was 85°.  This deviation was 
ascribed to the spatial restrictions forced on the atoms as result of being 
part of a bidentate ligand.  (Table 3.10)   
 
Table 3.10: Deviations (×104 Å) (d) and standard deviations (×104 Å) (s) of selected atoms 
through weighted least squares planes of the imidazole ring and 
coordination sphere in Pt(mmtei)Cl2
Imidazole 
. 
 
Platinum 
 
Atom d s  Atom d s 
N(1) 47 44  Pt 11 2 
C(2) -92 50  S -217 13 
N(3) 65 44  N(1) 31 43 
C(4) -54 54  Cl(1) -3 14 
C(5) -8 49  Cl(2) -292 15 
Chi-squared = 7.717 (5.99)  Chi-squared = 706.034 (5.99) 
 
As mentioned earlier one of the reasons for doing the single crystal determination 
was to gather information about how the R2 group could effectively protect the 
platinum atom.  However, the determination showed that the R2 group was 
bending away from the platinum, therefore not providing any protection.  The 
torsion angle (Pt,S,C12,C13) was found to be 179.22º.  It may be noted that this 
behaviour is restricted to the solid state.  This was not to say that the torsion angle 
would be similar in solution, as there might be free rotation.  Molecular modelling 
was then done on the compound which would give the behaviour under gas phase 
conditions.  This would provide a closer approximation of the compound behaviour 
in solution.   
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The equilibrium conformer was calculated under DFT conditions using the 6-31G*
Figure 3.26
 
subsets.  The resultant structure is shown in .  The molecular modelling 
structure was found to be within experimental error of the crystal determination.  
The only major deviation from the crystal structure was the (Pt,S,C12,C13) torsion 
angle.  The torsion angle was calculated at -50.30°.   
       
Figure 3.26: The molecular modelling calculation of J5.2 under DFT condition. 
Due to this discrepancy it was decided to determine the energy profile of all the 
conformers formed by rotating the R2
Figure 
3.27
 group through 360°.  This calculation was 
also done under DFT conditions.  The resultant energy profile is shown in 
.  From the profile it was evident that three energy minima were present.   
These were:  
• Dihedral (Pt,S,C12,C13) at -50.30° (Conformer A) 
• Dihedral (Pt,S,C12,C13) at 76.60° (Conformer B) 
• Dihedral (Pt,S,C12,C13) at 179.99° (Conformer C) 
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Figure 3.27: Energy profile under DFT conditions for J5.2 by rotating the R2
It was of interest to note that all three minima were very close in energy.  
 group 
through 360º.   
Figure 
3.28 shows the three conformers related to each energy minima and their 
corresponding dihedral angles.   
   
A) Conformer A (-50.30º)  B) Conformer B (76.60º) C) Conformer C (179.99º) 
Figure 3.28: The three minimum conformations of J5.2 with their corresponding dihedral 
angles.   
Conformer A was the equilibrium conformer and its energy was used as reference.  
Conformer B had an energy difference of 25.6 cal/mol higher while conformer C 
was 13.1 cal/mol.  The differences in energy between these conformers were 
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small thus suggesting that all three could be present in solution.  It was noted that 
the dihedral angle of conformer C was different by 0.77 degrees compared to the 
crystal structure.   
 
The unit cell packing diagram, Figure 3.29, of J5.2 gave an indication as to why 
the equilibrium conformer was not found in the crystal structure.  It can be seen 
that the complexes are packed in a staggered conformation with the ethyl group 
bending away from the platinum.  This packing would not be possible with the 
ethyl group bent over the platinum.  The stereochemical view of the packing can 
be viewed in appendix A.   
 
Figure 3.29: An illustration of the packing of Pt(mmtei)Cl2
3.3.4.2 Structural Determination of Pt(mmtbzi)Cl
. 
 
2
The Ortep diagram of Pt(mmtbzi)Cl
.   
2 Figure 3.30 is given in .  The stereo view of 
the complex can be viewed in Appendix A.   
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Figure 3.30: The structural representation of Pt(mmtbzi)Cl2. 
The structure was determined in an analogous manner to the previous one.  The 
structure was solved using the space group P2(1)/c
Table 3.11: Selected bond lengths in Pt(mmtbzi)Cl
.  A Goodness-of-fit of 0.997 and 
R-Value of 0.0276 (l > 4σ[l]) and 0.0392 (all data), indicated that the structure had 
converged and refined.  There were no unusual temperature factors and bond 
distances.  A summary of the structure details, fractional coordinates and 
isotropic/anisotropic factors are provided in Appendix A.   
2
Atom 
.   
Distance Atom Distance 
Pt - N(1) 1.995 (38) N(3) - C(4) 1.3614 (59) 
Pt - S 2.2378 (11) N(3) - C(6) 1.471 (57) 
Pt - Cl(1) 2.2955 (13) C(4) - C(5) 1.3622 (69) 
Pt - Cl(2) 2.319 (12) C(1) - C(11) 1.5106 (64) 
S - C(3) 1.8242 (45) C(11) - C(12) 1.3877 (68) 
S - C(1) 1.8287 (44) C(12) - C(13) 1.3849 (68) 
N(1) - C(2) 1.3301 (55) C(13) - C(14) 1.3749 (64) 
N(1) - C(5) 1.3826 (60) C(14) - C(15) 1.3811 (71) 
C(2) - N(3) 1.3448 (59) C(15) - C(16) 1.3927 (66) 
C(2) - C(3) 1.4776 (64) C(16) - C(11) 1.3967 (60) 
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Table 3.12: Selected bond angles in Pt(mmtbzi)Cl2
Atoms 
.   
Angle Atoms Angle 
S – Pt - N(1) 85.72 (11) C(2) - N(3) - C(6) 125.55 (42) 
N(1) - Pt - Cl(2) 92.06 (11) N(3) - C(4) - C(5) 107.17 (45) 
Cl(2) - Pt - Cl(1) 91.94 (5) C(4) - C(5) - N(1) 107.75 (42) 
S – Pt - Cl(1) 90.27 (4) S - C(3) - C(2) 109.42 (30) 
Pt – S - C(3) 101.93 (15) C(11) – C(1) – S 110.80 (33) 
C(1) – S - C(3) 101.46 (22) C(12) – C(11) – C(16) 119.35 (35) 
C(1) – S - Pt 106.92 (16) C(11) – C(12) – C(13) 102.58 (42) 
C(2) - N(1) - C(5) 107.25 (39) C(12) – C(13) – C(14) 119.71 (48) 
C(2) – N(1) - Pt 119.37 (32) C(13) – C(14) – C(15) 120.79 (46) 
N(1) - C(2) - N(3) 109.60 (42) C(14) – C(15) – C(16) 119.79 (44) 
N(1) - C(2) - C(3) 123.54 (40) C(15) – C(16) – C(11) 119.76 (46) 
C(2) - N(3) - C(4) 108.21 (40)   
 
A Number of observations can be made:   
• As in the case with J5.2 the bond length of the Pt-Cl(2) (2.319(12)) was 
significantly longer than that of Pt-Cl(1) (2.2955(13).  This difference was 
less in the case of J5.2.  It was found that the bonds of J5.2 were slightly 
longer than that of J16.2.   
• As in the case of J5.2 the imidazole ring exhibited band distances typical for 
sp2
Table 3.13
 C-C and C-N bond distances.  Again the ring was found to be close to 
planar symmetry.  ( )   
• The coordination sphere of the platinum was not perfectly square planar.  
The platinum atom is slightly raised out of the plane towards the benzene 
group.  The N(1)-Pt-S angle was 85° which was the same as found in J5.2.  
The deviation was ascribed to the restrictions resulting from a bidentate 
ligand.  (Table 3.13)  In the case of J16.2 the deviation from planarity was 
significantly greater.   
• The benzene ring was found to be planar as would be expected.   
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Table 3.13: Deviations (×104 Å) (d) and standard deviations (×104 Å) (s) of selected atoms 
through weighted least squares planes of the imidazole and benzene rings 
and the coordination sphere in Pt(mmtbzi)Cl2
Imidazole 
.   
 Platinum 
Atom d s  Atom d s 
N(1) -14 35  Pt 15 2 
C(2) -30 43  S 364 11 
N(3) 50 37  N(1) 64 36 
C(4) -94 46  Cl(1) -12 13 
C(5) 72 46  Cl(2) -423 12 
Chi-squared = 9.013 (5.99)  Chi-squared = 2544.363 (5.99) 
       
       
Benzene     
Atom d s     
C(11) -54 52     
C(12) 33 53     
C(13) 29 56     
C(14) -72 58     
C(15) 41 58     
C(16) 26 56     
Chi-squared = 4.005 (7.81)     
 
Similar molecular modelling calculations were done on J16.2 to obtain the 
equilibrium conformers under DFT conditions.  The structure created by the 
program is shown below.   
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Figure 3.31: The equilibrium conformer for J16.2 under DFT conditions. 
As in the J5.2 case the structure was very similar to the crystal structure except in 
the dihedral angle of the R2 group.  The angle was found to be -175.90º in the 
crystal structure were as in the molecular modelling calculation it was -60.97º.  
This meant that the benzene ring is bent over the platinum and could act as a roof, 
thus providing protection from attack.  Again the energy profile of J16.2 was 
calculated by rotating the R2
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 group through 360º but this time the calculation was 
done under molecular mechanics conditions.  This had to be done for not all the 
conformer in the sequence converged.  The energy profile is shown below.   
 
Figure 3.32: Energy profile for the rotation of the R2 group of J16.2 under molecular 
mechanics conditions.   
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The energy profile shows three minimum configurations.  These were further 
refined under DFT conditions.  Conformer C could not be refined for it converted to 
conformer B under these conditions.  The three conformations are shown in Figure 
3.33.   
 
A) Conformer A         B) Conformer B   C) Conformer C  
Figure 3.33: The three minimum conformations of J16.2 from the energy profile.   
As conformer C converted to B under DFT conditions it could be assumed that 
only two minima exist, and it was found that conformer A was 29 cal/mol higher in 
energy.  The dihedral angles of conformer A was calculated to be -166.08º which 
was 9.82º out from the crystal structure.  There was a small difference in the 
dihedral angle (S, C1, C11, C16) calculated from that found in the crystal 
structure, namely 109.80º and 118.50º respectively.  As in the case of J5.2 the 
difference in the above dihedral angles was ascribed to packing effects in the 
crystal structure.   
 
Figure 3.34 shows that J16.2 packs in such a way that the benzene group points 
in the same direction for all the complexes in a plane.  They are packed end-to-
end in a row.  Then one gets a plane perpendicular to the first but in this plane the 
benzene groups are parallel to each other.   
 
Efficient packing in a molecule containing two independent rings forces these rings 
into positions that may not be energetically the most favourable.  As seen above, 
the energy difference between the different conformers is small therefore packing 
considerations would determine the position of the benzene ring in the solid state.   
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Figure 3.34: An illustration of the packing of Pt(mmtbzi)Cl2. 
Dissolution studies showed that although both chloride atoms were labile the first 
ionized far more rapidly that the second.  Furthermore, in the case of J5.2 they 
ionized significantly faster than J16.2.  This can readily be rationalized using the 
structural data.  It was mentioned that in both structures one of the Pt-Cl bond 
lengths was longer than the second.  This implied a weaker bond and therefore a 
more labile chlorine atom.  The reason for the discrepancy in bond length can also 
be explained.  In both cases the longer bond are trans to the sulfur atom.  It is well 
established that the trans-effect for sulfur is far greater than for nitrogen.  It was 
noted that the Pt-Cl bond lengths in J5.2 were longer than in J16.2.  This would 
account for the greater lability.  The fact that the bond distances were greater can 
be rationalized as follows.  The donor strength of the sulfur atom in the case of 
J5.2 is expected to be greater than that of the J16.2 compound.  In J5.2 the R2
The compounds described in this chapter had been thoroughly characterized.  A 
great wealth of data was collected for both the solid and solution state.  This 
provided insight which had not been available before.  It was speculated that a 
reason for the cytotoxic properties of the halo-complexes being inferior to that of 
cisplatin was their labile nature.  This turned our attention to ways in which to 
overcome this problem.   
 
group was an ethyl which has a positive inductive effect while in J16.2 it was a 
benzyl with a negative inductive effect.  The greater the donor strength of the 
sulfur in J5.2 results in a decrease in Lewis acidity of the platinum with respect to 
J16.2.  This weakened the Pt-Cl bonds.   
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3.4 Data 
Table 3.14: The molecular ion clusters detected in all NS complexes by the FAB mass 
spectrometry method. 
Complexes 
Detected clusters 
M+H M-X + M-2X (PtL2 (PtL)-R 2
J7.2 (Ag) 
)-2R 
408 372       
J7.2 (D) 408         
J7.3 498         
J7.5 591         
J5.2 (Ag) 427 389 351     
J5.2 (D)       477 448 
J5.3 512 432 350     
J5.5 606         
J13.2 (Ag) 436   363     
J13.2 (D)     363 492 448 
J13.3 526         
J13.5 619 491       
J14.2 (Ag) 471         
J14.2 (D) 471   398     
J14.3 559         
J14.5 653 526       
J16.2 (Ag) 485         
J16.2 (D) 484   412   448 
J16.3 574         
J16.5 668         
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Figure 3.35: The ESI-MS of J7.5. 
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Figure 3.36: The ESI-MS of J13.5. 
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Figure 3.37: The ESI-MS of J14.5. 
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Figure 3.38: The ESI-MS of J16.5. 
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Figure 3.39: The ESI-MS of J7.3. 
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Figure 3.40: The ESI-MS of J5.3. 
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Figure 3.41: The ESI-MS of J13.3. 
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Figure 3.42: The ESI-MS of J14.3. 
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Figure 3.43: The ESI-MS of J16.3. 
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Figure 3.44: The ESI-MS for J7.2. 
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Figure 3.45: The ESI-MS of J5.2. 
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Figure 3.46: The ESI-MS of J13.2. 
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Figure 3.47: The ESI-MS of J14.2. 
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Figure 3.48: The ESI-MS of J16.2. 
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CHAPTER 4 
PLATINUM(II) OXALATO-COMPLEXES WITH 
BIDENTATE NS LIGANDS 
4.1 Introduction   
In the previous chapter it was shown that the ionization rates of the 
halo-complexes were all rapid.  Changing the halogen ion had little effect.  As a 
result the cytotoxic properties of these compounds were inadequate.  One way in 
which to retard the rate of ionization would be to exchange the halogen leaving 
group with a dicarboxylate group.  The reasons were discussed in Chapter 1.  Two 
dicarboxylic acid ligands had been used in the literature namely, oxalate and 
malonate.  Figure 4.1 shows the rates of ionization of cisplatin, carboplatin and 
oxaliplatin.  It can be seen that carboplatin which contains a malonic acid leaving 
group and oxaliplatin which contains a oxalate leaving group ionizes far more 
slowly than cisplatin.   
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Figure 4.1: Graph detailing the ionization rate compared with carboplatin and oxaliplatin 
in water at 37°C.   
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Although ligand exchange plays a very important role numerous other parameters 
influence the anticancer action of these compounds.  Even though cisplatin ionizes 
more rapidly it is highly effective as an anticancer agent.  It must be remembered 
that the rate of ionization of the Pt(NS)X2
4.2 The Oxalato-Complexes   
 compounds discussed in the previous 
chapter were all greater than that of cisplatin.  It would be expected that the 
substitution of the halogen leaving groups by an oxalato group would decrease the 
ionization rate significantly.  However, due to the complex nature of anticancer 
activity it is impossible to predict the consequences this substitution would have.  
The only way to discover this is by preparing and characterizing the compounds.    
 
The identification of the complexes prepared follows the similar convention that 
was used in the halo-complexes.  The oxalato leaving group is indicated by the .1 
integer, for example J7.1.   
 
4.2.1 Synthesis   
The syntheses of the oxalato-complexes were similar to those described for their 
chloro analogues.  Both the direct ligand exchange method using K2Pt(C2O4)2
4.2.1.1 Direct Method   
 
and silver method were used, Chapter 2.   
 
The results obtained by this method were similar to those for the direct method 
using K2PtCl4
Figure 4.2
.  The products were analysed by both FAB and ESI mass 
spectrometry.  The two methods gave different results.  The FAB method did not 
detect the presence of the auto-ionized species in some cases.  (  and 
Figure 4.3)   
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Figure 4.2: The FAB mass spectrum of J5.1 obtained using the direct method.   
 
 
Figure 4.3: FAB mass spectrum of J7.1 obtained by the direct method.   
The ESI mass spectrometry technique showed the presence of auto-ionized 
species in all the compounds except J5.1.  The ESI mass spectrum of J7.1 is 
shown below in Figure 4.4.   
Molecular specie 
Molecular specie 
Auto-ionized specie 
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Figure 4.4: The ESI mass spectrum of J7.1 synthesized by the direct method in both 
positive and negative ion modes.   
In Figure 4.4, the mass spectrum results for J7.1 synthesized by the direct method 
are given with maxima at 447 [Pt(NS)2-2R], 463 [Pt(NS)2-R], 477 [Pt(NS)2]2+ and 
504 [Pt(NS)]CN in the positive ion mode which all corresponds to the auto-ionized 
specie.  The peak at 371 m/z in the negative ion mode refers to the doubly 
charged [Pt(C2O4)2]2-
4.2.1.2 Silver Method 
 specie.  The product is almost pure auto-ionized specie.  
This method of synthesis was then discontinued and only the silver method was 
used.   
 
The method of preparation of the oxalato-complexes by the silver method was 
similar to the analogous chloro-complexes.  The iodo-complexes formed were 
used as precursors for the oxalato-complexes.  (Chapter 2)   
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4.2.2 Characterization of the Oxalato-Complexes   
The compounds prepared by both methods were characterized using infrared 
spectroscopy, mass spectrometry and chromatographic studies.   
 
The CHNS analyses are reported in Chapter 2.   
 
4.2.2.1 Infrared Spectroscopy 
The spectra of the oxalato-complexes were obtained and a labelled spectrum of 
J7.1 is shown in Figure 4.5.  Tentative assignments of selected vibrations for the 
complexes are provided in Table 4.2.   
 
 
Figure 4.5: Infrared spectrum of J7.1. 
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The main focus was the carboxylate region in the infrared spectra of these 
complexes.  The spectrum of potassium oxalate was acquired for comparative 
purposes.  The presence of the carboxylate group resulted in two bands in the 
infrared spectrum, namely, υs(C=O) and υas(C-O).  The force constants in these 
bands were an intermediate between the C=O and C-O bond strengths due to 
resonance.  These two oscillators were strongly coupled resulting in strong 
asymmetric υas(OCOˉ) stretching vibrations in the region 1604-1647 cm-1 and a 
symmetric υs(OCOˉ) stretching vibration in the region 1319 cm-1.  Upon 
coordination, the equivalence of the carbon-oxygen bonds would be somewhat 
diminished, resulting in shifts in their frequencies.  Since all the complexes 
synthesized contained imidazole ring structures, the identification of the υ(C=N) 
stretches were complicated due to the fact that the stretching vibrations coincided 
with those of the υas(OCOˉ).  It was possible to assign the υas(OCOˉ) stretching 
vibration for the intensity was much higher than that of the υ(C=N) band.  For this 
reason the υ(C=N) stretch vibration was not included in the identification.  All the 
complexes showed a shift in the two stretching vibrations to a higher frequency, 
namely, to 1616-1698 cm-1 and 1354-1368 cm-1, respectively.109,110   
 
The two bands associated with the imidazole rings were assigned in all the 
complexes.  The υ(C=C) stretch frequency was found in the 1485-1508 cm-1 
region whereas the δ(C=N-C=C) was identified in the 1439-1462 cm-1
Since the υ(C=N) stretch could not be assigned the coordination of the nitrogen 
atom in the ring could not be confirmed.  Thus the υ(CH
 region.   
 
2-S) vibrations in the 
spectra of the complex were highly diagnostic.  A shift in these bands with respect 
to those of the free ligand confirmed Pt-S interaction.  The υ(CH2
Table 4.1
-S) bands could 
be assigned in most of the complexes.  The shifts were calculated and reported in 
.   
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Further evidence of Pt-S interaction could be obtained from the υ(Pt-S) band. 
However, this was a weak band and could not be assigned with certainty for any of 
the complexes.   
The assignments of both the υ(Pt-N) and υ(Pt-O) stretch frequencies were difficult, 
for these vibrations were usually medium to weak bands.  The bands in the region 
462-478 cm-1 were assigned to the υ(Pt-N) vibrations.  The υ(Pt-O) stretch 
frequency was found in the region of 551-563 cm-1.111
Table 4.1: Shifts in υ(CH
  The presence of both these 
vibrational bands confirmed the coordination of at least one oxalato oxygen atom 
and an imidazole nitrogen atom.  It was assumed that both carboxylato groups in 
the oxalate coordinated in a similar manner as different coordination would result 
in splitting of the υ(C=O) bands.   
 
The infrared data collected for the complexes synthesized by the direct method 
were very similar to those prepared by the silver method.  This confirmed that 
infrared spectroscopy could not be used to identify the auto-ionized species.   
2
Complex 
-S) with respect to the free ligand of the oxalato-complexes.   
Shifts in (cm-1) 
υ(CH2
Shifts in (cm
-S) Def 
-1) 
υ(CH2
J7.1 
-S) Wag 
-17 - 
J7.1D - -20 
J5.1 -12 0 
J5.1D -12 - 
J13.1 -1 - 
J13.1D -12 - 
J14.1 - 0 
J14.1D 0 -12 
J16.1 -10 9 
J16.1 D -16 7 
 
 
Table 4.2: IR data for all the oxalato-complexes.   
Ligand/ υ(C=O) υ(C=C) ring 
δ(C=N-
C=C) 
υ(CH2 υ(CH-S) 
def 
2 υ(C-O) -S) wag υ(M-N) υ(M-O) Complex 
J7   1497(s) 1454(m) 1427(m) 1285(s)       
J7.1 1695(s), 1668(s) 1507(s) 1439(w) 1410(w) - 1361(s) 465(sh) 559(s) 
J7.1D 1690(s), 1667(s) 1505(w) 1462(w) - 1265(w) 1366(s) 463(sh) 563(sh) 
                 
J5   1497(s) 1454(s) 1420(m) 1285(s)       
J5.1 1694(s), 1667(s) 1500(m) 1455(m) 1408(s) 1285(w) 1354(s) 460(sh) 559(s) 
J5.1D 1616(s), 1671(s) 1505(w) 1458(w) 1408(s) - - 467(m) 579(w) 
                 
J13   1497(s) 1458(s) 1420(m) 1285(s)       
J13.1 1698(s), 1653(s) 1506(m) 1457(m) 1419(w) - 1368(s) 458(w) 555(w) 
J13.1D 1698(s), 1671(s) 1505(m) 1458(m) 1408(m) - 1354(s) 459(sh) 559(sh) 
                 
J14   1485(s) 1439(s) 1408(s) 1285(s)       
J14.1 1695(s), 1666(s) 1508(s) 1441(m) - 1285(m) 1356(s) 482(s) 561(m) 
J14.1D 1694(s), 1667(s) 1500(m) 1458(m) 1408(m) 1273(w) 1354(s) - 559(w) 
                 
J16   1493(s) 1454(s) 1420(m) 1285(s)       
J16.1 1695(s), 1668(s) 1497(m) 1457(m) 1410(w) 1294(w) 1363(s) 458(s) 556(s) 
J16.1D 1694(s), 1655(s) 1497(s) 1454(s) 1404(s) 1292(w) 1366(s) 467(m) 563(m) 
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4.2.2.2 Mass Spectrometry 
The mass spectra of all the complexes were determine by two different methods.  
The first being by FAB mass spectrometry which identifies the compounds in their 
solid states.  The second was ESI mass spectrometry which records the 
compounds in solution.  The samples were dissolved in a water/acetonitrile 
mixture before injection.  Refer to Chapter 2 for a more detailed description of the 
methods.   
 
This section will only deal with the oxalato-complexes for the iodo-complexes were 
already discussed in the previous chapter.   
 
The mass spectral data obtained by the FAB method shows that only the 
monomolecular specie was formed by the silver method.   
 
Figure 4.6: The FAB mass spectrum of J7.1 by the silver method.   
The ESI mass spectrum, Figure 4.7, shows only the presence of the molecular 
species.  Only one peak was present in the positive ion mode which was related to 
the molecular ion.  The negative ion mode had three peaks related to the 
molecular ion.   
Molecular specie 
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Figure 4.7: The ESI mass spectrum of J7.1 obtained by the silver method.   
The identified peaks in the mass spectra are reported in Table 4.3.   
Table 4.3: ESI mass spectral data for the oxalato-complexes.   
  J7.1 J5.1 J13.1 J14.1 J16.1 
Positive Mode           
Molecular species           
1) M+H 425 + 439 453 486 501 
2) M+NH4 442 + 457 471 504 518 
3) M-Ox 337 349 363 (D) 398 (D) 412 
4) M-Ox+H2 353 O/OH 368 381 416 (D) 429 
5) M-Ox+H2 371 O+OH 385 400 433 (D) 447 
            
Auto-ionized species           
6) [PtL2] 477 (D) 2+ 506 534 (D) 602 630 
7) (PtL2 463 (D) )-R 477 491 (D) 525 539 (D) 
8) (PtL2 448 (D) )-2R 448 448 (D) 448 448 (D) 
9) [(PtL2)CN-] 504 (D) + 532 560 628 655 (D) 
10) [(PtL2)X-] - + - - - - 
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  J7.1 J5.1 J13.1 J14.1 J16.1 
Negative Mode           
11) M-H 423 + 438 451 485 500 
12) M+CHOO 469 - 483 497 529 544 
13) M-R 409 - 409 409 409 409 
* The same key applies here as was used in Chapter 3.
4.2.2.3 Chromatographic Studies   
   
It is evident from the table that the silver method produced only the 
monomolecular specie while the direct method produced mixtures.   
 
The complexes were analysed chromatographically.  No impurities were detected 
in the compounds J7.1, J5.1, J13.1 and J14.1.  The compound J16.1 was 95% 
pure.  An example of the chromatogram of J7.1 is given in Figure 4.8.  The 
chromatograms of the other complexes can be viewed at the end of the chapter.   
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Figure 4.8: The LC-UV separation of the J7.1 sample prepared by the silver method.   
 
4.2.3 Properties of the Oxalato-Complexes   
4.2.3.1 Solubility   
The aqueous solubilities of the oxalato-complexes by both methods were 
determined as described in Chapter 2.  The data obtained is shown in Table 4.4.   
 
~ 120 ~ 
 
Table 4.4: Aqueous solubility values calculated for the oxalato-complexes.   
Complex 
Solubility (mM) 
Silver Method Direct Method 
J7.1 4.1 0.4 
J5.1 2.9 2.5 
J13.1 2.1 0.6 
J14.1 1.1 4.1 
J16.1 1.7 4.9 
 
The results showed that replacing the halogen leaving groups with anions 
containing the more polar oxygen atoms, increased solubility of the complexes.  
The aqueous solubility of almost all the complexes decreased as the hydrophilic 
nature of the ligands increased.  The complex J16.1 was the only one that did not 
conform to this trend.  When comparing the complexes made by the silver method 
to the ones made by the direct method it is shown that the direct methods ones 
are more soluble.  This was also found to be the case with the halo-complexes.  
The higher solubility of the oxalato-complexes compared to their halogen 
analogues would make their cytotoxic testing at the desired 100 µM possible.   
 
4.2.3.2 Thermal Stability   
The thermal behaviour of three representative complexes was studied up to a 
maximum temperature of 450-500°C.  The results are depicted in Figure 4.9.   
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Figure 4.9: Thermogravimetric curves for the three representative oxalato-complexes.   
All the complexes were stable up to 190°C.  Thereafter, a clear mass loss 
transition was observed, followed by a gradual mass decrease until the end of the 
selected temperature range.  An interesting phenomenon was observed that the 
stability of the complexes decreased as the size of the R2
4.2.3.3 Ionization of the Oxalato-Complexes   
 group on the sulfur atom 
increased, which was in contrast to the chloro analogues.   
 
Ionization studies were performed on the oxalato-complexes.  This study was 
done for two reasons, firstly, to determine whether the chelating oxalato group 
would effectively counter act the strong trans-effect of the sulfur atom, thus 
slowing down the ionization rate.  Secondly to determine the effect of the NS 
ligands on the ionization rates of their corresponding complexes.   
 
The study was done by monitoring the concentration of the molecular specie as a 
function of time in 10% acetonitrile aqueous solution at room temperature.  The 
tests were repeated in an aqueous solution at room temperature and 80°C.  The 
results are tabulated in Table 4.5.  The ion clusters producing the largest signal 
~ 122 ~ 
 
are listed.  Although individual species have different detector response factors, 
the relative size of each cluster does give a rough indication of the relative ion 
concentration.  In some cases where the mass spectrum exhibited two major 
clusters both are listed but separated by an arrow (→).  For comparison the 
halogen results are also given.   
Table 4.5: Summary of the major ion clusters (positive ion mode) observed in the mass 
spectra of the complexes in acetonitrile, water and at 80°C after ≥ 18 hours   
   Solution Chloro- Bromo- Iodo- Oxalato- 
    Complexes Complexes Complexes Complexes 
J7 MeCN [M+NH4]→[M-Cl+H2
[M-
Br+HO] 2O]→[M+NH4 [M-I+H] 2 [M+H] O] 
  Water [M-Cl+H2 [M-Br+HO] 2 [M-I+HO] 2 [M+H] O] 
  Water 80°C [M-Cl+H2  O] [M-2I+OH+MeCN] [M+H] 
      [M-115]   
           
J5 MeCN [M+NH4 [M-2Br-H]→[M+NH]→[M-2Cl-H] 4 [M-2I-H] ] [M+H] 
  Water [M-2Cl-H] [M-2Br-H] [M-2I-H] [M+H] 
  Water 80°C [M-2Cl-H] [M-2Br-H] [M-2I-H] [M+H] 
      [M-2I+OH+MeCN]   
      [M-115]   
J13 MeCN [M+NH4   ]→[M-2Cl-H] [M-2I-H] [M+H] 
  Water [M-2Cl-H]  [M-2I-H] [M+H] 
  Water 80°C [M-2Cl-H]  [M-2I-H] [M+H] 
      [M-2I+OH+MeCN]   
        [M-115]   
J14 MeCN [M+NH4]→[M-Cl+H2   O] [M-I+H2 [M+H] O] 
  Water [M-2Cl-H]  [M-2I-H] [M+H] 
  Water 80°C [M-2Cl-H]  [M-2I-H] [M-Ox-H] 
      [M-2I+OH+MeCN]   
        [M-115]   
J16 MeCN [M+NH4   ]→[M-2Cl-H] [M-I]→[M-2I-H] [M-Ox-H] 
  Water [M-2Cl-H]  [M-2I-H]→[M-I] [M-Ox-H] 
  Water 80°C [M-2Cl-H]  [U351] [M-Ox-H] 
      [M-2I+OH+MeCN]   
        [M-115]   
 
The ionization results were surprising since all, but two of the oxalato-complexes 
hardly ionized under the aqueous conditions even after 18 hours.  The study 
indicated that the molecular specie of J7.1, J5.1 and J13.1 were very stable.  
Ionization had occurred in both J14.1 and J16.1.  The J14.1 sample only ionized in 
aqueous solution at 80°C.  The J16.1 sample displayed ionization under all three 
test conditions.   
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These results are in contrast to the results obtained from the halo-complexes, 
were ionization to the monocationic specie was almost instantaneous.  The 
stability of the oxalato-complexes can almost certainly be related to the chelate 
effect of the dianionic five-membered ring of the oxalato group.  The results show 
that the trans-effect of the thioether has little effect.   
 
The ionization behaviour of J7.1 and J5.1 were compared with that of oxaliplatin in 
aqueous solution at 80°C for 71 hours.  The study revealed that J7.1 had a drop of 
30% of the presence of the molecular specie while oxaliplatin showed a drop of 
25%.  Under similar conditions J5.1 only had a 5% drop.   
 
In light of the above study the low ionization of the oxalato-complexes would lead 
to the suspicion that these compounds would have superior anticancer properties 
compared to their halogen analogous.   
 
4.2.3.4 Cytotoxicity Evaluation   
The cytotoxicity of the oxalato-complexes was measured by testing them on three 
types of cancer cell lines as described in Chapter 2.  The results of these testing 
are shown in Table 4.7.   
 
The table shows a very significant improvement in cytotoxicity compared to the 
halogen analogues.  One complex in particular, J7.1 showed very promising 
results when compared to cisplatin.  (Figure 4.10)  Due to the promising results of 
J7.1 its IC50 values were also calculated at each cell line.  The results are 
tabulated below.   
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Table 4.6: IC50
Cell Lines 
 values obtained for J7.1 compared to cisplatin and oxaliplatin.   
IC 50 Values  
J7.1 cisplatin oxaliplatin 
HeLa 17.56 10.66 11.92 
HT 29 22.53 8.15 12.3 
MCF 7 18.91 14.26 6.21 
 
 
 
 
Table 4.7: Cytotoxic testing of the oxalato-complexes by the silver method.   
Complex HeLa HT 29 MCF 7 Actual Conc (uM) 
  10 50 100 10 50 100 10 50 100 10 50 100 
Cisplatin 64 (3) 82 (1) 79 (1) 33 (2) 62 (2) 62 (2) 46 (8) 57 (3) 65 (3) 9.01 45.1 90.1 
J7.1 41 (6) 81 (1) 82 (1) 5 (4) 65 (1) 66 (1) 36 (4) 71 (1) 71 (1) 10.49 52.4 104.9 
J5.1 16 (6) 13 (2) 3 (5) 10 (9) 12 (4) 10 (8) 0 (12) 5 (2) 7 (3) 3.86 19.3 38.6 
J13.1 15 (4) 33 (2) 43 (3) 20 (4) 23 (3) 46 (3) 15 (6) 32 (4) 56 (1) 9.34 46.7 93.4 
J14.1 10 (7) 22 (4) 42 (8) 34 (3) 30 (7) 30 (9) 20 (8) 27 (5) 46 (3) 8.49 42.5 84.9 
J16.1 19 (2) 32 (4) 44 (1) 37 (6) 37 (5) 45 (6) 18 (3) 31 (3) 54 (5) 5.76 28.8 57.6 
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Figure 4.10: A graphical representation of the anticancer action of J7.1 compared to cisplatin in all three cancer cell lines.   
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The IC50
4.2.3.5 Thermodynamic Stability   
 results of J7.1 were somewhat inferior to cisplatin and even oxaliplatin.  
However, further investigations showed promising STAT 3 activity.   
 
The evaluation of the relative bond strength of the oxalato-complexes was 
accomplished using EV-CAD as described in Chapter 2.  EV-CAD can give an 
indication of the stability of the complexes.  The oxalato-complexes were studied 
by this method.  The results are shown in Figure 4.11.  The data for the analogous 
chloro-complexes are shown for comparative purposes.   
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Figure 4.11: Results obtained from the EV-CAD study of the various NS oxalato-
complexes depicting the amount of energy required to cause a 50% 
reduction of the [Pt(NS)Ox] specie.   
The following observation could be made from the data.   
• The stabilities of the oxalato-complexes are very similar to their chloro 
analogues except for J14.1 which is slightly more stable.   
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• The complex stability decreases as the non-leaving group becomes larger 
except for J14.1.   
 
4.2.4 Structures   
4.2.4.1 Structural determination of Pt(mmtphi)Ox   
The Ortep diagram of Pt(mmtphi)Ox can be viewed in Figure 4.12.  Appendix A 
contains the stereo view of the complex.   
 
Figure 4.12: The structural representation of Pt(mmtphi)Ox. 
The compound crystallized out as yellow needles.  The diffraction data was 
collected at -100 ºC, was found to be of good quality and corrected for absorption.  
Both the structure solution and refinement was accomplished without any difficulty.  
The structure of the compound was solved using the space group P2(1)/c.  A 
Goodness-of-fit of 1.002 and R-Value of 0.0221 (l > 4σ[l]) and 0.0274 (all data), 
indicated that the structure had converged and refined.  A summary of the 
structure details, fractional coordinates and isotropic/anisotropic factors are 
provided in Appendix A.   
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The refinements of the non-hydrogen atoms were done anisotropically.  The 
temperature factors were all satisfactory: Ueq
Table 4.8: Selected bond lengths of Pt(mmtphi)Ox.   
 varied from 0.015 to 0.038 (for O3).   
The hydrogen atoms were positioned geometrically and allowed to ride on their 
respective parent atoms.   
Atom Distance Atom Distance 
Pt - N(1) 1.9874 (26) C(7) - C(8) 1.5555 (47) 
Pt - S 2.2501 (8) C(2) - N(2) 1.3381 (41) 
Pt - O(1) 2.0143 (22) C(2) - C(3) 1.4826 (49) 
Pt - O(2) 2.0160 (22) N(2) - C(4) 1.3910 (43) 
S - C(3) 1.8197 (33) N(2) - C(6) 1.4624 (41) 
S - C(11) 1.7932 (35) C(4) - C(5) 1.3532 (46) 
N(1) - C(2) 1.3307 (41) C(11) - C(12) 1.3829 (44) 
N(1) - C(5) 1.3706 (43) C(12) - C(13) 1.3823 (50) 
O(1) - C(7) 1.2961 (38) C(13) - C(14) 1.3787 (51) 
O(2) - C(8) 1.2927 (41) C(14) - C(15) 1.3935 (52) 
O(3) - C(7) 1.2122 (40) C(15) - C(16) 1.3843 (49) 
O(4) - C(8) 1.2119 (38) C(16) - C(11) 1.3819 (45) 
 
Table 4.9: Selected bond angles in Pt(mmtphi)Ox 
Atoms Angle Atoms Angle 
S – Pt - N(1) 84.80 (8) N(1) - C(2) - N(2) 109.86 (30) 
N(1) - Pt - O(1) 95.38 (10) N(1) - C(2) - C(3) 121.36 (29) 
O(1) - Pt - O(2) 82.65 (9) S - C(3) - C(2) 108.51 (23) 
S – Pt - O(2) 97.18 (7) C(2) - N(2) - C(4) 107.56 (28) 
Pt – S - C(3) 100.38 (11) C(2) - N(2) - C(6) 126.51 (31) 
C(11) – S - C(3) 103.33 (16) N(2) - C(4) - C(5) 106.50 (29) 
C(2) - N(1) - C(5) 107.54 (27) C(4) - C(5) - N(1) 108.54 (30) 
C(2) – N(1) - Pt 120.07 (23) C(12) - C(11) - S(1) 124.09 (27) 
Pt – O(1) - C(7) 113.30 (21) C(12) - C(11) - C(16) 121.00 (33) 
Pt – O(2) - C(8) 112.93 (20) C(11) - C(12) - C(13) 118.70 (32) 
O(3) - C(7) - O(1) 124.34 (33) C(12) - C(13) - C(14) 121.09 (33) 
O(3) - C(7) - C(8) 120.62 (30) C(13) - C(14) - C(15) 119.83 (36) 
O(4) - C(8) - O(2) 124.09 (32) C(14) - C(15) - C(16) 119.39 (33) 
O(4) - C(8) - C(7) 120.35 (31) C(15) - C(16) - C(11) 119.97 (33) 
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The bond distances and angles were as expected and the esds (estimated 
standard deviation) for both were low.  A Number of interesting observations can 
be made:   
• An interesting observation was made with respect to the Pt-O bond lengths.  
The Pt-O(1) (2.0143 (22)) bond length was similar in length to the Pt-O(2) 
(2.0160 (22)) bond length.  This meant that the trans-effect does not play a 
role in the case of a bidentate leaving group.   
• The bond lengths of the imidazole ring structure were in the region of 
1.33-1.39 Å which is typical for sp2
Table 
4.10
 C-C and C-N bond distances.  The 
aromatic character of the imidazole ring made it planar in symmetry.  (
)  However, this was not the case in the halo-complexes.   
• As with the halo-complexes the coordination sphere of the platinum was not 
a perfect square planar.  The platinum atom was positioned perfectly in the 
plane while atoms S and O(1) were below and N(1) and O(2) above the 
plane.  The N(1)-Pt-S angle was 85° the same as the halo-complexes.  This 
deviation can be ascribed to the spatial restrictions forced on the atoms as 
result of being part of bidentate ligands.  (Table 4.10)   
• The benzene ring was planar as would be expected.   
 
Table 4.10: Deviations (×104 Å) (d) and standard deviations (×104
Imidazole 
 Å) (s) of selected atoms 
through weighted least squares planes of the imidazole ring and 
coordination sphere in Pt(mmtphi)Ox. 
 Platinum 
Atom d s  Atom d s 
N(1) -15 27  Pt 0 1 
C(2) 9 35  S -26 9 
N(2) 8 29  N(1) 288 27 
C(4) -26 34  O(1) -248 25 
C(5) 31 35  O(2) 253 25 
Chi-squared = 1.824 (5.99)  Chi-squared = 315.498 (5.99) 
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Benzene     
Atom d s     
C(11) 55 32     
C(12) -46 35     
C(13) -8 37     
C(14) 40 35     
C(15) -21 36     
C(16) -34 36     
Chi-squared = 7.208 (7.81)     
 
Molecular modelling calculations under DFT conditions were done of J14.1.  The 
equilibrium conformer that was obtained had very similar structural parameters as 
that of the crystal structure.  The structure calculated is shown below.   
         
Figure 4.13: The equilibrium conformer for J14.1 under DFT conditions.   
From the structure it is evident that the benzene ring does not have the same 
orientation as in the crystal structure.  This difference could be attributed to the 
possible interaction between the platinum and one of the benzene hydrogens.  
This phenomenon was supported by the energy profile calculated for rotation 
around the S(1)-C(11) bond.  The energy profile revealed two energy minima 
which consisted of the hydrogen of C(12) and C(16) over the platinum.   
 
As in the case of all the molecular modelling calculations the deviation from the 
crystal structure was answered by the packing of the compounds and J14.1 is no 
different.  Revering to Figure 4.14 it is clear that the difference is due to a packing 
effect.   
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Figure 4.14: An illustration of the packing of Pt(mmtphi)Ox.   
4.3 Data 
Table 4.11: The molecular ion clusters detected in all NS oxalato-complexes by the FAB 
mass spectrometry method. 
Complexes 
Detected clusters 
M+H M-Ox + PtL (PtL2 2 (PtL)-R 2
J7.1 (Ag) 
)-2R 
426 336    
J7.1 (D) 426  477 463 448 
J5.1 (Ag) 440 350    
J5.1 (D) 440     
J13.1 (Ag) 453 363    
J13.1 (D) 453 363 534 491 448 
J14.1 (Ag) 486 398    
J14.1 (D) 486  602 525 448 
J16.1 (Ag) 501 412    
J16.1 (D) 501    448 
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Figure 4.15: The LC-UV separation of J5.1 via the silver method showing 100% purity.   
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Figure 4.16: The LC-UV separation of J13.1 via the silver method showing 100% purity.   
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Figure 4.17: The LC-UV separation of J14.1 via the silver method showing 100% purity.   
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Figure 4.18: The LC-UV separation of J16.1 via the silver method showing 95% purity.   
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CHAPTER 5 
MONONITROPLATINUM(IV) COMPLEXES 
5.1 Introduction   
In the previous chapter it was shown that the introduction of the bidentate oxalato 
group into the platinum coordination sphere greatly decreased the ionization rate.  
This led to vastly improving anticancer properties.  Halogen compounds with little 
cytotoxic properties competed with cisplatin for effectiveness after substitution with 
the oxalato group.  It was shown in Chapter 1 that the reaction rate could be 
greatly decreased by oxidizing the platinum(II) to platinum(IV).  If these two 
approaches were to be combined the resultant compound would have very slow 
ionization rates and possibly improved cytotoxicity.  The slow kinetics may make it 
possibly to administer these compounds orally.  Furthermore, the solubility of 
platinum(IV) compounds are known to be greater than their platinum(II) analogues.  
The introduction of four oxygen atoms into the complex in the form of oxalate 
would further enhance the solubility.  It was seen in Chapter 3 that the low 
solubility of the platinum compounds frequently limited their use as anticancer 
agents.   
 
The oxidation of platinum(II) to platinum(IV) is accompanied by the addition of two 
axial ligands.  Care must be exercised to select these ligands.  In literature studies 
on macrophages in the body showed that they produce nitric oxide (NO) in 
amounts sufficient to kill or inhibit the proliferation of tumour cells.112  It appears 
that nitric oxide attacks by bonding to the metal containing enzymes involved in 
respiration and prevents them from functioning.  The cells actually starve to 
death.113  This led to the interest in mononitroplatinum(IV) complexes.  Some of 
these compounds showed promise as anticancer agents.114  It was claimed that 
these complexes act in a different way in their anticancer action from traditional 
ones like cisplatin.115  The two complexes of interest were 
trichloronitroethylenediamineplatinum(IV) complex, Pt(en)(NO2)Cl3 or CPA 1 and 
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cis-diamminetrichloronitroplatinum(IV) complex, Pt(NH3)2(NO2)Cl3
Figure 5.1
 or CPA 7.  The 
latter was claimed to have superior therapeutic properties.  This compound was 
selected as a starting point in obtaining the knowledge and expertise for the 
development of novel platinum(IV) anticancer agents.  ( )   
 
Figure 5.1: Structure of the platinum(IV) derivative of cisplatin, CPA 7.   
 
5.2 CPA 7 Investigation   
5.2.1 Literature Preparation   
Numerous synthetic studies on this complex have been done over an extended 
period of time.116,117,118  However none of these have described a synthetic 
procedure in sufficient detail to be repeatable and none of the products were 
adequately characterized.  Recently two patents appeared in which a large 
number of similar complexes were prepared.119,120 Figure 5.2  ( )   
N
N
Cl
Cl
Pt
NO2
Cl    and   
N
N
Cl
Cl
Pt
NO2
L  
     (a)        (b)  
Figure 5.2: The general representation of the type of complexes.  (Where N denotes an 
am(m)ine and L a neutral donor ligand.)   
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The non-leaving groups (N) were ammine or ethylenediamine.  The two chloride 
atoms in the basal plane were substituted by a variety of other anions.   
 
The synthetic procedures described in these two patents were reproducible but the 
characterization data reported were not conclusive about purity of CPA 7.  In light 
of the above the synthesis was repeated.  The method consists of a reaction 
between the relevant platinum(II) complex with chloride ions (NaCl) in a 1:1 mole 
ratio in an aqueous solution into which NO2 gas was introduced.*
5.2.1.1 Characterization   
  The reaction 
proceeded as described with the formation of a blue intermediate solution which 
turned yellow overnight when exposed to air.  Upon evaporation of the solution a 
yellow precipitate was obtained.   
 
The product formed was analysed and characterized.   
 
Infrared spectroscopy was used to confirm the presence of NO2 and NH3
Figure 5.3
.  A 
infrared spectrum of the solid sample is shown in  and clearly exhibits 
the absorptions characteristics of an N-coordinated nitro group, υ(NO2) = 1471, 
1383 cm-1, δ(ONO) = 830 cm-1 and coordinated NH3, υ(NH3) = 3260, 3160 cm-1, 
δ(NH3) = 1550, 1325 cm-1.121,122,123  The Pt-Cl stretch was also found at 327 cm-1
                                            
* Unlike to the published method the reaction between concentrated HNO3 and pure copper was 
used as NO2 gas source, instead of the very expensive NO2 gas cylinder, as described in 
Chapter 2.   
.  
Thus the infrared spectrum verified the coordination of the ammine, nitro and 
chloro ligands.  The infrared data could not provide information concerning the 
stoichiometry or structure.   
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Figure 5.3: Infrared spectrum of the product obtained by the initial method.   
The product was analysed by mass spectrometry.  (Figure 5.4)   
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Figure 5.4: The mass spectrum of the initial synthetic method used.   
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Mass spectra are highly informative with respect to purity and nature of the 
impurities.  The spectrum of the product produced surprising results.  Not only was 
the product impure but four major products were indicated.  The probable 
structures of these products are given in Table 5.1.   
Table 5.1: The possible structures for the ion clusters present in the mass spectrum 
depicted in Figure 5.4.   
Cl
NO2
NH3
Cl
Cl
NH3
Pt
 
(A) 
CPA 7  
379 g/mol 
Cl
Cl
NH3
Cl
Cl
NH3
Pt
 
(B) 
Pt(NH3)2Cl4
Cl
OH
NH3
Cl
Cl
NH3
Pt
  
368 g/mol 
 
(C) 
Pt(NH3)2Cl3
NO2
NO2
NH3
Cl
Cl
NH3
Pt
(OH) 
350 g/mol 
 
(D) 
Pt(NH3)2Cl2(NO2)
Ion clusters detected in the positive ion mode 
2 
390 g/mol 
m/z 397 = [M+NH4]
m/z 386 = [M+NH
+ 
4]+ 
m/z 369 = [M+H]
m/z 351 = [M+H]
+ 
None + 
Ion clusters detected in the negative ion mode 
m/z 378 = [M-H]- 
m/z 414 = [M+Cl]- 
m/z 424 = [M+HCOO]- 
m/z 441 = [M+NO3]- 
m/z 592 = [M+HFBA]
m/z 367 = [M-H]
- 
- 
m/z 413 = [M+HCOO]- 
m/z 581 = [M+HFBA]
None 
- 
m/z 389 = [M-H]- 
m/z 452 = [M+NO3]- 
m/z 603 = [M+HFBA]- 
The data indicated that the four major products were CPA 7, Pt(NH
* HFBA = Heptafluorobutyric acid.   
3)2Cl4, 
Pt(NH3)2Cl2(NO2)2 and Pt(NH3)2Cl3(OH).  The relative intensities of the spectra 
suggest that CPA 7 constitutes the largest percentage of the product.  This 
however could not be stated emphatically without chromatographic evidence and 
knowledge regarding εM values of the compounds.   
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The extensive chromatographic studies corroborated the mass spectrum findings 
in that it also revealed the presence of four major products.  It is evident from the 
chromatogram, Figure 5.5, that three of the products have very similar separation 
factors.  The YMC Hydrosphere column utilized was not able to separate the 
products in a manner which would avoid overlap of peaks.   
 10 9 8 7 6 5 4 3 2 1 0 
300 
250 
200 
150 
100 
50 
0 
4.23 4.52 
4.78 
5.15 
5.57 
6.28 
RT [min] 
NewPt8_290.DATA mAU 
CPA 7 
Pt(NH3)2Cl4 
Pt(NH3)2Cl3(OH) 
Figure 5.5: The chromatogram of the product utilizing the YMC Hydrosphere.   
In an effort to achieve better separation a more polar column was used.  The 
chromatogram using the Phenomenex Curosil PFP column is shown in Figure 5.6.   
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Figure 5.6: The chromatogram of the Phenomenex Curosil PFP column. 
The increased number of symmetrical peaks, Figure 5.6, indicated improved 
separation.  The compounds associated with the peaks were identified by ESI 
mass spectrometry.  In Figure 5.7 the mass spectral results obtained of the peaks 
A and B indicated that A consisted of the required product, CPA 7, while B belongs 
to the major impurity Pt(NH3)2Cl4.  The mass spectral data collected of peaks C 
and D revealed them to represent Pt(NH3)2Cl3(OH) and Pt(NH3)2Cl2(NO2)2
Figure 5.8
 
respectively.  ( )  The peak at retention time 2.05 min was found to 
contain no platinum and was suspected to be due to nitrate salts.  Integration of 
the peak areas was used to calculate the relative quantities.  In this case CPA 7 
was found to be only 20% of the produced solid!   
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Figure 5.7: The mass spectra of peak A and B. 
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Figure 5.8: The mass spectra of peak C and D. 
It was obvious that from the above results that the method of preparation 
described in the patent was unsuitable for the synthesis of CPA 7 for clinical use.   
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Efforts were then directed to increase the purity by recrystallization but this proved 
to be unsuccessful due to the similar solubilities of CPA 7 and the Pt(NH3)2Cl4
The above results rendered doubt to the significance that can be attached to the 
anticancer properties of the patented product.  These results were due to the fact 
that the major contaminant, Pt(NH
.   
 
3)2Cl4, has similar anticancer properties to 
CPA 7.  Earlier cytotoxic testing on the patented compound could therefore not be 
taken as that of CPA 7 as it was only present as a minority component.  The 
structure of CPA 7 was confirmed by x-ray crystallography.  It is possible to grow a 
pure crystal from a solution containing a mixture of compounds if the solubility 
conditions are correctly controlled.  Therefore this study shed no light on the yield 
or purity.124
5.2.2 Synthetic Route Investigated   
  The exceptional anticancer potential of CPA 7 justified efforts at 
attaining a high yielding synthetic method delivering gram amounts of a high purity 
product.   
 
In an attempt to develop such a method the effect of several parameters were 
investigated.   
 
5.2.2.1 Solvent (Pt:Cl ratio of 1:3)   
The fact that a large amount of Pt(NH3)2Cl4
Figure 
5.9
 formed in spite of the fact that the 
amount of chloride ions added resulted in a platinum to chloride ratio of 1:3 
indicated a secondary source of chloride.  This source was the significant 
ionization of cisplatin in water, a protic solvent with high dielectric constant.  
 shows the ionization of cisplatin in water over a period of three hours.  
Identification of the ionization products showed the presence of hydroxyl species 
such as Pt(NH3)2Cl(OH), the significance of which will be discussed later.   
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Figure 5.9: The ionization of cisplatin in water at 37 ºC showing the decrease in 
concentration of the molecular specie.   
Besides the ionization of chloride a number of other equilibria can be postulated.   
Pt(NH3)2Cl2  +  2NO2(g)  +  Cl- Pt(NH3)2Cl3NO2  +  NO3-
H2O
     Eq: 1 
Pt(NH3)2Cl(H2O)+  +  Cl-Pt(NH3)2Cl2  +  H2O        Eq: 2 
Pt(NH3)2Cl2  +  2Cl-  +  2NO2 Pt(NH3)2Cl4  +  2NO3
-
H2O
     Eq: 3 
Pt(NH3)2Cl(OH)  +  H+Pt(NH3)2Cl(H2O)+         Eq: 4 
Pt(NH3)2Cl2  +  2NO2 Pt(NH3)2Cl2(NO2)2         Eq: 5 
The synthesis of CPA 7 is shown by equation 1.  Equation 2 illustrates the 
ionization of cisplatin.  The resultant platinum(II) product hydrolyses as is shown in 
equation 4.  The ionization of cisplatin increases the free chloride ion 
concentration, which enables the formation of the more symmetrical Pt(NH3)2Cl4, 
equation 3.   
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Therefore the formation of equation 3 and 4 are directly related to the ionization of 
cisplatin in water.  Less of these by-products would be expected if the ionization of 
cisplatin was suppressed.  A possible means of accomplishing this would be 
changing the solvent system to a lesser ionizing one.  The solvent properties 
which effect ionization are:   
• Protic or Aprotic – Hydrogen bonding will promote ionization.   
• Donor number – Electron donating capability.   
• Dielectric constant – Degree of ionization and ion pair formation.   
The solvent characteristics of some selected solvents are listed in Table 5.2.   
Table 5.2: Properties of solvents used in the synthesis. 
Solvent Donor Number Dielectric 
Constant 
Type Relative 
Polarity 
Water 18 81.7 Protic 1.000 
Acetonitrile 14.1 37.5 Aprotic 0.460 
Acetone 17 20.7 Aprotic 0.355 
DMF 26.6 36.7 Aprotic 0.404 
THF 20 7.6 Aprotic 0.207 
MeOH 19 32.6 Protic 0.762 
 
The effect of each of the solvents was investigated.  This was done by repeating 
the preparation as described by the patent with the exception that the solvent 
mixture used was replaced by the solvent in the above table.  The products were 
analysed chromatographically.  The results obtained from the experiments are 
summarized in Table 5.3.   
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Table 5.3: The approximate percentage of each compound in the total product formed 
in each solvent used.   
Solvent CPA 7 Pt(NH3)2Cl Pt(NH4 3)2
MeOH 
Cl(OH) 
10 36 50 
CH3 30 CN 40 10 
THF 40 35 10 
Acetone 59 25 20 
DMF 40 37 8 
Changing the solvent system to a non-aqueous system prevented the formation of 
the dinitro specie.  The formation of CPA 7, Pt(NH
* M = major, S = small and VS = very small. 
3)2Cl4 and Pt(NH3)2Cl3(OH) 
were common to all solvent systems.  The yield of CPA 7 was the lowest in MeOH, 
CH3CN and DMF.  The major contaminant Pt(NH3)2Cl4 was present in all 
systems.  In the case of THF the CPA 7 yield was on par with Pt(NH3)2Cl4
Figure 
5.10
.  The 
reaction in acetone resulted in the highest percentage purity as illustrated in 
.   
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Figure 5.10: The chromatogram of the product yielded from changing the solvent to 
acetone.   
The above spectrum illustrates that the use of an aprotic (non-aqueous) solvent 
system reduces the formation of the Pt(NH3)2Cl3(OH) and Pt(NH3)2Cl4 species.  
Using an acetone solvent system raised the CPA 7 purity to 59 % of the reaction 
product mixture.  Recrystallization did not improve this significantly.   
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In light of the above acetone was selected as the solvent used in further studies.   
 
As the best solvent had been identified, efforts were directed at decreasing the 
free chloride ion concentration by modifying other parameters.  It was expected 
that a decrease in temperature would suppress the ionization rate of cisplatin.  
Secondly was by controlling the amount of chloride added to the reaction.   
 
5.2.2.2 Effect of temperature   
The effect of temperature was investigated by performing the reaction at 0ºC for 
the first hour.  After which the reaction mixture was left for two hours at room 
temperature.  The product analysis is shown in Figure 5.11.   
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Figure 5.11: The product chromatogram of the reaction at 0°C.   
The chromatogram revealed that the decrease in temperature in the preparation 
did alter the distribution of species in the product.  However, the most important 
observation was that there was no decrease in the amount of Pt(NH3)2Cl4.  The 
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experiment was repeated at a higher temperature but this did not yield an 
improvement of the purity of CPA 7.  It was concluded that temperature control 
only would not result in a product of clinically expectable purity.   
 
5.2.2.3 Effect of the Sodium Chloride Ratio   
The Pt(NH3)2Cl4
This was done by repeating the patent method with the exception that acetone 
was used as solvent and the amount of chloride added was varied.  The mole 
ratios of added chloride to platinum were 0.9 to 0.  The results for mole ratios 0.9 
to 0.45 are tabulated in 
 being the major contaminant it was obvious that the formation of 
this contaminant is dependent on the chloride concentration.  The effect of chloride 
concentration was therefore studied.   
 
Table 5.4.   
Table 5.4: The approximate percentage of contaminants in the product in each 
controlled sodium chloride reaction.   
Ratio CPA 7 Pt(NH3)2Cl Pt(NH4 3)2
0.9 
Cl(OH) 
35 35 8 
0.75 40 30 10 
0.6 45 20 12 
0.45 47 16 12 
 
The results showed that as the sodium chloride ratio decreased so did the 
formation of the Pt(NH3)2Cl4
Figure 5.12
 specie.  However, the amount of unknown 
contaminants increased as the ratio was decreased.  The product chromatogram 
of the 0.45 mole ratio reaction is shown below in .   
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Figure 5.12: The product chromatogram of the reaction with 0.45 equivalent sodium 
chloride added.   
The above results show that decreasing the free chloride ion concentration 
resulted in the decrease of the Pt(NH3)2Cl4
5.2.2.4 Solvent (Pt:Cl ratio of 1:2)   
 specie.  However, when the 
experiment was performed with no added sodium chloride the product could not 
be isolated in a solid from.   
 
The fact that the product could not be isolated as a solid when no chloride was 
added and acetone was used as a solvent meant that another solvent had to be 
found.  This was done by repeating the experiment described in section 5.2.2.1.  
The only difference was that no sodium chloride was added.  During the 
experiments only THF and DMF produced products that could be isolated as 
solids.  This did not prevent the chromatographic analysis to be performed.  The 
results of these experiments are summarized in Figure 5.5.   
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Table 5.5: The product analysis of each solvent used under no sodium chloride added 
conditions.   
Solvent CPA 7 Pt(NH3)2Cl Pt(NH4 3)2
MeOH 
Cl(OH) 
45 8 12 
CH3 59 CN Not present 8 
THF 48 15 10 
Acetone 55 Not present 8 
DMF 50 10 17 
 
The table shows that CPA 7 could be prepared without the impurity, Pt(NH3)2Cl4
Figure 5.13
, 
when acetone and acetonitrile were used as solvents.  However, the use of 
acetonitrile resulted in a new major impurity.  ( )   
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Figure 5.13: The product chromatogram of the reaction using acetonitrile as solvent.   
This impurity was identified as the Pt(NH3)2(NO2)4
The chromatogram of the product obtained by using acetone as solvent is shown 
in 
 specie by its mass spectrum.  
This impurity could not be removed by recrystallization.    
 
Figure 5.14.  It was concluded that the use of the solvent acetone resulted in a 
product with the least impurities.  Therefore efforts were made to purify this 
product into a form suitable for clinical use.   
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Figure 5.14: The crude product of the acetone method with no addition NaCl by rotavap 
evaporation.   
 
5.2.2.5 Purification   
In the method used above the solvent was removed by rotavap evaporation.  This 
was replaced by blowing air over the reaction mixture at room temperature 
overnight.  This crude product was collected, a yellow powder was formed and 
from the chromatogram, Figure 5.15, it was evident that the amount of unknown 
impurities was less.  The purity of CPA 7 in this product was calculated to be 
64 %.   
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Figure 5.15: The crude product of the acetone method with no addition NaCl by air 
evaporation.   
The chromatogram showed that the major impurity was the Pt(NH3)2Cl3
Table 5.6
(OH) 
specie.  In an attempt to remove the impurity the precipitate was washed.  Various 
solvents were used ranging from polar to non-polar.  All washing procedures were 
done at room temperature.  The list of solvents used accompanied with 
percentage purity obtained for CPA 7 is shown in .   
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Table 5.6: The percentage purity of CPA 7 obtained with each solvent wash.   
Solvent used % Purity of CPA 7 % Present of 
Pt(NH
* 
3)2
Methyl Acetate 
Cl(OH) 
90 4 
Ethyl Acetate 88 8 
n-Butyl Acetate 70 15 
4-Methyl-2-Pentanone 84 10 
Di-iso-Butyl Ketone 64 20 
Tert-Butyl Alcohol 76 11 
Diethyl Oxalate 78 10 
Dimethoxy Propane 61 17 
Toluene 54 20 
*
From the above table it is evident that the optimal solvent should be polar but not 
too hydrophobic.  The two solvents that demonstrated the best results were methyl 
and ethyl acetate.  The final decision to use methyl acetate was due to the fact 
that the Pt(NH
 As determined chromatographically.   
 
3)2Cl3
Figure 5.16
(OH) contamination was less.  Furthermore CPA 7 was less 
soluble in the solvent.  The chromatogram of the washed product is shown in 
.   
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Figure 5.16: The chromatogram of the product after methyl acetate washes using the 
hydrosphere column.   
Further washing did not result in a percentage purity of higher than 95%.  A mass 
spectrum of the product was obtained in order to identify the nature of the 
impurities.  (Figure 5.17)   
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Figure 5.17: The mass spectrum of the methyl acetate washed product by the acetone 
method.   
The identification of the peaks present in the mass spectrum is summarized in 
Table 5.7.   
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Table 5.7: The associated complexes of each peak found in the final product of the 
acetone method.   
Peak Associated complex 
351 [Pt(NH+ 3)2Cl3(OH) + H]
397
+ 
[CPA 7 + NH+ 4]
378
+ 
[CPA 7 - H]- 
414
- 
[CPA 7 + Cl]- 
424
- 
[CPA 7 + HCOO]- 
441
- 
[CPA 7 + NO- 3]
 
The mass spectrum revealed no evidence of the presence of either the 
Pt(NH
- 
3)2Cl4 and Pt(NH3)2Cl2(NO2)2 compounds.  However the Pt(NH3)2Cl3
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impurity was still present.  The PFP column was then used to determine the 
percentage purity of CPA 7.  Using this column the purity measured dropped to 
83%.   
Figure 5.18: The chromatogram of the methyl acetate washed product using the PFP 
column.   
In an effort to optimise the acetone method and decrease the formation of the 
Pt(NH3)2Cl3(OH) specie dry acetone was used.  The surprising result was that 
almost pure Pt(NH3)2Cl4 was formed but with little Pt(NH3)2Cl3
Figure 5.19
(OH) present.  
( )   
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Figure 5.19: The acetone method under dry condition, showing mainly Pt(NH3)2Cl4.   
The work done up to this point showed that it was possible to remove two of the 
major impurities namely, Pt(NH3)2Cl4 and Pt(NH3)2Cl2(NO2)2 but the removal of 
the Pt(NH3)2Cl3(OH) specie still posed a problem.  As shown in equation 4 the 
Pt(NH3)2Cl3
5.2.3 Nitric Acid Method   
(OH) impurity was the result of the hydrolysis reaction.  It is obvious 
that this reaction can be potentially prevented if the preparation of CPA 7 was 
performed in acid medium.   
 
It was known that NO2 would be produced on reduction of concentrated HNO3.  
This was likely to occur if the latter reacted with cisplatin.  It was therefore decided 
to substitute acetone with concentrated HNO3 as solvent.  The new synthetic 
process comprised of the overnight stirring of cisplatin in 69 % HNO3
Figure 5.20
 at room 
temperature.  A pale yellow product resulted which upon analysis was found to be 
86% CPA 7.  ( )   
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Figure 5.20: The crude product obtained from the HNO3 method. 
The purity of the above product could be improved up to 96 % by washing with 
methyl acetate.   
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Figure 5.21: The methyl acetate washed product of the HNO3
By following the nitric acid method in preparing CPA 7 it seemed possible to 
eliminate the formation of the Pt(NH
 method.   
3)2Cl3
Figure 5.22
(OH) specie as well as the other 
contaminants previously mentioned.  This was confirmed by the above 
chromatogram obtained from the final product.  The mass spectrum of this product 
is represented in .  The compounds identified as being present are 
indicated on the chromatogram.  Although the chromatogram showed the 
Pt(NH3)2Cl3
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(OH) specie to be absent the mass spectrum does however confirm its 
presence.   
Figure 5.22: Mass spectrum of the product (CPA 7) prepared by the HNO3 method.   
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Figure 5.23: Infrared spectrum of the product (CPA 7) prepared by the HNO3
The infrared spectrum of the final product was recorded, showing its spectrum is 
very similar to the product from the initial method.  Refer 
 method.   
Figure 5.23 and Figure 
5.3.   
 
A compound can only be useful clinically if it can be prepared on a large scale.  
Attempts were made to increase the scale of both the acetone and nitric acid 
method discussed above.  It was found that these methods could only be applied 
to a scale of 2 g cisplatin.   
 
In light of the results reported above it was not surprising that a simple method of 
preparation with high yield and purity for CPA 7 is still lacking 30 years after its 
initial synthesis.   
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In the above investigation towards a satisfactory synthetic method for CPA 7 it was 
clearly illustrated that the ionization of platinum(II) chloro-complexes was the main 
reason for the multiple side reactions.  The final method described here is by far 
superior to any published procedures.  Firstly, since it exclude the major 
contaminates Pt(NH3)2Cl4 and Pt(NH3)2Cl3(OH).  Secondly, 98% pure CPA 7 at a 
yield of 40% can be produced.  Furthermore the method is simplified in that no 
NO2 gas needs to be added from an external source.  In this method NO2 is 
produced from concentrated HNO3
5.3 The Diamminetetrachloroplatinum(IV) Pt(NH
 in situ.   
 
3)2Cl
In the previous section the serendipitously discovery of a method for the 
preparation of almost pure Pt(NH
4 
3)2Cl4 was made.  This method was further 
investigated.  The compound Pt(NH3)2Cl4 appeared as a major contaminant in the 
preparation of CPA 7.  It was felt that a better understanding of the factors which 
led to the preparation of pure Pt(NH3)2Cl4 would give insight in how to prevent its 
formation as a contaminant in preparation of other compounds.   
 
The preparation of Pt(NH3)2Cl4
5.3.1 Synthesis 
 has been documented in the literature.  This 
method and, the method described in the previous section, were adapted using 
the knowledge gained in the investigation and repeated.  The results were then 
compared.   
 
5.3.1.1 Literature method  
The method comprised of bubbling the oxidant chlorine gas through a suspension 
of cisplatin and acetone.  The precipitate that was formed was filtered and dried.  
See Chapter 2 for the complete description.  The mass spectrum of the product is 
shown below.    
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[Pt(NH3)2Cl3(OH) + Cl]- 
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Figure 5.24: The mass spectrum of the products obtained in the synthesis of Pt(NH3)2Cl4
The mass spectrum shows the presence of a large amount of the 
Pt(NH
 
(Literature Method).   
3)2Cl3 Figure 
5.25
(OH) contaminant.  This was confirmed chromatographically.  (
)   
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[Pt(NH3)2Cl4] 
Figure 5.25: The chromatogram of Pt(NH3)2Cl4 by method 1.   
The chromatogram shows the presence of two complexes that are formed in the 
synthesis, one being the Pt(NH3)2Cl4 and the other the Pt(NH3)2Cl(OH).  The 
purity of Pt(NH3)2Cl4 was approximately 30%.   
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5.3.1.2 Nitrosyl Method  
The method described under section 5.2.2.5 that produced pure Pt(NH3)2Cl4 had 
a low yield as no extra chloride was added.  In an attempt to increase the yield 
NOCl was used instead of NO2
Figure 5.26
, nitrosyl chloride being a source of both NO and 
chloride.  The detailed method is described in Chapter 2.  The mass spectrum of 
the product produced from this method is shown in .   
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[Pt(NH3)2Cl4 + Cl]- 
[Pt(NH3)2Cl4 + HCOO]- 
[Pt(NH3)2Cl4 + HFBA]- 
[Pt(NH3)2Cl4 - H]- 
Figure 5.26: The mass spectrum of the product formed by the nitrosyl method.   
The mass spectrum shows that this method produced mainly the Pt(NH3)2Cl4, with 
very little evidence of Pt(NH3)2Cl3 Figure 5.27(OH).  The chromatogram, , of the 
product confirmed the result.  The Pt(NH3)2Cl4 was produced in an 80% yield and 
a purity in excess of 95%.   
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Figure 5.27: Chromatogram of Pt(NH3)2Cl4
The compound was further characterized by infrared spectroscopy, 
 produced by the nitrosyl method.   
Figure 5.28, 
this was to ensure that no NO or NO2 was present.  The infrared spectrum clearly 
exhibits the absorption characteristics of coordinated NH3 groups.  These being 
ν(NH3) = 3240, 3153 cm-1, δ(NH3) = 1554, 1318 cm-1.  The spectrum does show 
an absorption band at 857 cm-1 which can possibly be interpreted as δ(ONO) band 
(δ(ONO) for CPA 7 was 826 cm-1) but no other bands confirmed this assignment.  
This band however is more likely to be that of the NH3 rock.   
 
Figure 5.28: The infrared spectrum of PtCl4(NH3)2.   
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5.4 Characterization of CPA 7 and Pt(NH3)2Cl
CPA 7 and Pt(NH
4 
3)2Cl4
5.4.1 Thermogravimetric analysis   
 was characterized by thermal analysis, cyclic 
voltammetry, HPLC, solubility testing and cytotoxic testing.   
 
Thermogravimetric analysis was done on both CPA 7 and Pt(NH3)2Cl4
Figure 5.29
 to study 
their thermal behaviour up to a maximum temperature of 450-500°C.  The 
thermogravimetric curves of the two complexes are shown in  and 
Figure 5.30 respectively.   
 
Figure 5.29: The thermogravimetric curve of CPA 7.   
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Figure 5.30: The thermogravimetric curve of Pt(NH3)2Cl4.   
When the thermogravimetric curve of CPA 7 was compared to that of the 
Pt(NH3)2Cl4
• In both cases the final product was platinum metal.  This was produced at 
±424°C for CPA 7 and ±390°C for Pt(NH
 the following interesting characteristics were observed.   
3)2Cl4
• Both thermograms show the absence of solvent trap in the lattice.   
).   
• The onset temperature for decomposition of CPA 7 was 263°C while for the 
Pt(NH3)2Cl4
• The thermogram of Pt(NH
 was 320°C.   
3)2Cl4
Table 5.8
 shows a two step decomposition.  The first 
could correspond to the loss of the chlorides and the second, the loss of the 
ammine ligands.  ( ) 
• The decomposition of CPA 7 is more complex.  The first step in the 
decomposition might be the loss of a NO2 and NH3 molecule.  This might 
be due to the oxidizing action of NO2 and the close proximity of NH3
Table 5.8
 with its 
reducing capability which apparently leads to an oxidation/reduction 
reaction of N(III) and N(-III).  This becomes even more apparent if it is 
borne in mind that ammoniumnitrite decomposes to nitrogen and water.  
( )   
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Table 5.8: The calculations of the possible compounds loss during transition for 
Pt(NH3)2Cl4
 
 and CPA 7.   
Theoretical % Experimental % Possible compounds  
Pt(NH3)2Cl
Transition 1 
4 
38.54 31.84 4 x Cl 
Transition 2 9.24 12.67 2 x NH
CPA 7 
3 
Transition 1 16.51 15.55 NO2 and NH
 
3 
Supporting evidence for the assumption that the first loss can be attribitued 
to a reaction between NO2 and NH3 was found in the thermogravimetric 
behaviour of bisamminedinitroplatinum(II).  This compound decomposes 
very rapidly to the metal.  In this case the ligands are ideally spaced for 
complete auto oxidation/reduction reactions amongst the NO2 and NH3
Figure 5.31
 
having a 1:1 ratio.  ( )   
 
Figure 5.31: The thermogravimetric curve for Pt(NO2)2(NH3)2.   
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• The exact molecule losses at transition 2 and 3 for CPA 7 could not be 
assigned with any certainty.   
 
Although the above information is of interest from an academic perspective, the 
behaviour of aqueous solutions of these complexes give a better indication of 
anticancer potential.  The platinum(IV) to platinum(II) reduction potentials are of 
importance in this connection.  A rapid reduction by reducing agents in the body 
will result in a platinum(II) complex with all the toxic effects already discussed.   
 
5.4.2 Electrochemistry   
Cyclic voltammetry is a useful tool to evaluate the effects of ligands on the 
oxidation/reduction potential of the central metal ion in coordination complexes. 
Indeed, most of the data pertaining to the influence of the axial ligands on the 
reduction potential of platinum(IV) complexes, has been determined via this 
technique125,126.  The voltammograms of CPA 7 and Pt(NH3)2Cl4
Figure 
5.32
 were acquired at 
a scan rate of 100 mV/s at 25°C in a 0.1 M KCl solution, and are shown in 
. Potentials were determined relative to the Ag/AgCl reference electrode.   
 
The data show that the reductions of both these complexes are irreversible.  It 
therefore should be noted that the reported Ep
30
 values are cathodic forward half-
wave potentials, and are kinetic, not thermodynamic values.  It has been 
demonstrated that the reduction potential of a complex is more dependent on the 
axial ligands than those occupying the equatorial coordination plane.  For example 
the ease of reduction being Cl > OAc > OH. ,127  The reduction potential for 
Pt(NH3)2Cl4
30
 was found to be -329 mV which is within experimental error of the 
values found in literature.   It is known that Pt(NH3)2Cl4 reduces to cisplatin fast in 
vivo thus causing an increase in toxicity of the drug.  The reduction potential for 
CPA 7 was -493 mV which indicated that it is more stable towards reduction.  This 
would allow for a greater proportion of the drug to reach the target site intact as 
well as fewer side reactions (toxicity).   
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Figure 5.32: The voltammograms of both CPA 7 and Pt(NH3)2Cl4
5.4.3 Aqueous Solubility 
.   
 
The aqueous solubility of both CPA 7 and Pt(NH3)2Cl4
Table 5.9
 were determined as 
described in Chapter 2. The data is shown below in .   
Table 5.9: The aqueous solubility values calculated for CPA 7 and Pt(NH3)2Cl4
Complex 
.   
Solubility (mM) 
CPA 7 155 
Pt(NH3)2Cl 14.2 4 
 
The only difference between CPA 7 and Pt(NH3)2Cl4 is the substitution of the 
chloro by a nitro group.  It is surprising that the introduction of a polar NO2 group 
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can cause an order of magnitude increase in solubility.  The high solubility of 
CPA 7 makes it suitable for clinical use.   
 
5.4.4 Cytotoxic Testing   
The cytotoxicity of CPA 7 as well as for the Pt(NH3)2Cl4
Table 5.10
 was measured on three 
types of cancer cell lines as described in Chapter 2.  The results are shown in 
.  The results showed that their cytotoxicity were very similar to that of 
cisplatin.  The cytotoxic properties of Pt(NH3)2Cl4 has been well documented and 
are in agreement with the above results.128
Figure 5.33
  Both these compounds being in 
oxidation state (IV) suggest that part of their cytotoxicity will be due to the 
reduction to their platinum(II) analogues.  The reduction product in both cases 
probably is cisplatin.  It is therefore reasonable to assume similar cytotoxic 
properties to cisplatin.  ( )  However, the reduction of CPA 7 is expected 
to be slower since the reduction potential is 160 mV less than that of Pt(NH3)2Cl4.  
This would indicate that the amount of CPA 7 that reaches the cancer cells is more 
thus reducing the amount of side reaction that could occur.   
The IC50
 
 values for CPA 7 was also calculated but will be discussed later.   
 
 
Table 5.10: The cytotoxic results of CPA 7 and Pt(NH3)2Cl4
Complex 
 compared to cisplatin on three cancer cell lines.   
HeLa HT 29 MCF 7 Actual Conc (µM) 
  10 50 100 10 50 100 10 50 100 10 50 100 
Cisplatin 80.3 (3) 82.2 (1) 81.9 (1) 46.7 (2) 61.6 (1) 62.7 (2) 74.3 (1) 76.6 (1) 82.0 (1) 11 55 110 
CPA 7 80.4 (1) 80.3 (2) 80.5 (1) 47.4 (3) 56.5 (7) 61.0 (1) 72.5 (2) 69.6 (1) 75.2 (3) 10.6 53 106 
Pt(NH3)2Cl 75.6 (3) 4 77.7 (1) 76.8 (1) 41.2 (8) 57.9 (3) 59.8 (3) 72.2 (2) 65.5 (3) 74.2 (1) 9.6 48 96 
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Figure 5.33: The graphical representation of the cytotoxic effect of both CPA 7 and Pt(NH3)2Cl4
 
 compared to cisplatin.   
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5.5 Interpretation of Reactions Involved in NO2
During a literature study of the reactions of NO/NO
 with 
Platinum(II) Complexes   
2 with platinum(II) complexes it 
was noted that similar colour changes were observed in the present study of NO2
5.5.1 Blue product 
 
reactions.  In all literature blue and green complexes were found to be intermediates 
which were stable only at lower temperatures and could readily be oxidized to stable 
platinum(IV) complexes.  The reactions described in this chapter also went through a 
blue phase, followed by green in the absence of oxygen and then turning yellow upon 
exposure to air or oxygen.  The yellow compound was the product and its structure is 
known.  An attempt will be made to explain the nature of the intermediate complexes   
 
Initially, persistent dark blue solutions were obtained only when NO2
Abbot et al.
 was bubbled 
through a solution of platinum(II) oxalato complexes such as {bis-oxalato(dach)Pt(II)} 
in an effort to synthesize the dinitroplatinum(IV) complex (thus in the absence of 
chloride). 
 
129 prepared dark blue crystals of K[Pt(NO2)4(NO)H2O] by the reaction of 
3:1 H3PO4:H2O solution with K2Pt(NO2)4
Figure 5.34
.  A crystal structure determination of the 
product ( ) showed four planar nitro groups and one bent NO group trans 
to a H2O molecule.  The Pt-N bond length of the NO was slightly longer than the Pt-N 
bonds of the NO2 groups, 2.10 Å vs 2.04 Å and 2.06 Å.  The NO bond was shorter 
than those of the NO2 ones 1.19 Å vs 1.21 Å and 1.22 Å.  The Pt-O bond of the water 
molecule was relatively long 2.37 Å.  This suggested a very strong trans directing 
effect of the bent NO.  This in our opinion can be compared to the very similar 
behaviour found in the dimeric platinum(III) metal-metal bonded complexes were the 
trans-effect of the metal-metal bond is given as the reason why bonding trans to it 
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only allows for extended bond lengths.130  It therefore seems as if the odd electron on 
the NO pairs with the odd electron of the platinum(III) in a similar way as the 
metal-metal bond.  This provides some stability to the formed compound.   
 
The [Pt(NO2)4(NO)H2O]- was one of the very few dark blue monomeric species 
known, since this colour was common for dimeric “platinum blues” which have Pt-Pt 
bonds and bridging anions and thus formally regarded as platinum compounds of 
intermediate oxidation states (>2<4)131. The above anion was very unstable since the 
coordinated water molecule was readily replaced by coordinating anions such as the 
halides Cl- and Br-.  The complex was also very strongly reducing. 
 
The best description of this complex in terms of oxidation state is a platinum(IV) 
compound bonded to NO-, thus trans-aquo(nitrosyl)tetranitroplatinate(IV).  It therefore 
seems, reasonable to assume that the blue colour obtained from platinum(II) amine 
complexes studied in this thesis and NO2 can be seen as a similar aqua (nitrosyl) 
complex of platinum(IV).  The extent of the electron withdrawal can be regarded as 
sufficiently limited so that the milieu of the platinum approximate is that of a 
platinum(III) complex. The blue colour is maintained if the H2O molecule is replaced 
by a weakly coordinating anion like NO3, as found in K2[PtNO2)4(NO)(NO3)].132 
 
 
N(5)-O(5b)  1.19Å 
Pt-O(6)   2.37Å 
Pt-N(5)   2.10Å 
Pt-N(5)-O(5b) (angle) 129° 
Figure 5.34: Trans-aqua(nitrosyl)tetranitroplatinate(IV) anion 
~ 168 ~ 
 
5.5.2 Green product 
When three moles of potassium chloride were added to the dark blue solution the 
colour turned dark green.  Upon maintaining the temperature of the green solution at -
20°C under argon, green crystals of K2[Pt(NO2)2(NO)Cl3] gradually formed.   
 
In this complex two planar nitro groups were replaced by two bonded chlorides and 
the trans H2O molecule was similarly replaced by a bonded chloride.  Even though 
the NO was still bent, the Pt-N-O angle had changed from 129° in the former to 119° 
in the latter.  The latter angle suggested significant electron withdrawal from the NO 
bond.  The shorter Pt-N distance of 2.06 Å, as compared to 2.10 Å in the former, 
indicates a stronger Pt-N bond in the chloro-complex.  The Pt-Cl bond length of the 
trans Cl- is 2.562 Å, ~0.25Å longer than the planar chlorides, still suggesting a strong 
trans-effect. This transition therefore seemed to suggest that more electron 
withdrawal from the Pt occurred, leading to stabilization approaching what can be 
considered as platinum(IV).   
 
N(3)-O(3)  1.19Å 
Pt-Cl(2)  2.320Å 
Pt-Cl(3)  2.562Å 
Pt-N(3)  2.06Å 
Pt-N(3)-O(3) (angle) 119° 
Figure 5.35: Trans-dinitro-trans-dichloro-trans-nitrosylchloroplatinum(IV) ion 
 
In 1961 Wilkinson et al.133 obtained the green complexes K2[Pt(NO)Cl5] and 
K2[Pt(NO)(NO2)4Cl] by the reaction of NOCl in CHCl3 from K2PtCl4 and K2Pt(NO2)4, 
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respectively.  These complexes were described133 as six-coordinated platinum(II) 
complexes containing NO in the form of NO+ since the NO stretch frequency values 
were found to be in the 1700 cm-1 region.  Literature values in the vicinity of 1800 cm-1 
are regarded as NO+ groups whereas those in the vicinity of 1100 cm-1 be regarded134 
as NO-.  Judging from this data it seemed reasonable to assign it to platinum(II) even 
in light of the extremely rare cases of six-coordinate platinum(II) complexes.  More 
recently the X-ray crystallographic studies of these complexes clearly indicated the 
presence of a bent Pt-N-O entity suggesting their description as NO-
5.5.3 Yellow product 
 groups to be 
more appropriate.  These complexes could be regarded as an unstable platinum(IV) 
species.  It was previously stated that the green complexes were unstable and 
decomposed by water to become stable yellow platinum(IV) species.   
The colouration to yellow is then associated with the air oxidation of the coordinated 
NO ligand to a nitro ligand with increased electron withdrawal from the platinum 
producing an air stable platinum(IV) complex.  A resent crystal structure of the 
fac-isomer of CPA 7124 showed that the light yellow compound consists of a 
platinum(IV) complex with an NO2
Figure 5.36
 group trans to the chloro atom where the latter 
bond was significantly longer than the planar Pt-Cl bonds.  ( )   
 
Pt(1)-Cl(3)  2.278Å 
Pt(1)-Cl(1)  2.346Å 
Pt(1)-N(3A)  2.05Å 
Pt(1)-N(1)  2.04Å 
 
Figure 5.36: The crystal structure of the fac-isomer of CPA 7.   
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In conclusion it seemed that the best description of these reactions was the oxidative 
addition of the NO radical with simultaneous withdrawal of an electron to produce a 
bonded group best described as being in the NO- state.  Having a weakly bonded 
H2O in a trans position, resulting in a relatively unstable intermediate specie.  In the 
presence of excess chloride ions the H2O was replaced.  Further electron transfer 
occured from the platinum to the chloride atom followed by oxidation of the bonded 
NO group to a NO2
H2O
Pt(NH3)2Cl2
NO
Pt(NH3)2Cl2(NO)(H2O)
Cl-
Pt(NH3)2Cl3(NO)
O2
Pt(NH3)2Cl3(NO2)
Yellow Blue Green Light Yellow
 group thus completing the stabilization of the platinum(IV) 
complex.  The considered reaction sequence is given below:  
 
 
5.5.4 Source of NO 
Although NO was not directly synthesized and provided as such both HNO3 and NO2 
gas could be considered as a source of NO.  This is illustrated by the sequence of 
equations below.  
When concentrated HNO3
NO3-  +  2H+  +  e NO2  +  2H2O
 is used as reagent NO gas is produced by the following 
reaction.   
 
When NO2 gas reacts with a medium containing H2
2NO2  +  H2O HONO  +  H
+ NO3-
O NO is similarly formed by the 
equations below.   
 
3HONO 2NO  +  H+ NO3-  +  H2O  
In the case of NO2 gas a certain amount of water in the solvent system seemed to be 
a requirement for the secondary formation of NO through the auto ionization indicated 
above.  This fact was emphasized in a reaction where dried acetone was used as 
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solvent which produced a large amount of the Pt(NH3)2Cl4
5.6 Dicarboxylatomononitroplatinum(IV) specie 
 specie and almost 
insignificant amounts of the mononitro specie.   
 
In the introduction it was stated that the aim of this project was to prepare platinum 
compounds with low ionization rates.  It has been shown that this could be achieved 
by the introduction of a bidentate leaving group, Chapter 4.  It is known that by 
increasing the oxidation state of platinum from two to four will decrease the ionization 
rate.  It is obvious that the next step is to combine these two approaches.  A suitable 
compound had to be selected.   
 
The amminemononitroplatinum(IV) compounds have been patented.119,120  However, 
the patent mainly included the halo-complexes and no mention was made of 
oxalato-complexes.  Furthermore, not a single mononitrooxalatoplatium(IV) complex 
could be found in a literature search.  This can almost certainly be related to the 
reducing action of the oxalato specie.   
2CO2  +  2H+  +  2e H2C2O4 -0.49 V  
It is known that oxalate can reduce platinum(IV) to platinum(II) and even to platinum 
black.135
Some oxalato-platinum(IV) complexes with amine ligands have been isolated from 
platinum(II) by mild oxidation,
  In the presence of amine co-ligands, platinum(II) complexes, however, are 
relatively stable, for example oxaliplatin decomposes at 270°C.   
 
136 but this has never been done with NO2 as oxidant.  
Nitrogen dioxide in a polar solvent, such as water, disproportionates to HONO 
(nitrous acid) and HNO3.  The former is a strong oxidant, even stronger than HNO3, 
for example HNO3 oxidizes uranium metal only to uranium(IV) while HNO2 oxidizes it 
to uranium(VI).137  It can also oxidize oxalate to CO2 and H2O.  This may be the 
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reason why mononitrooxalatoplatinum(IV) complexes have not been prepared and 
reported.  In spite of this and as a result of the experience in this laboratory it was 
thought that stable mononitrooxalatoplatinum(IV) complexes could be isolated.  In 
selecting a suitable compound it was remembered that the platinum(IV) compounds 
are reduced in vivo.  It is essential that the reduction product must exhibit good 
anticancer properties.  Oxaliplatin was therefore selected.   
 
As a consequence of the importance of this project a small team of workers was 
selected to develop a method of preparation.  The oxidation of oxaliplatin with NO2
The preparation resulted in the isolation of trans-[(R,R)-1,2-
diaminocyclohexane]chloronitrooxalatoplatinum(IV), 
 
gas in the presence of chloride met with success almost immediately.  The colour 
changes that occurred during the preparation were similar to those found during the 
preparation of CPA 7, namely:   
Suspension → Blue solution → Green solution → Yellow solution 
This would indicate that the reaction mechanism described in the previous section 
also applied to this reaction.   
 
Figure 5.37, of a purity of excess 
of 95% and a yield of over 80%.138   
~ 173 ~ 
 
 
Figure 5.37: Trans-(R,R)-1,2-diaminocyclohexanechloronitrooxalatoplatinum(IV) [Mar 4.1.4] 
The characterization of this compound was done.  The thermal analysis showed the 
presence of two water molecules of crystallization.  The compound was stable up to 
260°C which was very similar to the stability of CPA 7.   
 
Single crystal x-ray crystallography confirmed the above structure and confirmed the 
presence of two uncoordinated water molecules.   
 
Cyclic voltammetry was used to determine the reduction potential of the compound.  It 
was found that the reduction potential was significantly lower than that of CPA 7.  
However, the potential was still higher than that of Pt(NH3)2Cl4 Table 5.11.  ( )   
Table 5.11: The redox potential values of CPA 7, Pt(NH3)2Cl4
Complex 
 and Mar 4.1.4.   
Potential (mV) 
CPA 7 493 
Pt(NH3)2Cl 329 4 
Mar 4.1.4 347 
~ 174 ~ 
 
Cytotoxic testing revealed very promising results.  For this reason IC50
Table 5.12
 values were 
measured.  ( )  These results showed the compound to be superior to 
cisplatin, oxaliplatin and CPA 7.   
Table 5.12: The IC50
Complex 
 results of CPA 7 compared to other compounds.  
Cancer Cell Lines Tested 
HeLa HT 29 MCF 7 
CPA 7 5.14 9.81 9.29 
Cisplatin 10.67 8.11 14.10 
Oxaliplatin 11.92 12.30 6.21 
Mar 4.1.4. 4.81 3.07 5.86 
 
The initial objective of this study was to develop a method for the manufacture of pure 
CPA 7.  This was partially successful.  An in depth understanding of the nature of the 
impurities were achieved and pure CPA 7 could be isolated in amounts of less than 
1 g.  However, the prepative method could not be upscaled for commercial use.   
 
The preparation of Mar 4.1.4. was a triumph.  The compound showed great potential 
as an anticancer drug.  This compound was not serendipitously discovered.  It was 
designed as a result of the knowledge previously accumulated.  The first step was the 
selection of the non leaving group.  The diamine ligand dach was shown to have 
better anticancer properties than the diammine in cisplatin, as it bonds differently to 
the DNA.  It had the drawback of introducing low solubility in its complexes.  The 
introduction of oxalato and nitro groups into the complex, the polar nature of which 
resulted in a higher solubility, more than compensated for this.  It was shown that 
kinetic stability was important in improving cytotoxic properties.  In this study, two 
~ 175 ~ 
 
methods were tested to achieve this, namely, the introduction of bidentate oxalato 
group and the oxidation of platinum(II) to platinum(IV) by mild oxidation using NO2.  It 
was shown that the oxidation process went through a two step process which 
prevented associated ligands from being decomposed.  It was the work done in this 
thesis that provided the necessary knowledge and experience to enable a method to 
be developed for the preparation of Mar 4.1.4.   
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CHAPTER 6 
CONCLUSIONS 
6.1 NS Complexes 
• The large trans-effect as exhibited in the virtually instantaneous ionization of 
the halo-complexes is very characteristic of these complexes.  The trans-effect 
is clearly shown in the crystal structure by the lengthening of the Pt-Cl bond 
trans to the sulfur atom.   
• The particular poor anticancer properties are likely to be related to the above 
property.   
• The apparent absence of the trans-effect in the oxalato-complexes of which 
the extent of ionization is very similar to the diamine analogues is likely to be 
related to the chelate action of the dicarboxylate group.   
• The oxalato-complexes in general have poor anticancer action though better 
than their chloro analogues.  However, one of these has very good anticancer 
properties and has exceptional STAT 3 behaviour.   
• Both halo- and oxalato-complexes are stable.  Decomposition starts at 200°C 
and 190°C respectively.   
 
The two methods used for these syntheses improved our understanding of the 
equilibria involved in the chemical processes.  Although thioether sulfur donors can 
be regarded as platinum reservoirs their large trans-effect seemed to hamper their 
anticancer action.   
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6.2 Mononitrochloroplatinum(IV) complexes:  
After the extensive study on CPA 7 important conclusions could be made.   
• The multiplicity of the numerous simultaneous equilibria was shown by the 
great variety of compounds obtained in following the patented synthetic 
method.  These included: Pt(NH3)2Cl3NO2, Pt(NH3)2Cl4, Pt(NH3)2Cl2(NO2)2 
and Pt(NH3)2Cl3(OH), in which the Pt(NH3)2Cl4
• By limiting the free chloride ion concentration the production of the Pt(NH
 was the major contaminant.   
3)2Cl4 
• The alteration of the method by using concentrated nitric acid as the source of 
NO
could be prevented and the yield of the required product drastically increased.   
2 minimized the formation of another contaminant namely, 
Pt(NH3)2Cl3
• Through the application of a suitable washing agent, methyl acetate, the purity 
of the product could be increased to 95%.   
(OH).   
• However, all the successful modifications did not enable us to produce the 
pure product in quantities greater than two grams.   
• The determination of the Eo values of CPA 7 and Pt(NH3)2Cl4
• A feasible interpretation of the sequence of reaction occurred in this syntheses 
could be arrived at when compared with similar previous work.  The conclusion 
could be made that the oxidative addition of the NO occurs in the initial 
process of the reaction.   
 showed that the 
former is relative stable in solution whereas the latter is unstable.  (Difference 
of 160 mV) 
• The oxidation of platinum(II) to platinum(IV) occurs in a two step process which 
were relatively mild conditions of oxidation.   
• The knowledge obtained by this study led to the subsequent development of a 
very important mononitrochloro-complex in this laboratory.   
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Table A.1: Crystal data and structure refinements for Pt(mmtei)Cl2
Crystal Data 
   
Empirical formula C7H12N2SCl2
Formula weight 
Pt 
422.24 g/mol 
Crystal size 0.30 × 0.20 × 0.10 mm 
Crystal description Yellow Prisms 
Crystal system Prismic 
Space group P
Unit cell dimensions 
-1 
a = 8.3553(11) 
b = 8.4918(11) 
c = 9.5355(13) 
α = 92.61(9)° 
β = 112.73(8)° 
γ = 113.65(8)° 
Volume 555.28 Å
Z 
3 
2 
Wavelength 0.71073 Å 
Density (calculated) 2.525 g/cm
Absorption coefficient  
3 
13.26 mm
F(000) 
-1 
392 
Data Collection 
Temperature 173(2) K 
Max. 2θ  56 
Index ranges -11 ≤ h ≤11, -11 ≤ k ≤ 11, -12 ≤ l ≤ 11 
Reflections collected 9351 
Independent reflections 2683 [Rint = 0.0791] 
Absorption correction T min 0.0449 
T max 0.3264 
Solution and Refinement 
Data / restraints / parameters 2683 / 0 / 119 
Goodness-of-fit on F2 All Data 1.084 
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Restrained 1.084 
R Indices 
[I > 4σ(I)] R1 = 0.0218 
All data R2 = 0.0232 
wR2 = 0.054 
Weights2 a  0.0116 
b 0.5 
Largest diff. peak and hole 0.78 and –1.57 e Å
 
-3 
Table A.2: Atomic coordinates (×105) and equivalent isotopic displacement parameters of 
Pt(mmtei)Cl2
ATOM 
.  Estimated standard deviations are supplied in parenthesis. 
x y z Ueq 
Pt 
97383 
(2) 
43225 
(2) 
71176 
(1) 
1878 
(6) 
Cl2 
80771 
(18) 
12505 
(15) 
65116 
(13) 
3089 
(22) 
Cl1 
123298 
(16) 
43821 
(15) 
92399 
(12) 
2859 
(21) 
S 
113138 
(15) 
72825 
(14) 
76169 
(11) 
2215 
(19) 
N1 
76150 
(51) 
44959 
(47) 
53216 
(39) 
2197 
(67) 
C2 
78203 
(58) 
60962 
(55) 
50634 
(43) 
2169 
(75) 
N3 
62952 
(51) 
59208 
(46) 
37714 
(38) 
2296 
(67) 
C3 
95381 
(65) 
77951 
(56) 
61119 
(45) 
2662 
(83) 
C4 
50695 
(63) 
41401 
(60) 
31359 
(48) 
2669 
(84) 
C5 
58779 
(57) 
32648 
(55) 
40932 
(43) 
2219 
(74) 
                                            
2 Weighting Scheme: 1/[σ2(Fo2)+(a×P)2+(b×P)] where P=[Max(Fo2)+(2×Fc2)]/3 
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ATOM x y z Ueq 
C6 
60332 
(72) 
73878 
(64) 
31092 
(48) 
3195 
(97) 
C12 
112759 
(71) 
81025 
(58) 
94001 
(47) 
2910 
(90) 
C13 
123067 
(83) 
101203 
(67) 
98686 
(56) 
3808 
(108) 
 
Table A.3: Anisotropic displacement parameters (×105) of selected atoms in Pt(mmtei)Cl2
ATOM 
.  
Estimated standard deviations are supplied in parenthesis. 
U11 U22 U33 U23 U13 U12 
Pt 
2267 
(9) 
1742 
(9) 
1905 
(9) 
532 
(6) 
926 
(7) 
1151 
(7) 
Cl2 
3836 
(58) 
1928 
(47) 
3225 
(50) 
721 
(40) 
1229 
(45) 
1363 
(46) 
Cl1 
2912 
(51) 
2916 
(53) 
2689 
(46) 
957 
(40) 
741 
(40) 
1717 
(47) 
S 
2279 
(46) 
2065 
(48) 
2355 
(45) 
475 
(36) 
994 
(38) 
1071 
(41) 
N1 
2491 
(171) 
1833 
(164) 
2468 
(162) 
660 
(132) 
1172 
(142) 
1079 
(150) 
C2 
2707 
(195) 
2289 
(193) 
1948 
(167) 
547 
(146) 
1060 
(152) 
1498 
(174) 
N3 
3116 
(183) 
2260 
(173) 
2082 
(151) 
842 
(130) 
1198 
(141) 
1662 
(159) 
C3 
3321 
(224) 
2095 
(197) 
2317 
(188) 
692 
(157) 
744 
(170) 
1465 
(187) 
C4 
2764 
(211) 
2632 
(210) 
2252 
(190) 
474 
(160) 
989 
(169) 
1024 
(187) 
C5 
2422 
(192) 
2103 
(185) 
1871 
(168) 
366 
(144) 
770 
(150) 
971 
(169) 
C6 
4423 
(270) 
3212 
(238) 
2230 
(194) 
1064 
(175) 
794 
(188) 
2595 
(231) 
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ATOM U11 U22 U33 U23 U13 U12 
C12 
4326 
(250) 
2645 
(220) 
2158 
(183) 
566 
(163) 
1623 
(180) 
1766 
(207) 
C13 
5265 
(302) 
2839 
(235) 
3059 
(228) 
585 
(189) 
1985 
(223) 
1477 
(231) 
 
Table A.4: Hydrogen coordinates (×105) an isotropic displacements (×105) for Pt(mmtei)Cl2
ATOM 
   
x y z Ueq 
H3A 91164 84968 66130 3194 
H3B 101408 85007 54934 3194 
H4 38815 36244 22023 3203 
H5 53459 20160 39491 2663 
H6A 64989 83883 39608 4792 
H6B 46490 69908 24262 4792 
H6C 67777 77577 25012 4792 
H12A 99093 76701 92299 3492 
H12B 119268 76373 102590 3492 
H13A 136134 105527 99258 5713 
H13B 124110 105249 108936 5713 
H13C 115580 105798 90876 5713 
 
 
Figure A.1: Stereochemical view of Pt(mmtei)Cl2 
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Figure A.2: The stereochemical view of the packing in Pt(mmtei)Cl2 
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Table A.5: Crystal data and structure refinements for Pt(mmtbzi)Cl2
Crystal Data 
   
Empirical formula C12H14N2SCl2
Formula weight 
Pt 
484.30 g/mol 
Crystal size 0.17 × 0.14 × 0.10 mm 
Crystal description Yellow Prisms 
Crystal system Monoclinic 
Space group P
Unit cell dimensions 
2(1)/c
 
a = 13.2494(7) 
b = 9.7042(5) 
c = 12.5376(8) 
α = 90.00° 
β = 117.0960(10)° 
γ = 90.00° 
Volume 1435.09 Å
Z 
3 
4 
Wavelength 0.71073 Å 
Density (calculated) 2.242 g/cm
Absorption coefficient  
3 
10.278 mm
F(000) 
-1 
912 
Data Collection 
Temperature 173(2) K 
Max. 2θ  55.99 
Index ranges -15 ≤ h ≤17, -10 ≤ k ≤ 12, -16 ≤ l ≤ 16 
Reflections collected 11451 
Independent reflections 3459 [Rint = 0.0372] 
Absorption correction T min 0.2906 
T max 0.5508 
Solution and Refinement 
Data / restraints / parameters 3459 / 0 / 163 
Goodness-of-fit on F2 All Data 0.997 
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Restrained 0.997 
R Indices 
[I > 4σ(I)] R1 = 0.0276 
All data R2 = 0.0392 
wR2 = 0.0597 
Weights3 a  0.0289 
b 0.00 
Largest diff. peak and hole 1.36 and –0.82 e Å
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Table A.6: Atomic coordinates (×105) and equivalent isotopic displacement parameters of 
Pt(mmtbzi)Cl2
ATOM 
.  Estimated standard deviations are supplied in parenthesis.   
x y z Ueq 
Pt 
84040 
(2) 
-15871 
(2) 
-8547 
(1) 
1649 
(6) 
Cl1 
67121 
(11) 
-16774 
(14) 
-7670 
(11) 
3009 
(29) 
Cl2 
91377 
(11) 
-34057 
(13) 
4801 
(10) 
2783 
(27) 
S 
77841 
(10) 
2244 
(12) 
-20910 
(9) 
1817 
(24) 
N1 
98302 
(33) 
-13993 
(38) 
-10111 
(31) 
1754 
(83) 
C2 
99175 
(39) 
-3953 
(49) 
-16867 
(36) 
1772 
(96) 
C3 
90068 
(39) 
6123 
(50) 
-23411 
(38) 
1904 
(100) 
N3 
109501 
(34) 
-4343 
(41) 
-16433 
(31) 
2015 
(85) 
C4 
115468 
(45) 
-14825 
(49) 
-9024 
(41) 
2417 
(107) 
C5 
108491 
(42) 
-21037 
(52) 
-5182 
(39) 
2192 
(102) 
C6 
113639 
(44) 
5146 
(56) 
-22722 
(42) 
2716 
(116) 
                                            
3 Weighting Scheme: 1/[σ2(Fo2)+(a×P)2+(b×P)] where P=[Max(Fo2)+(2×Fc2)]/3 
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ATOM x y z Ueq 
C1 
67751 
(42) 
-4366 
(51) 
-35588 
(36) 
2351 
(108) 
C11 
63714 
(40) 
7028 
(51) 
-44809 
(38) 
2050 
(104) 
C12 
57660 
(41) 
18171 
(52) 
-43763 
(40) 
2341 
(111) 
C13 
53892 
(42) 
28478 
(55) 
-52345 
(43) 
2479 
(107) 
C14 
56177 
(45) 
27668 
(56) 
-61980 
(43) 
2750 
(114) 
C15 
62040 
(46) 
16580 
(54) 
-63313 
(41) 
2818 
(117) 
C16 
65867 
(44) 
6188 
(53) 
-54708 
(40) 
2511 
(111) 
 
Table A.7: Anisotropic displacement parameters (×105) of selected atoms in Pt(mmtbzi)Cl2
ATOM 
.  
Estimated standard deviations are supplied in parenthesis.   
U11 U22 U33 U23 U13 U12 
Pt 
1671 
(10) 
1662 
(11) 
1521 
(8) 
53 
(7) 
647 
(7) 
-123 
(9) 
Cl1 
2141 
(64) 
3807 
(80) 
3402 
(60) 
523 
(55) 
1541 
(54) 
-178 
(60) 
Cl2 
2729 
(68) 
2572 
(68) 
2771 
(55) 
1012 
(51) 
1012 
(52) 
46 
(59) 
S 
1599 
(59) 
1906 
(62) 
1744 
(46) 
97 
(44) 
585 
(44) 
95 
(49) 
N1 
1905 
(212) 
1667 
(224) 
1620 
(162) 
38 
1(46) 
741 
(158) 
-118 
(169) 
C2 
1609 
(240) 
2008 
(259) 
1764 
(189) 
-371 
(178) 
825 
(183) 
-232 
(202) 
C3 
1737 
(252) 
1796 
(265) 
2105 
(203) 
326 
(178) 
809 
(194) 
-48 
(200) 
N3 
2191 
(224) 
1708 
(218) 
2217 
(179) 
-216 
(156) 
1066 
(171) 
-410 
(177) 
C4 
2090 
(264) 
2176 
(281) 
2529 
(221) 
-201 
(201) 
655 
(206) 
455 
(227) 
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ATOM U11 U22 U33 U23 U13 U12 
C5 
2273 
(271) 
1979 
(255) 
1964 
(204) 
82 
1(89) 
651 
(201) 
503 
(220) 
C6 
2206 
(278) 
3217 
(320) 
2940 
(237) 
258 
(218) 
1359 
(221) 
-617 
(240) 
C1 
2278 
(271) 
2355 
(283) 
1598 
(200) 
-11 
(187) 
166 
(193) 
-638 
(224) 
C11 
1620 
(256) 
2018 
(276) 
1912 
(201) 
-66 
(179) 
282 
(189) 
-698 
(201) 
C12 
1837 
(259) 
2864 
(312) 
2323 
(214) 
-561 
(198) 
948 
(203) 
-556 
(216) 
C13 
1530 
(257) 
2215 
(276) 
3533 
(257) 
249 
(218) 
1016 
(222) 
141 
(220) 
C14 
2458 
(284) 
2639 
(298) 
2737 
(236) 
809 
(217) 
820 
(222) 
-266 
(243) 
C15 
2881 
(294) 
3467 
(321) 
2099 
(215) 
154 
(216) 
1129 
(214) 
90 
2(60) 
C16 
2406 
(282) 
2490 
(295) 
2532 
(224) 
-69 
(202) 
1035 
(216) 
287 
(228) 
 
 
Table A.8: Hydrogen coordinates (×105) an isotropic displacements (×105) for 
Pt(mmtbzi)Cl2
ATOM 
.   
x y z Ueq 
H3A 87861 5672 -32084 2285 
H3B 92817 15559 -20564 2285 
H4 123073 -17337 -6926 2900 
H5 110301 -28816 -37 2630 
H6A 107654 11751 -27407 4074 
H6B 115728 -112 -28094 4074 
H6C 120292 10119 -16854 4074 
H1A 71416 -11676 -38119 2822 
H1B 61173 -8482 -35025 2822 
H12 56086 18734 -37102 2809 
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ATOM x y z Ueq 
H13 49746 36074 -51578 2974 
H14 53694 34822 -67790 3300 
H15 63457 16042 -70078 3381 
H16 69928 -1444 -55568 3013 
 
 
Figure A.3: Stereochemical view of Pt(mmtbzi)Cl2   
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Table A.9: Crystal data and structure refinement for Pt(mmtphi)Ox   
Crystal Data 
Empirical formula C13H12N2O4
Formula weight 
SPt 
487.40 g/mol 
Crystal size 0.32 × 0.12 × 0.11 mm 
Crystal description Yellow Needles 
Crystal system Monoclinic 
Space group P
Unit cell dimensions 
2(1)/c
 
a = 7.29830(10) 
b = 16.5571(3) 
c = 11.4501(2) 
α = 90.00° 
β = 95.77(10)° 
γ = 90.00° 
Volume 1376.61 Å
Z 
3 
4 
Wavelength 0.71073 Å 
Density (calculated) 2.352 g/cm
Absorption coefficient  
3 
10.361 mm
F(000) 
-1 
920 
Data Collection 
Temperature 173(2) K 
Max. 2θ  55.99 
Index ranges -9 ≤ h ≤ 8, -21 ≤ k ≤ 21, -15 ≤ l ≤ 14 
Reflections collected 18474 
Independent reflections 3327 [Rint = 0.0671] 
Absorption correction T min 0.1362 
T max 0.3953 
Solution and Refinement 
Data / restraints / parameters 3327 / 0 / 191 
Goodness-of-fit on F2 All Data 1.002 
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Restrained 1.002 
R Indices 
[I > 4σ(I)] R1 = 0.0221 
All data R2 = 0.0274 
wR2 = 0.0441 
Weights4 a  0.0153 
b 0.00 
Largest diff. peak and hole 0.86 and –1.33 e Å
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Table A.10: Atomic coordinates (×105
ATOM 
) and equivalent isotopic displacement parameters of 
Pt(mmtphi)Ox.  Estimated standard deviations are supplied in parenthesis.   
x y z Ueq 
Pt 23845 92272 42057 1538 
 (2) (1) (1) (5) 
N1 27163 103259 48935 1586 
 (37) (15) (24) (59) 
S1 29170 98319 25126 1877 
 (12) (5) (8) (18) 
O1 19433 86797 57233 2098 
 (35) (13) (20) (52) 
O2 19594 81041 35541 2253 
 (35) (13) (21) (54) 
O3 11173 74882 63852 3834 
 (42) (14) (23) (73) 
O4 9613 69118 40912 3337 
 (39) (14) (23) (66) 
C7 14630 79290 55911 2142 
 (48) (20) (31) (76) 
C8 14287 76015 43158 2069 
 (48) (20) (30) (74) 
C2 32569 109322 42465 1838 
 (48) (19) (31) (73) 
C3 38656 107903 30667 1964 
 (49) (19) (30) (73) 
N2 33125 116182 48668 2192 
                                            
4 Weighting Scheme: 1/[σ2(Fo2)+(a×P)2+(b×P)] where P=[Max(Fo2)+(2×Fc2)]/3 
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ATOM x y z Ueq 
 (40) (16) (27) (66) 
C6 37554 124225 44482 2981 
 (54) (20) (35) (89) 
C4 27780 114365 59692 2310 
 (47) (21) (30) (81) 
C5 24061 106357 59661 2228 
 (47) (20) (32) (81) 
C11 6409 100955 18935 1757 
 (46) (19) (28) (71) 
C12 -1325 108528 19816 2049 
 (50) (19) (31) (75) 
C13 -19210 109761 14941 2301 
 (51) (21) (32) (80) 
C14 -29299 103587 9360 2376 
 (52) (22) (30) (79) 
C15 -21475 95949 8635 2655 
 (49) (23) (31) (84) 
C16 -3559 94674 13478 2252 
 (51) (20) (31) (78) 
 
Table A.11: Anisotropic displacement parameters (×105
ATOM 
) of selected atoms in Pt(mmtphi)Ox.  
Estimated standard deviations are supplied in parenthesis.   
U11 U22 U33 U23 U13 U12 
Pt 1652 1552 1412 85 168 -71 
 (8) (7) (7) (5) (5) (5) 
N1 1485 1492 1813 -66 328 15 
 (144) (139) (153) (113) (117) (107) 
S1 1887 2137 1637 172 321 147 
 (45) (41) (43) (34) (35) (34) 
O1 3112 1629 1585 47 384 -541 
 (141) (119) (124) (94) (105) (101) 
O2 3129 1994 1683 -284 467 -130 
 (147) (123) (130) (100) (112) (101) 
O3 6676 2259 2709 347 1164 -1101 
 (221) (142) (152) (115) (144) (129) 
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ATOM U11 U22 U33 U23 U13 U12 
O4 5026 1870 3136 -758 518 -699 
 (189) (130) (158) (113) (137) (119) 
C7 2268 2012 2220 171 597 -68 
 (197) (174) (190) (146) (155) (142) 
C8 2062 2074 2002 -395 -135 193 
 (189) (177) (182) (145) (146) (143) 
C2 1502 2028 1963 42 71 -287 
 (176) (178) (184) (134) (141) (132) 
C3 1640 2440 1779 366 10 -160 
 (178) (179) (179) (142) (142) (139) 
N2 2290 1602 2711 -94 388 -170 
 (169) (143) (173) (123) (136) (116) 
C6 3206 1991 3792 281 576 -262 
 (228) (185) (234) (164) (182) (154) 
C4 2541 2396 2029 -612 402 -92 
 (209) (186) (197) (146) (163) (147) 
C5 2072 2341 2339 110 550 199 
 (199) (191) (203) (143) (162) (137) 
C11 1969 2277 1060 160 322 191 
 (180) (174) (164) (131) (141) (137) 
C12 2289 1797 2051 -69 172 -122 
 (190) (172) (186) (139) (152) (137) 
C13 2628 2249 2091 -14 551 540 
 (207) (182) (193) (145) (162) (145) 
C14 2065 3373 1667 -60 73 46 
 (191) (209) (184) (154) (150) (158) 
C15 2839 2807 2223 -594 -223 -635 
 (223) (199) (200) (160) (170) (160) 
C16 2760 1988 2078 -530 591 -104 
 (209) (170) (191) (144) (161) (147) 
 
 
 
~ 195 ~ 
 
Table A.12: Hydrogen coordinates (×105) an isotropic displacements (×105
ATOM 
) for Pt(mmtphi)Ox   
x y z Ueq 
H3A 52273 107745 31172 2357 
H3B 34282 112335 25289 2357 
H4 26912 118025 66002 2772 
H5 19984 103383 66007 2674 
H6A 43835 123722 37344 4472 
H6B 45622 127013 50551 4472 
H6C 26174 127329 42747 4472 
H12 5520 112799 23697 2459 
H13 -24639 114948 15443 2762 
H14 -41555 104538 6018 2852 
H15 -28373 91657 4851 3186 
H16 1881 89484 13051 2702 
 
 
Figure A.4: Stereochemical view of Pt(mmtphi)Ox 
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